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ABSTRACT 
 
 The assessment of the benefit/risk relation is conducted throughout the entire drug 
life cycle. Before a market authorization is granted, randomized clinical trials are designed to 
evaluate the efficacy and safety of a drug in a specific therapeutic indication. These studies 
are able to detect the most frequent adverse events. However, rare and/or long-latency 
harmful events are usually detected after a drug becomes available in the market. The 
increased seriousness of some adverse events may lead to label update with warnings or 
even to a drug withdrawal after being marketed for some years. Post-marketing 
observational studies may better reflect the nature of adverse events occurring in clinical 
practice since they include populations usually underrepresented in clinical trials, such as the 
elderly, pregnant women or patients with comorbidities.  
 The investigation of uncommon or long-term adverse events associated with 
pharmacological interventions has been discussed as a potential important application of 
meta-analysis. Meta-analysis is a systematic approach to synthesize and combine the results 
of selected studies. It is used to identify sources of variation among study findings and to 
provide an overall measure of effect to reach conclusions about a body of research. The 
meta-analytic technique has been applied with increasing frequency to clinical trials when 
efficacy assessments are needed. Although not frequently, meta-analysis conducted for safety 
purposes have also found increased risk estimates associated with some drugs, such 
cardiovascular adverse events due to rosiglitazone.  
 This project carried out in order to identify the role of meta-analysis as a 
Pharmacovigilance approach and to evaluate how best to combine safety information from 
both experimental and observational studies through this statistical technique. Only a limited 
number of meta-analyses are currently devoted to evaluate drug safety as a primary 
outcome. Of these, very few combine data from both observational and experimental 
studies. Although statistical significant risk estimates could be reached with the inclusion of 
observational studies in meta-analysis, isolated or in combination with clinical trials, the 
increased between-studies heterogeneity usually associated may preclude any definitive 
conclusions. 
 Authorities do not rely solely on risk estimates produced by meta-analysis and usually 
review additional sources of information to support benefit/risk ratio reevaluations due to 
safety issues. It was also demonstrated that cumulative meta-analysis was able to estimates 
increased iatrogenic risks years earlier than regulatory decisions have been taken by 
 34 
authorities for the corresponding safety issues. However, excessive heterogeneity resulting 
from different study designs included in these set of meta-analyses may be one of the 
reasons delaying the acceptance of this technique by regulatory authorities when evaluating 
medicines safety profile.  
 Although reliable risk estimates have shown to be produced from meta-analyses 
conducted to evaluate drug safety issues, between-studies heterogeneity may not let drawing 
robust conclusions from those results, in particular when observational studies are included. 
The results of this work do not let recommend that a meta-analysis of the existing evidence 
should be conducted whenever a safety alert is issued. Moreover, this technique does not 
replace further assessments when the benefit/risk ratio profile of a medicine needs to be 
revised due to safety issues.   
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RESUMO 
 
 A relação benefício/risco de um medicamento é avaliada durante todo o seu ciclo de 
vida. Antes de ser concedida a autorização de introdução no mercado, a eficácia e a 
segurança de um medicamento numa determinada indicação terapêutica são avaliadas através 
da condução de ensaios clínicos aleatorizados e controlados. Estes estudos são capazes de 
identificar a maioria dos eventos adversos associados ao tratamento com um medicamento. 
No entanto, após a introdução no mercado, eventos adversos raros e/ou de longo tempo de 
latência podem ocorrer durante o tratamento com um determinado medicamento, sem que 
antes tenham sido identificados durante o desenvolvimento clínico. Os estudos 
observacionais pós-comercialização permitem identificar eventos adversos raros e/ou de 
longo tempo de latência. A gravidade acrescida de alguns eventos adversos pode levar à 
inclusão de uma advertência no resumo das características do medicamento ou até mesmo à 
sua retirada do mercado. Os estudos observacionais pós-comercialização podem refletir 
melhor a natureza dos eventos adversos que ocorrem durante a prática clínica, uma vez que 
estes estudos permitem avaliar subpopulações de doentes que não são frequentemente 
incluídas nos ensaios clínicos, como os idosos, as grávidas ou as crianças. 
 A investigação do risco de ocorrência de eventos adversos raros e/ou de longo 
tempo de latência associados ao tratamento com intervenções farmacológicas tem vindo a 
ser discutida como uma potencial aplicação da meta-análise. A meta-análise é uma 
ferramenta estatística que permite sintetizar e combinar resultados de vários estudos. É 
utilizada para identificar causas para a variação dos resultados entre os estudos e permite 
obter uma medida de efeito. A meta-análise tem sido aplicada frequentemente a ensaios 
clínicos com o objetivo de conduzir avaliações da eficácia das intervenções. Embora menos 
frequentemente, também têm sido conduzidas meta-análises de segurança que em alguns 
casos identificaram riscos acrescidos para eventos adversos, como o risco acrescido de 
eventos cardiovasculares associado à rosiglitazona. 
 Este projeto foi conduzido com o objetivo de identificar o papel da meta-análise na 
Farmacovigilância e para avaliar como combinar diferentes fontes de informação sobre 
segurança, nomeadamente estudos experimentais e observacionais, através da técnica meta-
analítica. Apenas uma pequena proporção das meta-análises conduzidas atualmente 
considera a segurança como marcador primário. Destas, muito poucas combinam 
informação de estudos experimentais e estudos observacionais. Apesar das meta-análises 
que integram informação de estudos observacionais, de forma exclusiva ou em combinação 
 36 
com estudos experimentais, poderem produzir estimativas de risco estatisticamente 
significativas, a elevada heterogeneidade que normalmente lhes está associada não permite 
que se tirem conclusões definitivas com base nesses resultados.  
 As autoridades reguladoras não baseiam as suas decisões apenas nos resultados 
produzidos pelas meta-análises quando pretendem conduzir reavaliações da relação 
benefício/risco dos medicamentos devido a questões de segurança, e têm em conta a 
informação gerada por outros estudos. Os resultados obtidos durante este trabalho 
demonstraram também que a integração cumulativa dos resultados de vários estudos através 
da meta-análise permitiu estimar riscos acrescidos para o desenvolvimento de eventos 
adversos associados a medicamentos para os quais as autoridades tomaram decisões 
regulamentares posteriormente à data em que se alcançou essa estimativa. No entanto, a 
excessiva heterogeneidade que resultou da inclusão de estudos com diferentes 
delineamentos nestas meta-análises pode ter sido uma das razões que tem impedido uma 
melhor aceitação desta técnica pelas autoridades reguladoras. 
 Apesar de a meta-análise poder produzir estimativas de risco fiáveis quando se avaliar 
a segurança de medicamentos, a heterogeneidade excessiva que se verifica em alguns casos 
pode impedir os investigadores e as autoridades reguladoras de avaliar corretamente a 
relação causa-efeito entre a exposição ao medicamento e o evento adverso, particularmente 
quando se incluiem estudos observacionais. Os resultados deste trabalho não permitem 
recomendar que se conduza uma meta-análise sempre que ocorra um alerta de segurança. 
Desta forma, a meta-análise não substitui outras fontes de informação quando a relação 
benefício/risco dos medicamentos necessita de ser reavaliada devido a questões de 
segurança. 
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I. GENERAL INTRODUCTION 
 
I.1. INCIDENCE OF ADVERSE DRUG REACTIONS AND ITS IMPACT ON 
PUBLIC HEALTH 
 
 The effect of medical innovation over the last century is undeniable. Although 
pharmacological alternatives have been developed to effectively treat severe diseases, 
medicines can also cause iatrogenic effects. An adverse event (AE) is defined as any noxious 
and unintended occurrence that may present during treatment with a drug but which does 
not necessarily have a causal relationship with this treatment (EUROPEAN MEDICINE AGENCY, 
2013). This can be through the use of the drug in its approved conditions but also as a result 
of misuse (situations where the medicinal product is intentionally and inappropriately used 
not in accordance with the authorised product information), abuse (persistent or sporadic, 
intentional excessive use of medicinal products which is accompanied by harmful physical or 
psychological effects) or medication error (EUROPEAN MEDICINE AGENCY, 2013). An adverse 
drug reaction (ADR) is characterized by the suspicion of a causal association between the 
exposure to a drug and the occurrence of an adverse event, i.e. judged possible by the 
reporter or an established causal assessment method (LINDQUIST, 2007).  
 A survey conducted in noninstitutionalized adults in the United States of America 
(USA) estimated that more than 90% of the population aged 65 years or older takes at least 
one medication per week (KAUFMAN et al., 2002). Around 50% of the study’ population 
reported receiving treatment with at least one prescription medicine (KAUFMAN et al., 2002). 
All medicines can cause unwanted effects, which incidence is expected to increase along with 
its widespread use. From 1998 through 2005, reported serious adverse drug events in the 
USA increased 2.6-fold from 34 966 to 89 842, and fatal adverse drug events increased 2.7-
fold from 5519 to 15 107 (MOORE, COHEN, and FURBERG, 2007). Notoriously, during the 
same time period, the overall relative increase of serious AEs reporting was 4 times faster 
than the growth in total US outpatient prescriptions, which grew in the same period from 
2.7 billion to 3.8 billion (MOORE, COHEN, and FURBERG, 2007). 
 Adverse drug reactions have a significant impact on public health, accounting for 
considerable morbidity and mortality (GANDHI et al., 2003). Several studies were dedicated 
to characterize the incidence and the impact of iatrogenic medication disease. For patients 
receiving treatment in the ambulatory care, the average incidence of AEs is estimated to 
range from 4 to 91 per 1,000 person-months (THOMSEN et al., 2007). Almost 5% of total 
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hospital admissions are due to AEs, but in the elderly population this proportion is estimated 
to be 16.6% (BEIJER and DE BLAEY, 2002). A meta-analysis conducted by Lazarou and 
colleagues (1998) estimated the overall incidence of serious ADRs as being 6.7% and fatal 
adverse drug reactions as being 0.32%. Other studies conducted in the hospital setting 
estimated that 4 to 5% of the inpatients suffered AEs and that fatal AEs have been reported 
in 0.05 to 0.95% of inpatients. (LEENDERTSE et al., 2010; KANJANARAT et al., 2003; EBBESEN et 
al., 2001; JUNTTI-PATINEN, and NEUVONEN, 2002).  
 Additional costs from drug-related morbidity represent a considerable proportion of 
total costs of health care systems. A study conducted in Sweden estimated the proportions 
of patients with drug-related morbidity (DRM) and preventable DRM and the cost-of-illness 
(COI) of DRM in Sweden based on pharmacists ‘expert opinion (GYLLENSTEN et al., 2012). It 
was estimated that the cost-of-illness for treating patients attending healthcare services due 
to drug-related morbidity would cost 997€ per patient, corresponding to an annual cost of 
6.600 million euros to the Swedish healthcare system. In Germany, direct costs of ADRs 
were estimated as being 3.814€ per patient (STARK, JOHN and LEIDL, 2011). 
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I.2. BRIEF HISTORICAL BACKGROUND OF DRUG SAFETY AND DRUG 
SAFETY MONITORING 
 
 Pharmacological treatments are perhaps as old as mankind and their iatrogenic events 
have been reported in literature for many years, in both anecdotal and scientific ways 
(RÄGGO and SANTOSO, 2008). Drug regulation, in particular regulation for drug safety and for 
drug safety monitoring, has been impelled upon misfortunate events rather than a rational 
and knowledge based development (RÄGGO and SANTOSO, 2008). 
 The USA government established the Bureau of Drugs in order to implement the 
Biologics Control Act of 1902 (AHMAD, MARKS and GOETSCH, 2006). In early XX century, 
antitoxin derived from the blood of tetanus-infected retired horses was used to treat 
diphtheria patients. By 1901, however, in St. Louis, Missouri, 13 children who had been given 
diphtheria antitoxin died of tetanus (US FOOD AND DRUG ADMINISTRATION, 2009a). The 
second incident occurred in New Jersey when nine children died from contaminated 
smallpox vaccine (US FOOD AND DRUG ADMINISTRATION, 2009b). The 1902 Act enacted by 
the US Congress required annual licensing of manufacturers and distributors and the 
labelling of all products with the name of the manufacturer (AHMAD, MARKS and GOETSCH, 
2006). 
 In 1906, the original Food and Drugs Act is passed by the US Congress and signed by 
the president Theodore Roosevelt, prohibiting interstate commerce in misbranded and 
adulterated foods, drinks and drugs (US FOOD AND DRUG ADMINISTRATION, 2009c). At this 
time, neither the efficacy nor the pre- and pro-marketing safety of medicines was regulated. 
It was only in the 1930s that drug safety started be regulated and again due to a disaster. 
 The S.E. Massengill Co. introduced a sulphanilamide flavoured elixir containing 
diethylene glycol, an antifreeze. Although the toxic effects of diethylene glycol have been 
documented 1931 it did not avoid the death of more than 100 people by 1937 (AHMAD, 
MARKS and GOETSCH, 2006). The Federal Food, Drug and Cosmetic Act was passed by the 
US Congress in June 1938, requiring that new drugs should be submitted for safety tests 
before marketing, with the results being submitted to the FDA (AHMAD, MARKS and 
GOETSCH, 2006). Additionally, this law says that sulphanilamide and other selected dangerous 
drugs must be administrated under the direction of a qualified person, thus launching the 
requirement for prescription only (non-narcotic) drugs (US FOOD AND DRUG 
ADMINISTRATION, 2009c). 
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 Little attention was paid to ADRs until the 1950s when, partially impelled by the 
developments conducted during the Second World War, pharmaceutical industry 
experienced an expansion and an increase number of new launched products (AHMAD, 
MARKS and GOETSCH, 2006). Chloramphenicol was approved in 1949 as a broad-spectrum 
antibiotic. In 1952 an investigation conducted by FDA revealed that chloramphenicol had 
caused nearly 180 cases of fatal blood diseases, such as fatal aplastic anaemia (US FOOD AND 
DRUG ADMINISTRATION, 2009c). In order to gather data to investigate this safety issue, FDA 
ordered the staff in all 16 district offices to contact every hospital, medical school, and clinic 
in cities with populations of at least 100.000 to collect information on any cases of blood 
dyscrasias associated with chloramphenicol (AHMAD, MARKS and GOETSCH, 2006). In few 
days, 217 cases of chloramphenicol-associated blood dyscrasias were identified (AHMAD, 
MARKS and GOETSCH, 2006). The result of this experience, coupled with the need to identify 
serious AEs, as quickly as possible, led the American Medical Association to establish a 
Committee on Blood Dyscrasias which collected case reports of drug-induced blood related 
illness (AHMAD, MARKS and GOETSCH, 2006). In 1956, the American Society of Hospital 
Pharmacists, the American Association of Medical Record Librarians and the American 
Medical Association piloted the first US drug ADR surveillance program (US FOOD AND 
DRUG ADMINISTRATION, 2009c). This program began with six hospitals and by 1965 had 
grown to over 200 teaching hospitals reporting to FDA in a monthly basis. 
 In the district of Castelo Branco, Portugal, several children died after receiving 
treatment with an antibiotic during 1957 (CABRITA DA SILVA, SOARES and MARTINS, 2012). This 
event led the Portuguese authorities to pass the Decree law nº 41448/57, demanding a 
previous evaluation of new medicines before market access authorization could be granted. 
At that time, this was a pioneering legislation in Europe (CABRITA DA SILVA, SOARES and 
MARTINS, 2012). Despite the measures, the Portuguese drug safety monitoring system 
remained practicly inexistent until the country’s admission to the European Economic 
Community, in 1986.  
 The so called “thalidomide disaster” is the most remarkable case of iatrogenic 
worldwide. Thalidomide was a mild hypnotic and sedative which was often used to alleviate 
morning sickness in pregnant women, going on sale for the first time in Western Germany in 
1956 and approved in several countries in the following years (RÄGGO and SANTOSO, 2008). 
Shortly after thalidomide being approved, it was observed an increase in the frequency of a 
previously rare birth defect, phocomelia – malformation of limbs (AHMAD, MARKS and 
GOETSCH, 2006). Dr. William McBride, an Australian physician, reported this adverse drug 
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reaction for the first time in 1961 (MCBRIDE, 1961). It is estimated that thousands of babies 
had been exposed to thalidomide during pregnancy. This event led several countries to 
legislate new regulatory procedures. Although thalidomide was never approved in USA, the 
US Congress approved the 1962 Kefauver-Harris Amendments to the Food, Drug, and 
Cosmetic Act of 1938 requiring drug manufacturers to prove to FDA the efficacy and safety 
of new products before the approval (AHMAD, MARKS and GOETSCH, 2006). Moreover, and 
for the first time, this law also mandated that pharmaceutical manufacturers must report AEs 
to FDA for any of their products having a New Drug Application (AHMAD, MARKS and 
GOETSCH, 2006). The Committee on the Safety of Drugs was established in the United 
Kingdom (UK) in 1963 and in the following year the Yellow Card Scheme was created 
allowing physicians to report suspected adverse drug reactions (MEDICINES AND HEALTHCARE 
PRODUCTS REGULATORY AGENCY, 2013). Other countries like Australia, Canada, 
Czechoslovakia, Ireland, the Netherlands, New Zealand, Sweden, the United States, and 
West Germany initiated the systematic collection of cases of suspected adverse drug 
reactions (EDWARDS et al., 2006). 
 In 1967, the World Health Assembly of the World Health Organization (WHO) 
adopted the World Health Assembly (WHA) 20.51 Resolution (Pilot Research Project for 
International Monitoring of Adverse Reactions to Drugs) which laid the basis for the 
international system of monitoring ADRs (VENULET and HELLING-BORDA, 2010). The WHO 
Pilot Research Project for International Drug Monitoring started its operation in Alexandria, 
Virginia, USA in 1968, with ten countries from Europe, Australasia and North America 
pooling all reports that had been sent to their national monitoring centres in this WHO 
project (VENULET and HELLING-BORDA, 2010; EDWARDS et al., 2006). The centre was 
transferred to the WHO headquarters in Geneva in 1970 before being finally established in 
Sweden in 1978 as the WHO Uppsala Monitoring Centre (VENULET and HELLING-BORDA, 
2010; EDWARDS et al., 2006). 
 The Portuguese Decree law nº 72/91 adopted the European Union directives, 
requiring market authorization holders, physicians, pharmacists and other healthcare 
professionals to report suspected adverse drug reactions to national competent authorities 
(CABRITA DA SILVA, SOARES and MARTINS, 2012). In 1992, the Normative order nº 107/92 
established the Portuguese National Pharmacovigilance System. A year latter the Portuguese 
national regulatory authority was created under the Decree law nº 353/93 and named 
Instituto Nacional da Farmácia e do Medicamento (INFARMED), now INFARMED - Autoridade 
Nacional do Medicamento e Produtos de Saúde (CABRITA DA SILVA, SOARES and MARTINS, 2012). 
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This legislation also established the National Pharmacovigilance Centre, which the main 
purpose was to continue the implementation of the Portuguese National Pharmacovigilance 
System (CABRITA DA SILVA, SOARES and MARTINS, 2012).  
 In 1997 it was developed the Computerized Online Medicaid Analysis and 
Surveillance System (STROM, 2006a). This system used Medicaid billing data to conduct 
pharmacoepidemiology studies. In 1980 it was developed what today is called the Drug 
Safety Research Unit in the UK, which is known for being a pioneer in performing 
Prescription Event Monitoring studies (STROM, 2006a). Both of these novel approaches gave 
important contributions in the pharmacovigilance field since investigators have gained new 
tools to generate and investigate research hypothesis on safety issues. 
 Until the beginning of the 1990s there were five different forms for manufacturers 
and health care professionals to report medicines’ related problems to FDA (AHMAD, MARKS 
and GOETSCH, 2006). In 1993, it was launched the FDA’s MedWatch Adverse Event 
Reporting Program aiming to facilitate, support and promote the voluntary reporting of 
suspected adverse drug reactions by health care professionals and consumers (AHMAD, 
MARKs and GOETSCH, 2006; US FOOD AND DRUG ADMINISTRATION, 2009c).  
 The European Agency for the Evaluation of Medicinal Products (EMEA) was 
established in 1995 as well as a new regulatory system which includes procedures for a 
centralised authorisation (BAHRI, TSINTIS and WALLER, 2007). The agency created the 
Pharmacovigilance Working Party (PhVWP) of the Committee for Medicinal Products for 
Human Use (CHMP) to provide recommendations to the CHMP on all matters relating 
directly or indirectly to pharmacovigilance (EUROPEAN MEDICINES AGENCY, 2005). Upon 
request of national authorities, the PhVWP could provide recommendations for non-
centrally authorised medicines (EUROPEAN MEDICINES AGENCY, 2005). The European Union 
(EU) pharmacovigilance system was created to supervise the safety of the medicines on the 
European market. In 2004 EMEA changed its designation to European Medicines Agency 
(EMA). 
 The FDA announces the Drug Safety Board, consisting of FDA staff and 
representatives from the National Institutes of Health and the Veterans Administration (US 
FOOD AND DRUG ADMINISTRATION, 2009c). This board will advise the Director, Centre for 
Drug Evaluation and Research (CDER), FDA, on drug safety issues and work with the agency 
in communicating safety information to health professionals and patients (US FOOD AND 
DRUG ADMINISTRATION, 2009c). 
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 In 2010, the European Commission reviewed the EU pharmacovigilance system and 
proposed new legislation (EUROPEAN MEDICINES AGENCY, 2013). This new legislation entered 
in to force in 2012. Over the years, several EU Member States established schemes for 
patients directly to report suspected adverse drug reactions to healthcare authorities. The 
recently implemented EU pharmacovigilance legislation introduced the legal right for 
European citizens to report suspected adverse drug reaction (EUROPEAN MEDICINES AGENCY, 
2013). The Pharmacovigilance Risk Assessment Committee (PRAC) was created and it will 
meet monthly. The PRAC will advise the CHMP and the Coordination Group for Mutual 
Recognition and Decentralised Procedures (CMDh) on safety issues associated with 
medicines authorised for the EU market (EUROPEAN MEDICINES AGENCY, 2013). The PRAC 
replaced the PhVWP.  
 Scientific societies dedicated to study the field of drug safety have been created. The 
International Society on Pharmacoepidemiology (ISPE) was officially launched in 1989 during 
the 5th International Conference on Pharmacoepidemiology and Risk Management 
(INTERNATIONAL SOCIETY FOR PHARMACOEPIDEMIOLOGY, 2014). The ISPE is a non-profit 
international professional membership organization provides a forum to the open exchange 
of scientific information for the field of pharmacoepidemiology, including pharmacovigilance, 
drug utilization research, outcomes research, comparative effectiveness research, and 
therapeutic risk management (INTERNATIONAL SOCIETY FOR PHARMACOEPIDEMIOLOGY, 2014). 
It counts with members of more than 53 countries. The International Society of 
Pharmacovigilance (ISOP) aims to foster Pharmacovigilance both scientifically and 
educationally, and enhance all aspects of the safe and proper use of medicines, in all 
countries (INTERNATIONAL SOCIETY OF PHARMACOVIGILANCE, 2014). It was created in 1992, 
initially under the name of European Society of Pharmacovigilance. The European Network 
of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) was created in 2006 
by the EU as a project within the European Risk Management Strategy (ERMS) (EUROPEAN 
NETWORK OF CENTRES FOR PHARMACOEPIDEMIOLOGY AND PHARMACOVIGILANCE, 2014). Its 
goal is to further strengthen the postauthorisation monitoring of medicinal products in 
Europe by facilitating the conduct of post-authorisation studies focusing on safety and on 
benefit-risk (EUROPEAN NETWORK OF CENTRES FOR PHARMACOEPIDEMIOLOGY AND 
PHARMACOVIGILANCE, 2014). This ENCePP comprises relevant research centres, healthcare 
databases, electronic registries and existing European networks covering certain rare 
diseases, therapeutic fields and adverse drug events of interest (EUROPEAN NETWORK OF 
CENTRES FOR PHARMACOEPIDEMIOLOGY AND PHARMACOVIGILANCE, 2014). 
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I.3. PHARMACOVIGILANCE 
 
 During the clinical development, medicines are tested in a relatively short number of 
patients. Therefore, a randomized clinical trials (RCT) design are more likely to identify the 
most frequent and acutely ADRs (MADRE et al, 2006 LESKO and MITCHELL, 2012). Once a 
drug is marketed, more patients will receive treatment and their demographic characteristics 
are somehow more heterogeneous. Rare and long-latency AEs may arise and subsequently 
change the initial established benefit/risk profile. Data on drug safety from all available 
sources need to be collected and managed systematically in order to identify potential drug 
safety hazards as soon as possible (MADRE et al, 2006; STROM, 2012).  
 The identification of iatrogenic drug disease and the monitoring of its impact on a 
population perspective led to the development of a discipline of Pharmacoepidemiology - 
Pharmacovigilance (RAWLINS, 1995). The term “Pharmacovigilance” first appeared in medical 
literature in 1974 (MOORE, 2013).  
 Pharmacovigilance is defined as the science and activities relating to the detection, 
assessment, understanding and prevention of adverse effects or any other possible drug-
related problems (WHO COLLABORATING CENTRE FOR INTERNATIONAL DRUG MONITORING, 
2002). It is a multidisciplinary issue involving major disciplines as basic and clinical 
pharmacology, clinical medicine, toxicology, epidemiology and genetics (AKICI and OKTAY, 
2007). The task of Pharmacovigilance is monitoring the safety of medicines and ensuring that 
the risks of a medicine do not outweigh the benefits, in the interests of public health 
(EUROPEAN MEDICINES AGENCY, 2013). 
 Pharmacovigilance has seen significantly developed over the past years (PAL et al., 
2011).  In developed countries, regulatory authorities have in force rigorous 
Pharmacovigilance legislations in order to seek greater transparency, accountability and 
access to information on safety (PAL et al., 2011). In Europe, a new Pharmacovigilance 
legislation is in force since July 2012 (COMMISSION DIRECTIVE 2010/84/EU, 2010). This new 
legislation allows EMA to maintain and further develop its tasks, in particular as regards the 
management of the Union pharmacovigilance database and data-processing network (the 
‘Eudravigilance database’), the coordination of safety announcements by the Member States 
and the introduction of the legal right for individual European citizens to report suspected 
adverse drug reactions. 
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I.4. METHODS USED IN PHARMACOVIGILANCE 
 
 Spontaneously reported suspected ADRs by health care professionals, patients or 
market authorisation holders (MAHs) are the main source of information on drug safety 
issues to national pharmacovigilance systems. Since there is a need to quantify and 
characterize risks to individuals and communities from their medicines and, lately, to 
minimize their iatrogenic effects, other methodological designs are therefore needed (PAL et 
al., 2013). The best method to address a specific safety issue depends on a number of 
variables that should be considered, such as the drug in cause and its therapeutic indication, 
the population being treated and the AE of interest (EUROPEAN MEDICINES AGENCY, 2005).   
 The nature of pharmacoepidemiologic study designs which support regulatory 
decisions on safety issues can be descriptive or analytical (MADRE et al., 2006). Descriptive 
studies generate hypotheses and describe the occurrence of events related to drug toxicity 
and/or efficacy (HÄRMARK and VAN GROOTHEEST, 2008). These studies used to obtain the 
background rate of events and/or establish the prevalence of the use of drugs in specified 
populations (EUROPEAN MEDICINES AGENCY, 2005). Descriptive studies limit the inference 
made about causality and include spontaneous case reports, case series, uncontrolled 
cohorts and registries (MADRE et al., 2006; STROM, 2012). Analytic studies are conducted to 
test research hypotheses aiming to evaluate the causal association between an observed 
event and a particular drug or drugs (HÄRMARK and VAN GROOTHEEST, 2008). Analytic 
studies include a comparator group and there are a variety of designs, such case-control 
studies, cohort studies and RCTs (MADRE et al., 2006; STROM, 2012). Meta-analyses can be 
used to combine results from different studies (MADRE et al., 2006; STROM, 2012). 
 This section aims to provide a summary of the most common pharmacovigilance 
methods used to study drug safety. 
 
I.4.1. DESCRIPTIVE STUDIES 
 
I.4.1.1. Spontaneous reports 
 
 According to the International Conference on Harmonisation of Technical 
Requirements for Registration of Pharmaceuticals for Human Use (ICH) definition, a 
spontaneous report is an unsolicited communication by a healthcare professional or 
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consumer to a company, regulatory authority or other organization (e.g. WHO, Regional 
Centre, Poison Control Centre) that describes one or more adverse drug reactions in a 
patient who was given one or more medicinal products and that does not derive from a 
study or any organized data collection scheme (EUROPEAN MEDICINES AGENCY, 2003). 
Pharmacovigilance centres collect reports of ADRs and evaluate the risk for new safety 
signals (HÄRMARK and VAN GROOTHEEST, 2008). Marketing authorisation holders also receive 
reports of their drugs (HÄRMARK and VAN GROOTHEEST, 2008).  
 Spontaneous reporting systems are the main source of post-marketing information 
on drug safety (HÄRMARK and VAN GROOTHEEST, 2008). A study conducted to evaluate FDA 
safety-related drug label changes in 2010 concluded that spontaneous reports contributed to 
safety-related label changes more than any other evidence source (LESTER et al., 2013). 
Statistical methods can be applied to spontaneously reported data for signal detection, such 
as the Proportional Reporting Ratio (PRR), or the method used by the WHO, the Bayesian 
Confidence Propagation Neural Network (BCPNN). A safety signal can be defined as 
“information that arises from one or multiple sources (including observations and 
experiments), which suggests a new potentially causal association, or a new aspect of a 
known association, between an intervention and an event or set of related events, either 
adverse or beneficial, which would command regulatory, societal or clinical attention, and is 
judged to be of sufficient likelihood to justify verifiable and, when necessary, remedial 
actions” (HAUBEN and ARONSON, 2009). When spontaneously reported cases are the data 
source, a signal can be defined as a higher than expected relative frequency of a drug-event 
pair (MADRE et al., DAL PAN, LINDQUIST and GELPERIN, 2012).    
 Spontaneous report of ADRs is a valuable method to identify rare a serious AEs with 
an acute onset and occurring with a close temporal relationship between the start of the 
treatment or following a dosage increment (MADRE et al., 2006; DAL PAN, LINDQUIST and 
GELPERIN, 2012). Spontaneous reporting systems operate with a relatively low cost, allowing 
monitoring all drugs in market during their entire life cycles and covering the whole patient 
population (HÄRMARK and VAN GROOTHEEST, 2008). However, some limitations should be 
noted.  
 Adverse events with a long-latency period are less likely to be reported, since only 
unexpected and severe AEs are prone to be noticed by patients and healthcare 
professionals. The data accompanying spontaneous reports are frequently incomplete and 
the rate at which cases are reported is dependent on many factors including the length of 
time a drug has been on the market, media attention, and the indication for use of the drug 
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(EUROPEAN MEDICINES AGENCY, 2005). Other limitations of most importance are the 
underreporting and the selective reporting. A systematic review estimated the median 
underreporting rate across the included studies was 94% (HAZELL and SHAKIR, 2006). New 
drugs in market of drugs claiming to be safer are more likely to have their AEs reported 
(EDWARDS et al., 2006).  
 Despite the irreplaceable value of spontaneous reporting systems, analytic studies 
should be conducted to follow-up safety signals generated by this method (EDWARDS et al., 
2006; STROM, 2012). 
 
 I.4.1.1.1. Targeted Spontaneous Reporting 
 
 The Targeted Spontaneous Reporting (TSR) is a variant method from the 
spontaneous reporting and was developed by the WHO (WORLD HEALTH ORGANIZATION, 
2012). With TSR, healthcare professionals managing a group of patients are encouraged to 
report specific harmful events which are thought to be drug-related (PAL et al., 2013). This 
method is sustainable and feasible and is being applied as a pharmacovigilance tool in 
countries with limited human and financial resources (PAL et al., 2013). TSR was piloted for 
Human Immunodeficiency Virus (HIV) treatment programs in Kenya, Uganda and Vietnam 
and WHO is planning to use it to collect data on iatrogenic events from tuberculosis 
treatments (PAL et al., 2013). 
 
I.4.1.2. Case series 
 
 A case series are collections of cases, all of whom were subject to the same 
exposure, whose clinical outcomes are then exposed and evaluated (STROM, 2006; STROM, 
2012). Alternatively, case series can be defined as collections of patients suffering the same 
outcome who will be evaluated in order to identify their previous exposure (STROM, 2006; 
STROM, 2012). No control group is included in case series. Cases occurring in the same 
hospital or medical practice constitute often a case series (STROM, 2006; STROM, 2012). This 
type of study can provide evidence of an association between a drug and an AE, but is more 
useful as a hypothesis generator methodology (EUROPEAN MEDICINES AGENCY, 2005).  
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I.4.1.3. Intensive Monitoring 
 
 Commonly known as Prescription-Event Monitoring (PEM), an Intensive Monitoring 
programme is a method of active pharmacovigilance surveillance (EUROPEAN MEDICINES 
AGENCY, 2005). This methodology was developed in New Zealand (the Intensive Medicines 
Monitoring Programme) and in the UK (Prescription Event Monitoring) (HÄRMARK and VAN 
GROOTHEEST, 2008). The design of PEM consists in a non-interventional, observational 
prospective cohort with the aim of detecting any AE that may present during the treatment 
with a medicine (SHAKIR, 2007).  This type of studies is frequently conducted for new drugs 
in the early postmarketing phase based on routine clinical practice (PAL et al., 2013). In drug 
event monitoring, patients might be identified from electronic prescription data or 
automated health insurance claims (EUROPEAN MEDICINES AGENCY, 2005). Then, a 
questionnaire is sent to each prescribing physician or patient at specified intervals in order 
to obtain information on any AE (EUROPEAN MEDICINES AGENCY, 2005). Demographic 
characteristics of patients, indication for treatment, duration of therapy, dosage, clinical 
events, and reasons for discontinuation can be included in the questionnaire (EUROPEAN 
MEDICINES AGENCY, 2005). The physician or patients then return the questionnaire. 
 This method has a number of strengths (SHAKIR, 2007). It is a non-interventional 
study which does not interfere with the treatment chosen by the physician, diminishing the 
risk of selection bias. All the events occurring during the treatment should be reported 
which can lead to the detection of AEs which could be initially judge as non-related to the 
drug. Long-term latency ADRs can be explored and the patients’ cohort can be followed 
after the end of the study (SHAKIR, 2007). However, as any other pharmacoepidemiologic 
study, some limitations should be considered. Not all the questionnaire forms are returned 
to the sponsor of the study. A PEM depends on physicians reporting, so the underreporting 
is possible to exist (LAYTON and SHAKIR, 2012). The PEM process developed in the UK by 
the Drug Safety Research Unit is described in Figure I.1. 
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Figure I.1 - The Prescription-Event Monitoring process (LAYTON and SHAKIR, 2012). 
Legend: DSRU: Drug Safety Research Unit; NHS: National Health Service; Authority; GP: general practitioner; 
NHSRxS: NHS Prescription Services; PEM; Prescription-Event Monitoring; ADRs: adverse drug reactions. 
 
 
I.4.2. ANALYTIC STUDIES 
 
I.4.2.1. Randomized controlled clinical trials 
 
 Randomized clinical trials are classified in four phases: phase I, phase II, phase III and 
phase IV (STANLEY, 2007). RCTs where the pharmacokinetics and pharmacodynamics are 
initially study are known as phase I RCTs. Phase I RCTs include healthy volunteers. Phase I 
and phase II RCTs are conducted to establish the initial safety profile, to set the dose range 
and to collect the first data on the efficacy of the drug (STANLEY, 2007). The initial clinical 
development of a drug usually includes few hundreds of individuals (ROSENSTOCK et al., 
2012). The best evidence on the efficacy and safety of a drug seeking market authorisation or 
extension of its therapeutic indication is retrieved from RCTs, in particular from Phase III 
RCTs which include hundreds to thousands of patients (MADRE et al., 2006; LESKO and 
MITCHELL, 2012). The time length depends on the relative incidence of the chosen endpoint 
and the simple size is estimated based on the power required to demonstrate a statistical 
DSRU notifies NHS Prescription Services (NHSRxS) of study drug under surveillance 
DSRU receives data from dispensed NHS prescriptions (NHSRxS) issued in England by GPs 
from the data of market lauch, in strict confidence from the NHSRxS 
PEM (standard/modified) questionnaires sent to GPs (e.g., ≥3,6,12 months after first primary 
care prescripton  issued for patient)  
Information requested on questionnaire includes: baseline demographic data, drug exposure 
details, events and other outcomes, important risk factores and prescribing patterns 
PEM (standard/modified) questionnaires returned, scanned, reviewed and data entered onto 
DRSU database 
Selected events of medical interest (suspected ADRs, deaths, pregnancies) and other 
outcomes which required further evaluation may be followed-up 
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different between groups on a clinical effect (MADRE et al., 2006; LESKO and MITCHELL, 2012). 
The phase IV RCTs, conducted after a medicine is marketed, aim to provide additional 
details about the medicine's efficacy or safety profile (AMGEN, 2012). The detection and 
more rigorous assessment of previously unknown or inadequately quantified AEs are an 
important role of phase IV RCTs (STROM et al., 2008). A particular type of clinical trial useful 
to conduct postmarketing safety profile assessments is the Large Simple Trial (LST). Large 
Simple Trials are considered the best solution when it is not possible to completely contro 
confounding by means other than randomization (LESKO and MITCHELL, 2012). This type of 
RCT has been used to study the risk of adverse drug effects when observational designs may 
be judged inadequate (LESKO and MITCHELL, 2012; LESKO and MITCHELL, 1995). 
 The most frequent and acute drug-related AEs can be detected during the pre-
market clinical development (MADRE et al., 2006; LESKO and MITCHELL, 2012). Most of what is 
known about the safety profile of a drug comes from harmful effects reported during RCTs. 
Nonetheless, it is highly probable that serious unexpected suspected ADRs may occur after 
a drug being introduced in market. The total patient size of Phase III RCTs commonly rounds 
the few thousands (MADRE et al., 2006; LESKO and MITCHELL, 2012). Clinical trials are not 
designed to evaluate the risk for rare and/or long-term latency AEs. Other limitation of 
RCTs is the inclusion/exclusion criteria for patients (MADRE et al., 2006; LESKO and MITCHELL, 
2012). Patients included in RCTs are treated in well-defined indication and may receive a 
limited number of concomitant drugs (MADRE et al., 2006; LESKO and MITCHELL, 2012). 
Additionally, individuals of particular groups such as elderly, children or pregnant women are 
usually underrepresented or excluded (HÄRMARK and VAN GROOTHEEST, 2008). When safety 
issues arise from RCTs they usually occur unexpectedly and most of the times they are not 
prespecified outcomes (BOMBARDIER et al., 2000). 
 Since RTCs are mainly conducted to demonstrate clinical efficacy during clinical 
development they tend to be unnecessary after a market authorization to be granted 
(STROM, 2006; STROM, 2012). The exception is when therapeutic indication extensions are 
required. Ethical issues restrain RCTs to be conducted in order to evaluate safety issues. 
However, in some situations such studies can be conducted in order to analyze the serious 
risks arising from medicines, in particular if such safety concerns could be adequately 
expressed as safety endpoints (US FOOD AND DRUG ADMINISTRATION, 2011). According to 
FDA guidance, examples include RCTs designed to (US FOOD AND DRUG ADMINISTRATION, 
2011):  
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 Evaluate the occurrence of asthma exacerbations associated with an irritative 
component of inhalation treatments for asthma in a RCT, where the increased risk of 
drug-related exacerbation has the potential to offset the effectiveness of the inhaled 
drug;  
 Determine the incidence of myocardial infarction in patients treated with the 
approved drug in a follow-on trial after approval, using the original randomized 
population;  
 Evaluate differences in safety outcomes between patients withdrawn from treatment 
after some period of treatment and patients who remain on the treatment 
(randomized withdrawal trial);  
 Evaluate the potential for QT interval prolongation in a thorough QT interval RCT;  
 Measure growth and neurocognitive function in pediatric patients treated chronically 
with the drug*; 
 Evaluate safety in a particular racial or ethnic group or vulnerable population such as 
the immunocompromised*; 
 Evaluate the safety of the drug in pregnant women*; 
 Evaluate drug toxicity in patients with hepatic or renal impairment*;  
 Evaluate long-term safety of cell and gene therapy products depending on the type of 
vector used and the inherent risk of integration;  
 Evaluate the safety of a drug in patients with HIV-1 co-infected with hepatitis C or B* 
* - Patients are treated with the drug at a dose and schedule specified in the RCT protocol. 
 
 Due to ethical and design limitations of RCTs, observational study designs are main 
data sources supporting pharmacovigilance activities.  
 
I.4.2.2. Observational studies 
 
I.4.2.2.1. Case-control studies 
 
 A study authored by Janet Lane-Claypon in 1926 and published by the British Ministry 
of Health entitled “A further report on cancer of the breast: reports on public health and 
medical subjects.” is considered the first case-control study (PANETH, SUSSER and SUSSER, 
2002). In case-control studies, cases with a disease (or event) are compared with controls 
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without the disease looking for differences in previous exposures (Figure I.2) (STROM, 2006; 
ROSENBERG, COOGAN and PALMER, 2012). The prevalence of exposure among the controls 
should represent the prevalence of the exposure in the source population (EUROPEAN 
MEDICINES AGENCY, 2005).  
 
 
Figure I.2 - Schematic diagram of a case-control study design (SCHULZ and GRIMES, 2002). 
 
 
 Case-control studies are useful when it is aimed to study multiple causes of a disease 
since the same cases and controls can be used to examine any number of exposures as 
potential risk factors (STROM, 2006; ROSENBERG, COOGAN and PALMER, 2012). This design is 
often used to investigate the risk for developing rare AEs or the cause of a disease with a 
long latency period, since conducting a cohort study with the same objective would be less 
efficient in terms of time, money and efforts (SCHULZ and GRIMES, 2002). Information on 
individuals’ exposures is generally obtained in a retrospective fashion. Patients are commonly 
recruited from databases containing their medical records, but data can be collected 
specifically for the study, by administering questionnaires or conducting interviews 
(EUROPEAN MEDICINES AGENCY, 2005). This retrospective data collection procedure on the 
exposure has the risk of a poor validation (STROM, 2006; ROSENBERG, COOGAN and PALMER, 
2012). Moreover, controls selection is difficult and its inappropriate sampling can introduce 
bias in the study (STROM, 2006; ROSENBERG, COOGAN and PALMER, 2012). 
 Incidence rates cannot be estimated from case-control studies (SCHULZ and GRIMES, 
2002). Instead, the odds ratio (OR) should be used to compare the different proportion of 
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exposed individuals among cases and controls groups (SCHULZ and GRIMES, 2002; EUROPEAN 
MEDICINES AGENCY, 2005). The OR is a good estimate of the relative risk (RR) when rare 
events are being studied (SCHULZ and GRIMES, 2002). 
 
I.4.2.2.2. Cohort studies 
 
 Wade Hampton Frost, an epidemiologist, was the first to use the word “cohort” in 
his publication assessing the age-specified mortality rates and tuberculosis, in 1935 (FROST, 
1935; SONG and CHUNG, 2010). In cohort studies, a population-at-risk for a disease or an 
event is followed over time for the occurrence of such disease or event (EUROPEAN 
MEDICINES AGENCY, 2005). Cohort studies can be prospective or retrospective, since 
investigators can go forward in time or go back in time to select the cohort (Figure I.3) 
(GRIMES and SCHULZ, 2002).  
 
 
Figure I.3 - Schematic diagram of cohort study design possibilities: concurrent (prospective), retrospective 
and ambidirectional (GRIMES and SCHULZ, 2002). 
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 A bidirectional design can also exist when data is collected in both directions (GRIMES 
and SCHULZ, 2002). Typically, two or more groups of patients are followed from exposure 
to outcome (GRIMES and SCHULZ, 2002). Usually, cohort studies are used to compare a 
group of exposed patients to a group of unexposed or to compare groups under different 
exposures (STROM, 2006; STROM, 2012). If the groups have different frequencies in outcomes, 
then an association can be suggested (GRIMES and SCHULZ, 2002). 
 The basic difference between cohort and case-control studies is the way that the 
patients are recruited into the study (GRIMES and SCHULZ, 2002). Into a cohort study, 
patients are recruited based on presence of absence of an exposure and are then followed 
over time to study their disease course (GRIMES and SCHULZ, 2002). Patients are recruited 
into a case-control study based on presence of absence of an outcome (e.g: AE or disease), 
and their previous exposures are then evaluated (GRIMES and SCHULZ, 2002). 
 Cohort studies offer several advantages. They are the best design to document the 
natural history of a disease or the incidence of an AE (GRIMES and SCHULZ, 2002). Multiple 
outcomes can be investigated using the same data source (EUROPEAN MEDICINES AGENCY, 
2005). However, this can arise methodological issues since the sample size may not be large 
enough to study rare events. Cohort studies are useful to estimate incidence rates and 
relative risks (RRs) and they can reduce the risk of survival bias when compared with case-
control studies (GRIMES and SCHULZ, 2002). As examples of limitations of cohort studies, one 
can be pointed out are the risk for selection bias, the difficult of studying the risk for rare 
and long latency events and the lost for follow-up of patients (STROM, 2006; STROM, 2012; 
GRIMES and SCHULZ, 2002). 
 
I.4.2.2.3. Nested case-control studies 
 
 The nested case-control design differs from the traditional case-control design in that 
it is “nested” in a well-defined cohort, for which information on all members can be obtained 
(ESSEBAG et al., 2003). The nested case-control design was introduced by Mantel in 1973. 
There are four crucial steps in the design of nested case-control studies: define the cohort’s 
time axis; select all the cases (all subjects with the outcome of interest); form all risk sets 
corresponding to the cases, and; randomly select one or more controls from each risk set 
(SUISSA, 2006; SCHNEEWEISS and SUISSA, 2012). The risk set consist in all noncases (considered 
to be at risk of becoming cases) present in the cohort at the time the case becomes a case 
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(ESSEBAG et al., 2003). The most appropriate method to select controls is random selection, 
without replacement, of noncases presented at the risk set of each case (ESSEBAG et al., 
2003). Selection of controls only from noncases or not use subjects more than once as 
controls can introduce bias in the risk estimation (SUISSA, 2006; SCHNEEWEISS and SUISSA, 
2012). A case-control study design is illustrated in Figure I.4 (ESSEBAG et al., 2003).  
 
 
Figure I.4 - The design of a nested case-control study (ESSEBAG et al., 2003). In this example, there are 2 
controls (white circles with a X) for every case (black circles). Follow-up is represented by horizontal black 
lines, beginning at the zero-time. One should be notice that a future case may be selected as a control for a 
prior case, and that a given subject may be selected as a control for 2 different cases. 
 
 
 Nested case-control studies are used to conduct internal comparisons (within the 
cohort) between exposures to different drugs (SUISSA, 2006; SCHNEEWEISS and SUISSA, 2012). 
This design can also be used to compare the rates of AEs within a cohort with those 
occurring in the general population, with proper adjust for variables such sex or age (SUISSA, 
2006; SCHNEEWEISS and SUISSA, 2012).  
 
I.4.2.2.4. Case-cohort studies 
 
 The design of a case-cohort study was proposed by Prentice in 1986 (PRENTICE, 1986; 
ESSEBAG et al., 2003). A case-cohort study begins with the definition of a cohort time axis, 
followed by the selection of all cases, like a nested case-control design (Figure I.5) (SUISSA, 
2006; SCHNEEWEISS and SUISSA, 2012). The difference is the controls’ selection process. In a 
case-cohort study, a random sample of a predetermined size, usually called subcohort, is 
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selected from the cohort (SUISSA, 2006; SCHNEEWEISS and SUISSA, 2012). For every case, a risk 
set is established (as in the nested case-control study) of all noncases at risk at the time the 
case becomes a case (ESSEBAG et al., 2003). All members of the predefined subcohort present 
in a case’s risk set are used as controls for the case (as opposed to the random selection of 
X controls from each case’s risk set in the nested case-control study) (ESSEBAG et al., 2003). 
It is possible that a future case included in the subcohort serves as a control for all cases 
occurring before the future case becomes a case (ESSEBAG et al., 2003). 
 
 
Figure I.5 - The design of a case-cohort study (SUISSA, 2006). In this example, there are 4 cases (black 
circles). Follow-up is represented by horizontal black lines, beginning at the zero-time.  
 
 
I.4.2.2.5. Cross-sectional studies 
 
 A cross-sectional study examines exposure(s) and outcome(s) in a population at one 
point in time; they have no time sense. These studies are conducted to gather data for 
surveys or for ecological analyses (EUROPEAN MEDICINES AGENCY, 2005). No temporal 
relationship between an exposure and an outcome can be directly addressed (EUROPEAN 
MEDICINES AGENCY, 2005). These studies can estimate the prevalence of an event at a time in 
a population. 
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I.4.2.3. Registry studies 
 
 According to the Agency for Healthcare Research and Quality (AHRQ) definition “a 
patient registry is an organized system that uses observational study methods to collect 
uniform data (clinical and other) to evaluate specified outcomes for a population defined by a 
particular disease, condition, or exposure, and that serves one or more predetermined 
scientific, clinical, or policy purposes.” (GLIKLICH and DREYER, 2010). Registries conducted to 
collect data on diseases, such blood dyscrasias, severe cutaneous reactions, or congenital 
malformations can be used to investigate previous drug exposures or other factors 
associated with the clinical condition (EUROPEAN MEDICINES AGENCY, 2005). This method can 
be used to perform case-control studies since drug exposure from cases identified in the 
registry can be compared with drug exposure from controls which can be selected from 
either patients with other condition from the registry or patients outside the registry 
(EUROPEAN MEDICINES AGENCY, 2005). Registries can also be conducted to collect data 
exposure to drugs of interest, called exposure registries (EUROPEAN MEDICINES AGENCY, 
2005). Exposure registries focus on patients treated with a particular drug, studying the 
effects of the selected therapeutic in a population of interest, such pregnant women 
(GLIKLICH and DREYER, 2010). In both types of registries, forms such as a questionnaire or an 
AEs’ case report form can be used to collect the information from providers or patients in a 
prospective way (GLIKLICH and DREYER, 2010). Cohort studies can be conducted since 
registries allow patients to be followed over time (EUROPEAN MEDICINES AGENCY, 2005). 
Despite no control group is included in this methodology, registries allow studying the 
incidence of AEs and, in the presence of new evidence, they can be used for signal 
generation (EUROPEAN MEDICINES AGENCY, 2005).     
 
I.4.2.4. Studies conducted based on automated databases 
 
 Once a hypothesis for a safety signal is generated it is necessary to test the 
hypothesis, most of times by conducting longitudinal studies, such cohorts or case-controls. 
Since rare and/or long-term latency serious suspected adverse drug reactions are those of 
most concern, postmarketing studies usually included 10000 exposed persons in a cohort 
study or enrol diseased patients from a population of equivalent size for a case-control study 
(STROM, 2006b; STROM, 2012a). It may not be feasible and cost-effective to conduct studies 
requiring such sample sizes and time length by collecting original primary data. For all these 
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reasons, the use of computerised automated databases as data sources for 
pharmacoepidemiology studies has grown in the past decades (STROM, 2006b; STROM, 
2012a). Automated databases have been used for pharmacoepidemiology research in North 
America since 1980s and they were initially created for administrative purposes (STROM, 
2006b; STROM, 2012a). 
 There are two main types of automated databases (EUROPEAN MEDICINES AGENCY, 
2013). Those that contain comprehensive medical information, which include prescriptions, 
diagnosis, referrals and discharge reports, such the Clinical Practice Research Datalink 
(CPRD). The other type of databases are those mainly created for administrative purposes, 
which require a record-linkage between pharmacy claims and medical claims databases, such 
the PHARMO system in The Netherlands or the Medicaid in the USA (EUROPEAN MEDICINES 
AGENCY, 2013). These databases may include data on millions of patients. However, they 
may not have the detailed information on some variables that are valuable more accurate 
research, such as validated diagnostic information or laboratory data (EUROPEAN MEDICINES 
AGENCY, 2013). Guidelines were created to assist investigators in the selection and use of 
data resources for an observational study in pharmacoepidemiology by highlighting potential 
limitations and recommending tested procedures (HALL et al., 2012).  
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I.4.3. STUDIES’ METHODOLOGICAL QUALITY ASSESSMENT 
 
 The critical appraisal of the methodological quality of studies included in systematic 
reviews or meta-analysis is an essential feature (MOJA et al., 2005). The methodological 
quality can be considered a multidimensional concept, which could relate to the design, 
conduct, and analysis of a study, its clinical relevance, or quality of reporting (JÜNI, ALTMAN 
and EGGER, 2001). Defects in the methodological quality of studies may bias their results, and 
hence the results of meta-analyses where they were included (WOOD et al., 2008). 
Kjaergard and colleagues (2001) conducted a study to explore whether reported 
methodologic quality affects estimated intervention effects in RCTs and contributes to 
discrepancies between the results of large sized RCTs and small sized RCTs in meta-
analyses. The authors found that, compared with large RCTs, estimates of intervention 
benefits were exaggerated in small RCTs with inadequate allocation sequence generation, 
inadequate allocation concealment, and no double blinding (KJAERGARD, VILLUMSEN and 
GLUUD, 2001). Effect size estimates from large RCTs did not differ significantly from small 
RCTs with adequate generation of the allocation sequence, adequate allocation concealment, 
or adequate double blinding (KJAERGARD, VILLUMSEN and GLUUD, 2001). Moher and 
colleagues (1998) replicated 11 meta-analyses in order to explore the effects of quality on 
the quantitative results. The authors concluded that the interpretation of the benefit of an 
intervention from the results of a meta-analysis including low methodological quality studies 
can be altered (MOHER et al., 1998). However, other studies did not find a correlation 
between studies’ methodological quality and differences in estimated effect sizes (WOOD et 
al., 2008). 
 There are several instruments and checklists to assess the methodological quality of 
RCTs and non-randomized studies. The assessment of randomization process, concealment 
of allocation process, blinding of participants and outcomes assessment, patients’ withdrawal 
or selective outcome reporting are some of domains assessed by investigators regarding 
RCTs quality (JÜNI et al., 1999). Nevertheless, the number of items considered for evaluation 
from one instrument to another can vary significantly (JÜNI et al., 1999). The 
recommendations from the Cochrane Collaboration, or the scales of Jadad and colleagues 
(1996), Destky and colleagues (1992) or Chalmers and colleagues (1981) are examples of 
instruments frequently used to critically appraisal RCTs methodological quality. Deeks and 
colleagues (2003) conducted a review of methods and related evidence for evaluating bias in 
non-randomized studies. They identified 194 different instruments and scales used to assess 
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the methodological quality of non-randomized studies (DEEKS et al., 2003). The allocation 
process, the comparability of groups, and the adjustment of data for sociodemographic 
characteristics of patients, also called case-mix adjustment, are domains taken into 
consideration when assessing the methodological quality of non-randomized studies (DEEKS 
et al., 2003). The Downs and Black instrument (1998) and the Newcastle-Ottawa Scale 
(WELLS et al., 2014) are examples of instruments frequently used to assess the 
methodological quality of non-randomized studies.   
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I.5. META-ANALYSIS 
 
 Meta-analysis is defined as “the statistical analysis of a collection of analytic results for 
the purpose of integrating the finding” (BERLIN, CEPEDA and KIM, 2012). This involves the 
statistical combination of summary statistics from various studies but this technique can also 
combine raw data (EUROPEAN MEDICINES AGENCY, 2001). One should make a distinction 
between meta-analysis and systematic review. The term ‘meta-analysis’ should be restricted 
to the process of statistical synthesis. A systematic review comprises “the application of 
strategies that limit bias in the assembly and critical appraisal of all relevant studies on a 
specific topic” (CHALMERS and ALTMAN, 1995). A meta-analysis may be, but not necessarily, 
part of systematic review process.  
 There are a number of reasons to conduct a meta-analysis (EUROPEAN MEDICINES 
AGENCY, 2001): 
1) To provide a more precise estimate of the overall treatment effects; 
2) To evaluate whether overall positive results are also seen in pre-specified 
subgroups of patients; 
3) To evaluate an additional efficacy outcome that requires more power than the 
individual trials can provide; 
4) To evaluate safety in a subgroup of patients, or a rare AE in all patients; 
5) To improve the estimation of the dose-response relationship; 
6) To evaluate apparently conflicting study results. 
 
I.5.1. THE EVOLUTION OF RESEARCH SYNTHESIS AND META-ANALYSIS 
 
 An historical perspective on the evolution of research synthesis has been presented 
by Keith O’Rourke (2007) in a paper published in 2007. The study of Karl Pearson was one 
of the firsts to combine observations from different clinical studies (PEARSON, 1904). 
Published in 1904, this study was conducted to evaluate the effectiveness of typhoid vaccine, 
by comparing the infection and mortality rates among soldiers who have been inoculated 
with those who have not. Besides medical sciences, research synthesis was conducted 
addressing issues in other scientific fields, like astronomy and zoology (SUTTON, and HIGGINS, 
2008). 
 Despite initial research synthesis has been developed more than one century ago, 
their acceptance and frequent application took a while. Combine data from different studies 
Chapter I 
 
64 
and take conclusion on an investigational issue was frequently done throw narrative reviews 
(BORENSTEIN et al., 2009). Studies addressing a research question were reviewed by an 
expert in the field, who summarized the findings and discussed the results, and then reached 
a conclusion. However, since a narrative review is a subjective procedure by nature, this 
technique has been abandoned by researches. Systematic reviews and meta-analyses started 
to gain relevance due to the need for medical research and clinical practice to be based on 
the most robust scientific evidence (SUTTON, and HIGGINS, 2008). These techniques use a set 
of rules to search for studies, and then to determine which studies will be included or 
excluded from the analysis (BORENSTEIN et al., 2009). 
  The increasing number of research reports led investigators to develop methods to 
synthesize results from different studies (O’ROURKE, 2007). One of the first quantitative 
syntheses of identical studies concerning a common research issue was published in 1940 by 
JG Pratt and colleagues, which evaluated the more than 100 reports on extrasensory 
experiments (O’ROURKE, 2007). The term “meta-analysis” was coined by Gene V. Glass in 
1976 (1976), which he referred to “the statistical analysis of a large collection of analysis 
results from individual studies for the purpose of integrating the findings”. An editorial was 
anonymously published in The Lancet journal in 1980 reported a meta-analysis assessing 
whether aspirin could reduce the risk for myocardial infarction (ANONYMOUS, 1980; 
O’ROURKE, 2007). This meta-analysis was conducted by Archibald Cochrane and Peter 
Elwood due to doubts surrounding the beneficial effect of aspirin in cardioprotection 
(ELWOOD et al., 1974; O’ROURKE, 2007). Many meta-analyses have been published ever since, 
as well as books and papers on meta-analysis’ methodology (O’ROURKE, 2007).   
 Archibald Cochrane drew attention to the lack of organized critical summary of 
clinical evidence, by specialty, which could be updated periodically in order to support 
physicians to perform clinical judgments (VOLMINK et al., 2004). The UK’s National Perinatal 
Epidemiology Unit is a multidisciplinary research unit which was established at the University 
of Oxford in 1978. This working group conducted “methodologically rigorous research to 
provide evidence to improve the care provided to women and their families during 
pregnancy, childbirth, the newborn period and early childhood as well as promoting the 
effective use of resources by perinatal health services.” The investigators systematically 
reviewed RCTs in perinatal medicine, using meta-analysis when appropriate and possible, 
which resulted on a two-volume book “Effective Care in Pregnancy and Childbirth” and in a 
companion volume “Effective Care of the Newborn Infant” (STARR et al., 2009). The 
knowledge produced by this international collaboration led Michael Peckham, first Director 
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of Research & Development in the British National Health Service, to approve funding for 'a 
Cochrane Centre' "to facilitate the preparation of systematic reviews of RCTs of healthcare" 
(THE COCHRANE COLLABORATION, 2013a). In the following year, the Cochrane Collaboration 
was inaugurated in Oxford, England, as well as the firsts Cochrane Review Groups, aiming to 
collate and synthesize high-quality evidence on the effects of healthcare interventions which 
results could be consulted by a worldwide multi-disciplinary audience (SUTTON, and HIGGINS, 
2008). The contribution of the Cochrane Collaboration was recognized as leading to 
important methodological advances in the systematic reviews and meta-analyses field 
(GRIMSHAW, 2004). Additionally, the Cochrane Reviews were considered being of great 
quality (GRIMSHAW, 2004). In 2013, more than 31,000 dedicated people from over 120 
countries integrated the Cochrane Collaboration international network, with more than 
5000 Cochrane Reviews published online in the Cochrane Database of Systematic Reviews 
(THE COCHRANE COLLABORATION, 2013B).   
 
I.5.2. CLINICAL RELEVANCE OF CONDUCTING A META-ANALYSIS 
 
 Meta-analysis has been widely explored by investigators as a methodology to conduct 
clinical research (PATSOPOULOS, ANALATOS and IOANNIDIS, 2005). Investigators may have 
several interests to conduct a meta-analysis aiming to clarify a research question which may 
not be properly addressed with other study designs (BERLIN, CEPEDA and KIM, 2012). In 
several occasions, the study of rare AEs relies on pooled analysis. Meta-analysis may be a 
valuable tool when there is the need to explore inconsistencies across studies previously 
conducted, to evaluate subgroups of patients in whom an intervention may be more or less 
effective or to compare the efficacy and/or safety of several interventions.  
 By applying statistical methods and pooling an estimate of the effect size, meta-
analysis allows discussing the magnitude of the effect between the intervention being 
evaluated and the selected comparator (BORENSTEIN et al., 2009). Narrative reviews do not 
provide mechanisms to synthesise data and present a subjective evaluation of the selected 
studies (BORENSTEIN et al., 2009). 
 
I.5.3. A PROTOCOL TO CONDUCT A META-ANALYSIS 
 
 A meta-analysis should be conducted according to a prespecified protocol and the 
steps involved in the process should be clarified before starting the work (MOHER et al., 
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1999; MOHER et al., 2009; STROUP et al., 2000; EUROPEAN MEDICINES AGENCY, 2001). 
Guidelines have been developed to improve the quality of the reporting of meta-analyses. 
Investigators can find recommendations to report meta-analysis of randomised trials, like 
The Quality of Reporting of Meta-analyses (QUOROM) statement, lately updated by the 
Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) 
recommendations (MOHER et al., 1999; MOHER et al., 2009). The Meta-analysis Of 
Observational Studies in Epidemiology (MOOSE) guidelines have been developed to help 
reporting meta-analysis of observational studies (STROUP et al., 2000). These guidelines were 
also developed to help reviewers, editors, and readers to interpret meta-analyses. Defining a 
protocol based on such recommendations allows the replication of the meta-analysis. 
Generally, several points should be considered: 
1) Define precisely the objective of the meta-analysis and state the investigational 
hypothesis. 
2) Perform a literature search: 
The authors should report the search strategy with the keywords and the index 
terms, specify which databases were searched, report if hand searching or 
contact with authors were employed or not, if literature other than English was 
consulted, or if unpublished material was used.  
3) Establish the inclusion/exclusion criteria: 
Based on the initially established objective, the author should set of rules for 
including and excluding studies from the meta-analysis. These criteria are usually 
based on study design (e.g.: only RCTs, only observational studies or include 
both type), study populations (e.g.: elderly, pregnant, young patients, or establish 
age groups), different treatment dosages, or different studies’ duration. 
4) Describe the data collection process: 
Describe the methodology used to extract data from studies’ reports (e.g.: 
extraction by investigators in an independently fashion, extraction in duplicate) 
and the process used to confirm the data extracted. 
5) Statistical methods employed: 
The authors should describe the statistical methodology employed to conduct 
the meta-analysis. Which effect size was used (e.g.: OR, RR, Risk difference 
[RD]); which meta-analytic model was used (e.g.: fixed or random effects 
models) and the justification of whether the chosen models account for 
predictors of study results; describe if the association between two variables was 
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evaluated by means of a meta-regression (e.g: dose-response effect, age-severity 
of event); describe if cumulative meta-analysis was used to evaluate who results 
perform over time. The authors should also state which methods were used to 
evaluate between-study heterogeneity and the publication bias.  
6) Evaluate the consistency of the results: 
It is usual to describe a sensitivity analysis which allows evaluating the consistency 
of the results. For example, integrate data according different study designs, 
study durations, according different treatment doses or subpopulations. 
7) Formulate conclusions and recommendations according the results. 
 
I.5.4. EFFECT SIZE MEASURES 
 
 The effect size is the term used to refer to OR, RR or RD, which are common in 
meta-analyses that deal with medical interventions (BORENSTEIN et al., 2009). Different effect 
size measures are used depending on when there is a need to quantify a relationship 
between two variables or a difference between two groups must be calculated (BORENSTEIN 
et al., 2009). 
 According to Borenstein and colleagues (2009), there are some considerations that 
should drive the choice of an effect size. First, the effect size from different studies should be 
comparable to one another since they measure the same thing. Secondly, the estimate of the 
effect size should be computable from the information that is reported in the publish 
literature, as an article, and should not require the re-analysis of the raw data. Third, an 
effect size should have good technical properties, like knowing its sampling distribution in 
order to allow the estimation of its variance and confidence intervals. 
 Borenstein and colleagues (2009) also refer that most of the times the selected effect 
size is based on the kind of data that was reported in the primary studies. Table I.1 describes 
the more common effect sizes and the correspondent study designs. If the summary data 
reported in the primary studies are based on a binary outcome, such events and non-events 
in two groups, then the appropriate effect size to select it will be the relative risk (RR), the 
OR or the RD. These effect size measures can be calculated from 2 x 2 tables. If, instead, the 
summary data reported in the primary studies are based on means and standard deviations 
in two groups, it will be more appropriate to select the raw difference in means or the 
standardized mean difference. A correlation coefficient should be selected when a 
correlation between two variables is reported in primary data. There is also the option of 
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compute time-to-event outcomes, also called survival analysis (HIGGINS and GREEN, 2011). 
Time-to-event data arise when the interest is focused on the time elapsing before an event is 
experienced. The most appropriate way of summarizing time-to-event data is to use 
methods of survival analysis and express the intervention effect as a hazard ratio (HR) 
(HIGGINS and GREEN, 2011). The notion of risk and hazard is similar, but is subtly different in 
that it measures instantaneous risk and may change continuously (e.g.: the hazard of death 
changes as someone crosses a busy road) (HIGGINS and GREEN, 2011). Hazard ratio is 
interpreted similarly to RR, as it describes how many times more (or less) likely a participant 
is to suffer the event at a particular point in time if they receive the experimental rather than 
the control intervention. Hazard ratios are computed for each study and meta-analysis is 
used to integrate data from all studies (BORENSTEIN et al., 2009). 
        
Table I.1 - Most common effect size measures used in meta-analysis and their correspondent study designs 
(adapted from BORENSTEIN et al., 2009). 
Effect sizes based on means (continuous data) 
Raw (unstandardized) mean difference (D) 
Based on studies with independent groups 
Based on studies with matched groups or pre-post designs 
Standardized mean difference (d or g) 
Based on studies with independent groups 
Based on studies with matched groups or pre-post designs 
Effect sizes based on binary data 
Relative risk (RR) 
Based on studies with independent groups 
Odds ratio (OR) 
Based on studies with independent groups 
Risk difference (RD) 
Based on studies with independent groups 
Effect size based on correlational data 
Correlation (r) 
Based on studies with one group 
 
 
I.5.5. STATISTICAL ANALYSES 
 
I.5.5.1. Statistical models 
 
 Two models can be used to assess the way in which the variability of the results 
between the studies included in the meta-analysis is treated: the fixed effects model and the 
random effects model (PANESAR, SIOW and ATHANASIOU, 2010). 
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I.5.5.1.1. Fixed effects meta-analysis 
 
 Under the fixed effects model it is assumed that all studies in the meta-analysis share 
a common (true) effect size and that all differences in observed effects are due to sampling 
error (BORENSTEIN et al., 2009). In other words, if a meta-analysis of ORs is being conducted, 
it is assumed that all studies estimate the same OR (PANESAR, SIOW and ATHANASIOU, 2010). 
If each study had an infinite sample size the sampling error would be zero and the observed 
effect for each study would be the same as the true effect (BORENSTEIN et al., 2009). 
However, since the simple size of each study is not infinite, there is sampling error and the 
observed effect in the study is not the same as the true effect.  
 In the context of a fixed effects meta-analysis, each is assumed to be a random 
representative conducted on a homogeneous population of patients, assuming that each 
study is identical to one another (PANESAR, SIOW and ATHANASIOU, 2010). Thus, this model 
assumes that there is no statistical heterogeneity among the studies and the summary 
measure is a simple weighted average and can be interpreted as an estimate of a single 
population outcome measure (PANESAR, SIOW and ATHANASIOU, 2010). 
 In a fixed effects meta-analysis, the methods used to analyse binary outcome data are: 
the inverse variance-based method, the Mantel-Haenszel method, and the Peto’s method. 
The inverse variance-based method is so called because the weight attributed to each study 
is calculated as the inverse of the variance of the effect estimated, or the inverse of the 
square of its standard error (BORENSTEIN et al., 2009). Larger studies with smaller standard 
errors are given more weight than small sized studies with larger standard errors (PANESAR, 
SIOW and ATHANASIOU, 2010). The weighted average (estimated effect size) calculation based 
on the fixed effects model is given by: 
 
  
         
       
 
 
where Wi is 
 
   
 
   
 
 
    is the within-study variance for study i. 
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 For most purposes the inverse variance-based method is appropriate, but when 
studies have small sample sizes, or when events are rare, other methods can have better 
statistical properties (BORENSTEIN et al., 2009). When studies have large sample sizes, the 
variance estimation is close to the true variance of that study, as assumed by the inverse 
variance-based method. However, the variance may not be well estimated when studies are 
small or the events are rare (BORENSTEIN et al., 2009). The Mantel-Haenszel method uses a 
different weighting scheme based on which effect size measure is being used (e.g: RR, OR or 
RD) and not requiring variance to be estimated (BORENSTEIN et al., 2009). The Mantel-
Haenszel method has better statistical properties when there are few events and has 
become the default method for the fixed effects analysis (PANESAR, SIOW and ATHANASIOU, 
2010). The Mantel-Haenszel method was developed to combine OR across 2 x 2 tables and 
it has since been extended to combine RR or RD across 2 x 2 tables (BORENSTEIN et al., 
2009).   
 The Peto’s method, also called the one-step method, can only be used to pool ORs 
and is a variant of the inverse variance-based method (BORENSTEIN et al., 2009). This method 
uses an approximate method to estimate the log OR and uses different weights (PANESAR, 
SIOW and ATHANASIOU, 2010).  
 The inverse variance-based formula does not work well when one or more cells in 
the 2 x 2 table have a value of zero (BORENSTEIN et al., 2009). The approach is to add the 
value of 0.5 to all four cells. Both the Mantel-Haenszel and Peto’s methods are able to work 
with zero values and no adjustments are needed (BORENSTEIN et al., 2009). However, in the 
Peto’s method work better when one is aiming to pull data from studies with small 
treatment effects (OR close to 1), events are rare and the experimental and control groups 
have a similar number of participants (PANESAR, SIOW and ATHANASIOU, 2010). In other 
scenarios different than this, it has shown to give biased results. 
 The advantages and disadvantages of those methods have been pointed out (PANESAR, 
SIOW and ATHANASIOU, 2010). Peto’s method can produce biased results when there is a 
mismatch in the number of participants between the experimental and control groups. If the 
number of studies to be included is small but their simple sizes are large, then the inverse 
variance-based method is the most appropriate to be employed. If an opposite situation 
occurs, then the Mantel-Haenszel method should be chosen. It is recommended that a 
continuity correction should be used (add 0.5 to each cell of a 2 x 2 table) for sparse data, 
except when very little heterogeneity exists among studies. 
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I.5.5.1.2. Random effects meta-analysis 
 
 The previous described model of the fixed effects assumes that the true effect size is 
the same in all studies (BORENSTEIN et al., 2009). However, this assumption is not plausible 
for most of the systematic reviews and meta-analysis. One may assume that a group of 
studies have enough in common to be included in a meta-analysis, but there is generally no 
reason to assume that the true effect size is the same in all the studies (BORENSTEIN et al., 
2009). Despite studies may have addressed the same clinical question, they may differ in the 
demographic characteristics of the included participants and in the implementation of 
interventions (BORENSTEIN et al., 2009). In order to address these variations across the 
studies, a meta-analysis should be conducted under the random effects model (BORENSTEIN 
et al., 2009). The random effects meta-analysis assumes that each study estimates its own 
treatment effect, which follows a normal distribution (PANESAR, SIOW and ATHANASIOU, 
2010). 
 The DerSimonian and Laird random effects method incorporates the assumption that 
the different studies are estimating different but yet related treatment effects (PANESAR, 
SIOW and ATHANASIOU, 2010). This method is based on the inverse variance approach used 
in the fixed effects model. In the fixed effects model each study is weighted by the inverse of 
its variance (BORENSTEIN et al., 2009). In the random effects analysis too. However, the 
difference is that the variance now included the original (within-studies) variance plus the 
estimate of the between studies variance, T2 (BORENSTEIN et al., 2009). Under the random-
effects model, the weight assigned to each study is  
 
  
  
    
  
   
   
  
   
 
 
Where  
  is 
  
  
 
   
  
 
 When there is no heterogeneity among the studies (between studies variance = 0), 
the DerSimonian and Laird method and the inverse variance-based method on a fixed effects 
analysis will produce identical results (and thus also give results similar to the Mantel-
Haenszel method) (PANESAR, SIOW and ATHANASIOU, 2010). When heterogeneity is present 
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(between studies variance ≠ 0), the confidence intervals of the treatment effect estimate 
under the DerSimonian and Laird method will be wider when compared with an estimation 
under a fixed effects methods and, therefore, the claims of a statistical significance will be 
more conservative (PANESAR, SIOW and ATHANASIOU, 2010).  
 It is common the researchers to conduct sensitivity analyses in order to evaluate the 
robustness of the meta-analysis’ results. It is recommended that both fixed and random 
effects models should be used in such sensitivity analyses (PANESAR, SIOW and ATHANASIOU, 
2010). This gives a picture of the amount of between-studies variance (heterogeneity) 
influencing the results and helps investigators taking conclusions. 
 
I.5.6. CUMULATIVE META-ANALYSIS 
 
 Cumulative meta-analysis is performed by adding studies one by one, until all relevant 
studies have been included in the analysis (BORENSTEIN et al., 2009). Cumulative meta-analysis 
is not a different analytical method. It only displays the results the results into a sequence 
based on some factor and how the estimate of the effect size shifts as a function of such 
factor (BORENSTEIN et al., 2009). Cumulative meta-analysis is commonly used to displays the 
effect size estimate over time.  
 If conducted prospectively, cumulative meta-analyses can be updated every time a 
new study is published. If conducted based on study size, cumulative meta-analysis allow 
evaluating how small studies influence the overall result (PANESAR, SIOW and ATHANASIOU, 
2010). One should note that if the objective is to assess the relationship between a factor 
and the estimated effect size, then the most appropriate analysis is the meta-regression. 
 Figure I.6 displays a forest plot where it is shown the estimated RR and its 
correspondent 95% confidence interval (CI) of a cumulative meta-analysis of RCTs 
comparing rofecoxib with control (JÜNI et al., 2004). By 2000, an increased RR for 
myocardial infarction was already identified (RR 2,30; 1,22 - 4,33, p=0,01). Rofecoxib was 
withdrawn from market in 2004 due to cardiovascular adverse effects. 
  
 
 
General Introduction 
73 
 
Figure I.6 - Cumulative meta-analysis of randomised trials comparing rofecoxib with control (JÜNI et al., 
2004). 
 
 
I.5.7. META-REGRESSION 
 
 Regression can be used to assess a relationship between one or more covariates and 
a dependent variable (BORENSTEIN et al., 2009). This approach is essentially the same that is 
used in meta-analysis, except that the covariates are at the level of the study rather than the 
level of the subject, and the dependent variable is the effect size (e.g.: RR, OR or RD) in the 
studies rather than subject scores (BORENSTEIN et al., 2009). Using this procedure in meta-
analysis is called meta-regression. 
 Meta-regressions usually differ from simple regressions in two ways (HIGGINS and 
GREEN, 2011). First, studies with larger sample size have more influence on the relationship 
than small sample sized studies, since studies are weighted by the precision of their 
respective effect estimate (HIGGINS and GREEN, 2011). Second, there is a need to assign a 
weight to each study and to evaluate the existence of between-studies variance 
(heterogeneity) in order to select the most appropriate model (fixed versus random effects 
analysis) (BORENSTEIN et al., 2009). 
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 Meta-regression will return a coefficient which is interpreted in relation to an 
increase or a decrease in the effect size. Borenstein and colleagues give a simple example 
which will help to understand, using a meta-analysis and a meta-regression conducted by 
Colditz and colleagues (1994) and Berkey and colleagues (1995), respectively (BORENSTEIN et 
al., 2009). It is found a coefficient of -0,0292 for a meta-regression evaluating the association 
between a vaccine to prevent tuberculosis and latitude. The result means that everyone 
degree of latitude corresponds to a decrease of 0,0292 units in effect size.  
 Meta-regression has been used to evaluate the existence of heterogeneity between 
studies and how certain covariates could be responsible for excessive between-studies 
variance (BAKER et al., 2009). The meta-analysis used as an example by Borenstein and 
colleagues estimated a RR of 0,650, 95% CI 0,601 to 0,704. The I2 test for heterogeneity 
yielded a result of 92,12%, which is excessive. The studies included in the meta-analysis of 
Colditz and colleagues (1994) estimated RR ranging from 0,198 to 1,562. The meta-
regression allowed explaining how the efficacy of the vaccine depended on the latitude.  
 
I.5.8. HETEROGENEITY 
 
 Meta-analysis combines data across studies in order to achieve a summary effect size. 
The value of a meta-analysis increases when the results of the included studies show 
important effects of similar magnitude (HIGGINS et al., 2003). However, there are several 
issues in the process of integrating evidence from studies, in particular when they present 
conflicting results (HIGGINS et al., 2003; IOANNIDIS, 2008). In order to attempt assessing the 
consistency between the included studies, reports of meta-analyses commonly present a 
statistical test for heterogeneity (HIGGINS et al., 2003). The test for heterogeneity aims to 
determine whether the differences underlying the results of the studies are genuine 
(heterogeneity), or whether the differences in the findings are related with chance 
(homogeneity) (HIGGINS et al., 2003). The presence of heterogeneity can also be investigated 
using plots.  
 Heterogeneity may arise from differences in study designs, demographic 
characteristics of the included participants, administration mode, dosage or frequency of the 
interventions, duration of treatments, or methodological aspects specific to each study, as 
the outcomes assess procedure (IOANNIDIS, 2008; BORENSTEIN et al., 2009; EUROPEAN 
MEDICINES AGENCY, 2001; HIGGINS and GREEN, 2011).  
 
General Introduction 
75 
I.5.8.1. Statistical tests to investigate heterogeneity 
 
 Commonly used in meta-analysis, the Cochrane’ Q statistic test explores the 
existence of heterogeneity which may be considered significant or not based on a P-value 
(IOANNIDIS, 2008). Formally, a null hypothesis is formulated stating that all studies share a 
common effect size and then test this hypothesis (BORENSTEIN et al., 2009). Under the null 
hypothesis, the Q test follows a χ2 distribution with degrees of freedom to k-1, setting a P-
value for any observed value of Q (BORENSTEIN et al., 2009). It is usual to use a cut-off of 10% 
for significance, instead of 5%, due to the poor capacity of the Q test to detect true 
heterogeneity (HIGGINS et al., 2003). However a non-significant result may not be indicative 
of homogeneity (HIGGINS et al., 2003; BORENSTEIN et al., 2009). 
 The I2 statistic test offers a quantitative measure of the heterogeneity, by estimating 
the percentage of total variation across studies that is due to heterogeneity rather than 
chance (HIGGINS et al., 2003). It is computed as 
 
I2 = 
    
 
     
 
where Q is the χ2 statistic and df is its degrees of freedom. The value of the I2 statistic test 
ranges from 0 to 100%.   
 There is no formal categorization to classify the presence of heterogeneity as 
excessive or not (HIGGINS et al., 2003). Many authors consider statistical heterogeneity as 
low when 0% < I2 < 25%, moderate when 25% < I2 < 50% or high when I2 > 50%, although 
other considerations are accepted (HIGGINS and GREEN, 2011). 
 The I2 statistic test gives us an estimation of the excess of between-studies variance 
which may influence the meta-analysis’ results. However, it should be noted that this test is a 
descriptive statistic and not an estimate of any underlying quantity (BORENSTEIN et al., 2009).  
 It should be noted that the model used to conduct the meta-analysis should not be 
chosen based on the heterogeneity test (BORENSTEIN et al., 2009). In particular conducting 
two-stage meta-analysis, in which the meta-analytic model (fixed or random effects) is 
determined by the result of a statistical test. These strategies were found to be potentially 
misleading (HIGGINS et al., 2003). The meta-analytic model should be chosen based on the 
investigators’ understanding of whether all studies share similar methodological designs and 
common effect sizes (BORENSTEIN et al., 2009).   
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I.5.8.2. Visual investigation of heterogeneity 
  
I.5.8.2.1. L’Abbé plot 
 
 The L’Abbé plot is applicable to meta-analyses of studies with binary outcomes. The 
event rate in the intervention group (y-axis) is plotted against the event rate in the control 
group (x-axis) (FERRER, 1998). There is a central line indicating identical risks in each group 
(BAX et al., 2009). The L’Ábbé plot may also have a regression line indicating the meta-
analytic estimated size effect, usually represented by a dotted line (BAX et al., 2009). 
Sometimes, the dots representing each study can have sizes proportional to the study 
weights (BAX et al., 2009). If the intervention group has better results than the control 
group, the dots will be displayed under the central line. In the absence of heterogeneity, the 
dots will form a consistent band on the plot indicating a similar relationship from study to 
study (Figure I.7a). However, in the presence of heterogeneity, the dots may be substantially 
scattered (Figure I.7b). 
 
 
Figure I.7 - L’Abbé plots displaying the results of two meta-analyses, one suggesting lower evidence of 
between-studies heterogeneity (a) and other suggesting the existence of heterogeneity between the results of 
the studies (b) (FERRER, 1998).  
 
 
I.5.8.2.2. Galbraith plot 
  
 In the Galbraith plot, the y-axis will show the effect size divided by its standard error 
and the x-axis will show the inverse of the standard error (BAX et al., 2009). Like the L’Abbé 
plot, each study is represented by a single dot. A regression line representing the slope of 
the meta-analytic estimated size effect based on the fixed-effects model runs centrally (BAX 
a) b) 
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et al., 2009). Parallel to the regression line, two lines limit a 95% confidence interval in which 
most dots would be expected to fall (BAX et al., 2009). These two lines are separated by a 2-
standard deviation distance from the regression line. The distance between the dots and the 
regression line represents the extent in which each study contributes to the heterogeneity. 
Studies located outside the limits will be trials where the 95% confidence interval does not 
contain the pooled estimate and, therefore, may contribute to the excess of heterogeneity 
(BAX et al., 2009). In the absence of heterogeneity it is expected that all studies will fall inside 
the 95% confidence interval limit. Figure I.8 represents a Galbraith plot where several points 
are located outside the limits, representing studies that may contribute to excessive 
heterogeneity. 
 
 
Figure I.8 - Galbraith plot (BAX et al., 2009). 
 
 
I.5.9. PUBLICATION BIAS 
 
 Publication bias occurs when the studies selected to be included in a meta-analysis or 
systematic review do not represent all studies on the topic of interest (MACASKILL, WALTER 
and IRWIG, 2001). If the studies are a biased sample of the existent evidence, then the 
estimated effect sized will reflect this bias (BORENSTEIN et al., 2009). Theoretically, the 
literature search conducted would be able to identify all the relevant studies addressing the 
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same research issue. However, this may not be possible and even with existing electronic 
search tools some studies fitting the inclusion criteria may escape (BORENSTEIN et al., 2009). 
Moreover, studies with statistically significant positive results are more likely to be 
highlighted and easily published (MACASKILL, WALTER and IRWIG, 2001). This may induce bias 
in publish literature and subsequently induce bias in systematic reviews and meta-analysis 
(BORENSTEIN et al., 2009). Other sources of bias that can affect effect sizes estimates in meta-
analysis are the inclusion of studies written in specific languages or the search of a particular 
type databases or journals (BORENSTEIN et al., 2009). Herein is described some tools which 
help researchers to evaluate the presence of publication bias in meta-analysis. 
 
I.5.9.1. Funnel plot 
 
 The visual inspection of a funnel plot is one of the most common methods used to 
detect publication bias. The funnel plot is plotted with effect size on the X axis and the 
sample size or variance (or standard error) on the Y axis (BORENSTEIN et al., 2009; 
MACASKILL, WALTER and IRWIG, 2001). The plot is expected to take a shape of a funnel in the 
absence of publication bias, with the amount of scatter about the true effect (a vertical line 
of symmetry) decreasing with increasing sample size or, if this is the case, with decreasing of 
standard error (MACASKILL, WALTER and IRWIG, 2001). Large studies appear located toward 
the top of the graph and generally near the line representing the mean effect size 
(BORENSTEIN et al., 2009). Smaller studies tend to appear in the bottom of the graph and are 
usually spread across a broad range of values (BORENSTEIN et al., 2009). Figure I.9 represents 
two funnel plots of different meta-analyses, one where publication bias was not detected 
(Figure I.9a) and other funnel plot suggesting the presence of publication bias (Figure I.9b) 
(MACASKILL, WALTER and IRWIG, 2001).  
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Figure I.9 - Funnel plots based on simulation of meta-analyses, one where publication bias was not detected 
(a) and other where publication bias was present (b) (MACASKILL, WALTER AND IRWIG, 2001). 
 
 
 Since the interpretation of funnel plots is subjective, other tests have been suggested 
to test the presence of publication bias (BORENSTEIN et al., 2009). 
 
I.5.9.2. Begg and Mazumdar rank correlation test 
 
 The Begg and Mazumdar rank correlation test assesses the significance of the 
correlation between the effect size estimates and the meta-analysis weights (DEEKS, 
MACASKILL and IRWIG, 2005). The test involves standardizing the effect size estimates to 
stabilize the variances (dividing each estimate by the standard errors) and performing an 
adjusted rank correlation test based on Kendall’s tau (DEEKS, MACASKILL and IRWIG, 2005). 
However, this test has shown to have low power when the meta-analysis includes few 
studies.   
 
I.5.9.3. Egger regression test 
 
 One of the most used tests to evaluate the presence of publication bias is the Egger 
regression test. The Egger regression test assesses the funnel plot asymmetry based on a 
regression of the standardized effect size estimates and a precision estimate (standard 
error), testing whether the intercept deviates from zero (DEEKS, MACASKILL and IRWIG, 
2005). As an example, when outcomes are dichotomous, and intervention effects are 
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expressed as ORs, this approach corresponds to a linear regression of the log OR on its 
standard error, weighted by the inverse of the variance of the log OR (HIGGINS and GREEN, 
2011). When no publication bias is present, the intercept will pass through the origin 
(expected value of zero) and the slope will be an unbiased estimate of the true (underlying) 
effect (MACASKILL, WALTER and IRWIG, 2001). On the other hand, if publication bias is 
present, the fitted line will not pass through the origin (MACASKILL, WALTER and IRWIG, 
2001). The size of the intercept is taken as the basis of a test for publication bias. Figure I.10 
presents the results of the Egger regression test, in the presence (Figure I.10a) and in the 
absence (Figure I.10b) of publication bias, respectively. 
 
 
 
Figure I.10 - Plots showing Egger’s regression test results, one where publication bias was not detected (a) 
and other where publication bias was present (b) (MACASKILL, WALTER and IRWIG, 2001). 
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I.6. THE POSTMARKETING DRUG RISK ASSESSMENT 
 
I.6.1. THE BENEFIT-RISK ASSESSMENT PROCESS 
 
 The benefit-risk ratio assessment can be defined as the consideration of whether a 
drug, when prescribed or indicated to treat a specific condition, is worth the risk to the 
patient as compared with possible benefits. The benefit-risk ratio is evaluated in the context 
of two dimensions (CURTIN and SCHULZ, 2011). The dimension of benefits is measure in 
terms of clinical efficacy, which is the successful treatment of prevention of the condition for 
which the drug is being indicated or the improvement of the patients’ quality of life. The 
observed ADRs and potential risk for unanticipated ADRs consist in the dimension of the 
risk. To receive market authorisation, a drug is evaluated on the basis of scientific criteria of 
quality, safety and efficacy for its intended use (US FOOD AND DRUG ADMINISTRATION, 2013). 
The assessment of the benefit-risk relation should be based on the available RCTs designed 
to determine the efficacy and safety of the drug when used in the intended therapeutic 
indication (EUROPEAN MEDICINES AGENCY, 2007). Since all drugs have the ability to cause 
adverse effects, a drug is considered “safe” if its benefits outweigh its risks (US FOOD AND 
DRUG ADMINISTRATION, 2013). 
 The assessment of a drug’s benefit-risk ratio by a regulatory authority is essentially a 
qualitative procedure and relies heavily on expert panels committees’ opinions (CURTIN and 
SCHULZ, 2011). However, the information about the drug can be somehow limited and may 
not address all relevant questions, introducing uncertainties in the decision-making process 
(US FOOD AND DRUG ADMINISTRATION, 2013). Two experts may agree on the evidence 
supporting the efficacy of a certain drug, they may have different opinions regarding the 
safety profile; one expert may say it is worthwhile to have the drug in market while other 
may just recognize its value where other drugs have failed. The subjectivity of the benefit-
risk ratio assessment process takes into account the severity of the condition being treated, 
the population being treated, the effectiveness of the available treatments, the nature and 
severity of a specific AE as well as other factors (US FOOD AND DRUG ADMINISTRATION, 
2013; MADRE et al., 2006; DAL PAN and ARLETT, 2012). No method proves fully satisfactory 
solution regarding the benefit-risk ratio assessment, since it is difficult to reduce a 
multidimensional procedure to straightforward decisions (CURTIN and SCHULZ, 2011). The 
FDA and EMA do not use quantitative tools to conduct benefit-risk ratio assessments. Both 
agencies produced guidance for assessors in order to promote the transparency of the 
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decision process (US FOOD AND DRUG ADMINISTRATION, 2013; EUROPEAN MEDICINES AGENCY, 
2007). However, the need to further research in methodologies for quantitatively assess 
medical interventions benefit-risk ratio has been recognized (EUROPEAN MEDICINES AGENCY, 
2007). 
 The benefit-risk ratio assessment is a continuing procedure, starting during the drug’s 
preclinical development and continuing during the marketing period. Results from animal 
models determine if a drug is candidate to be administered in humans to continue further 
clinical evaluation (CURTIN and SCHULZ, 2011). The dynamic nature of this process is due to 
new findings that can arise in every phase of drug life cycle. Unknown adverse reactions can 
lead drugs withdrawal from market. FDA withdrawn natalizumab in 2005 after being 
associated with progressive multifocal leukoencephalopathy (CURTIN and SCHULZ, 2011). 
However, is was remarketed in 2006 since it was recognized that natalizumab improved 
multiple sclerosis patients’ quality of life and was more effective than the therapeutic 
alternatives approved at that time (US FOOD AND DRUG ADMINISTRATION, 2013). 
Thalidomide was also relauched to treat multiple myeloma and erythema nodosum leprosum 
(CURTIN and SCHULZ, 2011). 
 The removal of a drug from market after being associated with a rare and serious 
ADR has a major impact in society, since patients have become exposed to such risk. 
Therefore, on the interest of the public health, regulatory science has a critical role in the 
management of drug risk assessment during the postmarketing phase of a drug.  
  
I.6.2. THE ASSESSMENT OF RISK DURING THE DRUGS’ POSTMARKETING PHASE 
 
 During the clinical development phase, no more than hundreds or few thousands of 
patients are exposed to a drug. After receiving a market authorisation, a larger and more 
varied population will receive the medication (STAFFA and DAL PAN, 2012). The knowledge 
about the benefit-risk ratio of a drug increases with the everyday practice, since unknown 
rare and/or long-latency ADRs may occur after prolonged use, as well as those occurring in 
patients with comorbidities and interactions with other co-prescribed medicines (MADRE et 
al., 2006). This additional knowledge of drugs’ safety profile is subject of carefully evaluation 
by regulatory authorities. 
 The postmarket drug risk assessment can be segmented in three stages: the evidence 
generation, the evidence interpretation and integration, and the decision-making process 
(Figure I.11) (HAMMAD et al., 2013). Safety signals can be generated from more than one 
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evidence source, like spontaneously reported ADRs, RCTs, observational studies or meta-
analyses (LESTER et al., 2013). Each source of evidence is then assessed as its methodological 
quality. Regulatory authorities may require further studies to be conducted in order to 
clarify the potential risks of harm hypothesized by the safety signal.  
 
 
Figure I.11 - Dimensions of postmarket drug safety assessment (HAMMAD et al., 2013). 
 
 
 The second dimension involves weighting the contribution of each data source which 
supports the safety signal and to assess the level of residual uncertainty concerning the risks 
at the time of evaluation. For this, the causal association between the AE and the suspected 
drug should be assessed. The Bradford Hill’s criteria, decisional algorithms and guidelines to 
rate evidence may be consulted by regulatory authorities in order to better interpret the 
available evidence (HILL, 1965; GUYATT et al., 2008). Hierarchize the evidence based on the 
study design may be helpful (MADRE et al., 2006). Descriptive studies, such case reports, case 
series and uncontrolled cohorts, limit the inferences that are made about causality since they 
are mainly used as hypothesis generating. By including a comparator group, analytic studies 
like RCTs, cohort or case-control, allow confirming research hypotheses and are placed in 
higher levels of evidence hierarchy scales (MADRE et al., 2006; STROM, 2012). The amount and 
diversity of data sources available depends on the nature of the harm being evaluated, as well 
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as on the specific demographic characteristics of the population receiving treatment. Serious 
and rare AEs with acute onset are more likely to be spontaneously reported, an example 
being rhabdomyolysis associated with cerivastatin (CHANG et al., 2004). In fact, since 
rhabdomyolysis is a rare event, spontaneously reported cases were the only data evidence 
on this drug-adverse effect pair (STAFFA, CHANG and GREEN, 2002). The risk for long-latency 
AE is better reflected in longitudinal, observational epidemiologic studies, as it was for bone 
fractures and proton pump inhibitors (YANG et al., 2006; TARGOWNIK et al., 2008).  
 The decision taken by the regulatory authority addressing the safety issue is 
considered the third dimension. The regulatory action is taken considering the entire 
benefit-risk relation of the drug and not only the new knowledge about the safety profile. 
The therapeutic position of the drug in relation to other therapeutic alternatives, the 
severity of the condition for which the drug is being indicated and the potential impact of the 
risk minimization strategies are taken into account in this stage (HAMMAD et al., 2013). 
 The need for improvement in the regulatory science has been subject of debate. The 
Innovative Medicines Initiative has several projects ongoing aim to enhance the safety 
monitoring of drug to better support benefit-risk ratio evaluations (GOLDMAN, 2012). Since 
the evidence on safety issues can be generated from a diversity of sources, methods to 
integrate multiple studies continue to be developed (HAMMAD et al., 2013).  
 
I.6.3. COMBINE EVIDENCE ON HARMS FROM DIFFERENT DATA SOURCES 
 
 The decision-making process requires the best evidence on benefits and harms about 
an intervention. The methodological quality of clinical development programmes have 
improved over the last years (VANDENBROUCKE, 2004; SCHULZ et al., 2010). At the time to 
grant a license to a drug, regulatory authorities are in possession of a considerable volume of 
knowledge about its benefit-risk profile. Nonetheless, most evidence on harms from a 
medical intervention is obtained from observational research since it reaches the market 
(VANDENBROUCKE, 2006). 
 Clinical trials are considered to provide the strongest evidence of efficacy regarding 
an intervention (LESKO and MITCHELL, 2012; PAPANIKOLAOU, CHRISTIDI and IOANNIDIS, 2006). 
The random assignment allows having comparable groups of patients and the applying 
statistics to explore data on the basis of random sampling (VANDENBROUCKE, 2004). This 
provides better control against bias than other study designs. The sample size of a RCT is 
powered to test differences between groups regarding an efficacy outcome. However, most 
General Introduction 
85 
of RCTs are too small and don’t have enough follow-up time to detect AEs that fewer than 
about one per 200/year or taking longer than one or two year to develop (VANDENBROUCKE, 
2004). Yet, RCTs provide accurate information on the most common and acute AEs (LESKO 
and MITCHELL, 2012; VANDENBROUCKE and PSATY, 2008).    
 To evaluate rare and long-term AEs, longitudinal comparative observational studies 
such case-controls and population based cohorts are needed (STROM 2006; PAPANIKOLAOU, 
CHRISTIDI and IOANNIDIS, 2006; VANDENBROUCKE, 2006). Large-scale observational studies 
may be devoted to study specific AEs, unlike RCTs which may report fragmented pieces of 
evidence on harms which may deserve further investigation (PAPANIKOLAOU, CHRISTIDI and 
IOANNIDIS, 2006). The strict inclusion/exclusion criteria of RCTs usually exclude subgroups 
of patients, such as pregnant women, children, or elderly patients with or without 
comorbidities (MADRE et al., 2006). Once in the market, observational studies are the most 
appropriate ones to study the medicines’ safety profile since they may reflect better the 
nature and the frequency of AEs experienced by patients in clinical practice. 
 The decision-making process, whenever a physician intends to prescribe a drug in his 
clinical daily practice or when a regulatory authority decides to carry out a benefit-risk ratio 
assessment process, should combine information on the best evidence of benefits and harms 
(VANDENBROUCKE and PSATY, 2008). Clinical trials may constitute the most authoritative 
source of evidence for benefits. To evaluate safety issues, however, it is suggested that both 
experimental and observational evidence should be considered (VANDENBROUCKE and PSATY, 
2008; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY, 2014). Agency for Healthcare 
Research and Quality guidance on Effectiveness and Comparative Effectiveness Reviews 
recommends investigators to include both RCTs and observational studies aiming to assess 
harms when comparing medical interventions (AGENCY FOR HEALTHCARE RESEARCH AND 
QUALITY, 2014). Cochrane Handbook for Systematic Reviews of Interventions refers to the 
inclusion of nonrandomized and randomized trials when assessing adverse effects. It is 
strongly recommended investigators should make any attempt to combine evidence from 
experimental and observational data. A study conducted to assess how information about 
AEs is included in systematic reviews found that most of Cochrane reviews rely only on data 
from RCTs (HOPEWELL, WOLFENDEN and CLARKE, 2008). 
   Incorporate data on AEs from different sources in a systematic review process is 
challenging and requires proper assessment of their internal validity and possible sources of 
heterogeneity, as well as the necessary methods of analysis (CHOU and HELFAND, 2005).  
Such methodological issues are extended to meta-analysis when this methodology is 
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considered to integrate data from both experimental and observational studies. Criteria on 
how meta-analysis technique could be used to combine available information from both 
RCTs and observational studies in order to evaluate safety issues has been debated 
(COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES, 2013).  
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I.7. OBJECTIVES OF THIS THESIS 
  
 The meta-analytic technique can be useful as a Pharmacovigilance method to 
systematically evaluate emerging data on pharmacological interventions’ safety profile during 
their development, licensing and subsequent launch onto the healthcare market. Therefore, 
the primary objective of this project is to identify the role of meta-analysis as a 
Pharmacovigilance approach and to evaluate how best to combine safety information from 
both experimental and observational studies through this statistical technique.   
 
The specific objectives outlined for this project were the following: 
 
1) To perform a systematic review aiming at identifying meta-analyses from both 
experimental and observational studies where safety was found to be a primary 
outcome measure.  
 
2) To conduct a meta-analyses aiming at evaluating the risk of a frequent adverse event 
by pooling data from RCTs, and to explore the between-studies heterogeneity. 
 
3) To conduct a meta-analyses aiming at evaluating the risk of a rare adverse event by 
pooling data from both experimental and observational studies, and to explore the 
between studies heterogeneity. 
 
4) To identify the data sources supporting benefit/risk ratio reevaluations conducted by 
regulatory authorities on safety issues. 
 
5) To evaluate how risk estimates generated from cumulative meta-analysis performs 
over time for drugs having their benefit/risk ratio reevaluated due to safety issues 
and, additionally, compare the risk estimates with regulatory authorities’ conclusions. 
 
 To fullfil point 1), the study entitled “Data sources on drug safety evaluation: a review 
of recent published meta-analyses” was conducted (ALVES, BATEL MARQUES AND MACEDO, 
2012a); to fullfil point 2), the study entitled “Apixaban and Rivaroxaban Safety After Hip and 
Knee Arthroplasty: A Meta-Analysis” was conducted (ALVES, BATEL MARQUES AND MACEDO, 
2012b); to fullfil point 3), the study entitled “A meta-analysis of serious adverse events 
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reported with exenatide and liraglutide: Acute pancreatitis and cancer” was conducted 
(ALVES, BATEL MARQUES AND MACEDO, 2012c); to fullfil point 4), the study entitled “Sources 
of information used by regulatory agencies on the generation of drug safety alerts” was 
conducted (ALVES, MACEDO AND BATEL MARQUES, 2013); to fullfil point 5), the study entitled 
“Drug-safety alerts issued by regulatory authorities: usefulness of meta-analysis in predicting 
risks earlier” was conducted (ALVES, BATEL MARQUES AND MACEDO, 2014). 
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II. DATA SOURCES ON DRUG SAFETY EVALUATION: A REVIEW OF RECENT 
PUBLISHED META-ANALYSES  
 
II.1. ABSTRACT 
  
 Meta-analysis is a quantitative approach to summarize the findings from several 
studies and has been applied with increasing frequency to RCTs. Because of their sample size 
and duration limitations, experimental studies could not be able to detect late or rare AEs, 
which may be identified in well-designed observational studies. This study aims to identify 
and analyze meta-analyses from both experimental and observational studies where safety 
was found to be an outcome measure. The meta-analyses inclusion criteria was established 
as at least one AE as primary outcome. Safety outcomes were considered as the increase in 
the risk for an AE after a pharmacological intervention. A MEDLINE search for meta-
analyses published in the New England Journal of Medicine, The Lancet, Journal of American 
Medical Association, British Medical Journal, Annals of Internal Medicine, PLoS Medicine, 
Annual Review of Medicine, and Archives of Internal Medicine, between October 2005 and 
September 2010, was carried out. Sixty meta-analyses met the inclusion criteria. Of these, 53 
included only experimental studies, 4 included both experimental and observational studies, 
and 2 included only observational studies. Of the 6 meta-analyses that included observational 
studies, 4 included cohort and case–control studies, and 2 included cohort, case-control, and 
cross-sectional studies. One meta-analysis did not report the type of studies included. 
Experimental studies were found to be the main source of meta-analyses on drug safety. The 
role of meta-analyses in pharmacovigilance is a matter of ongoing debate, and efforts are 
being made to develop guidelines on the use of meta-analysis in drug safety assessments, to 
better combine evidence about harms. 
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II.2. INTRODUCTION 
 
 Medicine use is a fundamental component of health care, and the optimization of drug 
prescribing has become an important public health problem worldwide (BATES, 1995; AKICI 
and OKTA, 2007). It is now becoming clear that, to assess the overall effect of medical 
interventions, adverse effects should be reviewed with similar rigour as therapeutic benefits 
(HOPEWELL, WOLFENDEN and CLARKE, 2008; CANONICO et al., 2008; HICKS et al., 2008). 
 Meta-analysis is a systematic approach to identify, synthesize, and combine the results 
of selected studies (DERSIMONIAN and LAIRD, 1986; KIM and BERLIN, 2006). It is used to 
identify sources of variation among study findings and to provide an overall measure of effect 
to reach conclusions about a body of research. The meta-analytic technique has been applied 
with increasing frequency to RCTs, which are considered to provide the strongest evidence 
of efficacy regarding an intervention (STROM, 2006; VANDENBROUCKE, 2004a). This is due to 
the fact that randomized controlled designs have better control and protection against bias 
than other study designs. 
 However, evidence on AEs reported by RCTs can be considered insufficient at some 
point (VANDENBROUCKE and PSATY, 2008; IOANNIDIS et al., 2004). Clinical trials are able to 
identify the most frequent and common AEs that occurred during the intervention 
administration (MADRE et al., 2006). However, given the relatively small sample size, their 
average duration, and the homogeneity of the studied population, RCTs are less likely to 
detect rare or long-term AEs (IOANNIDIS and LAU, 2001; VANDENBROUCKE, 2004b). 
 Data from observational studies can be helpful to evaluate the safety of an 
intervention (LOKE, DERRY and ARONSON, 2004). In some situations, the best evidence 
regarding the safety of minority or underrepresented populations in RCTs, such as pregnant 
women, children, and elderly patients with or without comorbidities, is provided from 
observational studies (MADRE et al., 2006; ROTHWELL, 2005). The observational designs may 
reflect better the nature and the frequency of AEs experienced by patients in clinical 
practice, especially rare or late AEs (PAPANIKOLAOU, CHRISTIDI and IOANNIDIS, 2006). 
 The investigation of uncommon or long-term AEs associated with pharmacological 
interventions is an important application of meta-analysis. The use of meta-analysis to 
integrate data from different study designs can be affected by inherent biases of the 
considered studies (KIM and BERLIN, 2006). This study aims to identify and analyze meta-
analyses from both experimental and observational studies where safety was found to be an 
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outcome measure in the highest ranked general/internal medicine journals, which are more 
likely to influence clinicians’ perceptions on medicines benefit/risk ratios. 
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II.3. METHODS 
  
 An electronic search was carried out in MEDLINE to identify all the meta-analyses 
published over a period of 5 years (October 2005 to September 2010) in the New England 
Journal of Medicine, The Lancet, Journal of American Medical Association (JAMA), British 
Medical Journal (BMJ), Annals of Internal Medicine, PLoS Medicine, Annual Review of 
Medicine, and Archives of Internal Medicine. These journals were selected according to their 
impact factor. They are the eight higher ranked journals in the category of “general and/or 
internal medicine”, according to the Science Citation Index (THOMPSON REUTERS, 2014). 
Search was limited to meta-analyses. The search strategy is listed in the Supplemental Data 
1I.1. 
 Two researchers independently screened by hand the titles and abstracts and 
selected full papers for inclusion. Discrepancies were resolved by consensus involving a third 
investigator. Meta-analyses were included if they meet the following inclusion criteria: (i) to 
assess the risk for the occurrence of at least one AE related to a pharmacological 
intervention as a primary outcome; and (ii) to pool the results using the meta-analytic 
technique. Meta-analyses combining study summary results and meta-analyses combining 
individual patient data were eligible for inclusion. We considered drugs or medical devices 
eluting drugs as pharmacological interventions. An AE is de fined as “any untoward medical 
occurrence in a patient or clinical investigation subject administered a pharmaceutical 
product and which does not necessarily have to have a causal relationship with this 
treatment” (EUROPEAN MEDICINES AGENCY, 1995). For the purpose of the study, safety 
outcomes were considered as the increase in the risk for at least one AE after a 
pharmacological intervention. Therefore, we restricted the study to meta-analysis of 
increased risk for an AE because when an AE is lower on treatment than on control, which 
is still an AE but also may constitute an efficacy end-point. Meta-analyses that evaluated 
efficacy outcomes besides safety out-comes were included if the risk for the occurrence of 
any AE was a primary outcome. 
 The following information from each meta-analysis was extracted: (i) nature of the 
intervention; (ii) outcomes assessed – one specific or several; (iii) resources searched and if 
the search strategy was reported or not; (iv) type of meta-analysis design – safety and/or 
efficacy; (v) type of studies included and their publication status; (vi) assessment of 
publication bias; (vii) methodological quality assessment of the included studies; and (viii) use 
of meta-analysis reporting guidelines. Additionally, for meta-analyses that included both 
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experimental and observational studies, we evaluated if the pooled results were different 
and, if so, in which direction.  
 Meta-analyses that evaluated the same clinical question were analyzed. Two meta-
analyses were considered to be evaluating the same clinical question when, for a common 
study aim, they assessed the same safety out-come for the same pharmacological 
intervention. For those meta-analyses, we extracted information on the following: 
pharmacological intervention(s) assessed, common outcome(s) evaluated, type of studies 
included as data sources, and statistical analysis method used. The results of meta-analysis 
assessing the same clinical question were described and, if different, in which direction. 
Differences in the choice of the meta-analytic method between meta-analyses, which 
evaluated the same clinical question, were presented. 
 The pharmacological interventions were coded according to Anatomical Therapeutic 
Chemical (ATC) classification system, second-level therapeutic subgroup (WHO 
COLLABORATION CENTRE FOR DRUG STATISTICS METHODOLOGY, 2014). The AEs, which were 
established as meta-analyses’ primary outcomes were classified according to the Medical 
Dictionary for Regulatory Activities (MedDRA), high-level group term (HLGT) (MEDICAL 
DICTIONARY FOR REGULATORY ACTIVITIES, 2011). 
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II.4. RESULTS 
 
 The initial search yielded 459 citations. Twenty-one articles were excluded because 
they were not meta-analyses, resulting in 438 full papers identified as “possibly eligible” for 
inclusion. After reviewing the full publication, 60 meta-analyses were included in the study 
(Figure II.1) (Supplemental Data II.2). 
 
 
Figure II.1 - Flow diagram of identification of meta-analyses for inclusion. 
 
 
  
 Of the 60 included meta-analyses, 15 (25%) were published in the JAMA, 13 (22%) in 
The Lancet, 12 (20%) in the BMJ, 10 (17%) in the Archives of Internal Medicine, 6 (10%) in 
the Annals of Internal Medicine, 2 (3%) in the New England Journal of Medicine, and another 
 438 full papers eligible for 
inclusion  
21 excluded articles which were not 
meta-analyses 
  
 378 articles excluded for not meeting inclusion 
criteria: 
140 AE is not a primary outcome 
229 Not a pharmacological intervention 
9 Safety results not pooled using meta-analytic 
assessment 
60 Meta-analyses analysed: 
15 from JAMA 
13 from Lancet 
12 from BMJ 
10 from Arch Intern Med 
6 from Ann Intern Med 
2 from N Engl J Med 
2 from PLoS Med 
459 potentially relevant 
citations 
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2 (3%) in the PLoS Medicine. We did not identify any meta-analysis published in the Annual 
Review of Medicine throughout the studied period.  
 Meta-analyses were mainly directed toward evaluation of pre-specified adverse 
outcomes of interest (n=48; 80%). Twelve (20%) meta-analyses assessed the whole spectrum 
of AEs. Of the 60 included studies, 3 (5%) assessed the AEs associated with medical devices 
eluting drugs. The pharmacological intervention classification according to therapeutic 
subgroup of the ATC code is presented in Figure II.2. The most frequently assessed 
pharmacological interventions were “antithrombotic agents” (n=10) and “drugs used in 
diabetes” (n=10). The AEs of antihypertensive agents, such as “agents acting on the renin-
angiotensin system” (n=5), “beta blocking agents” (n=4), “calcium channel blockers” (n=2), 
and “diuretics” (n=2), also were assessed. One meta-analysis simultaneously assessed AEs of 
three different pharmacological interventions. 
 The classification of pre-specified AEs (primary outcome) established according to 
HLGT MedDRA dictionary is presented in Figure II.3 (48 meta-analyses). The most 
frequently evaluated AE was “fatal outcomes” (n=20), such as all-cause death outcomes. 
“Coronary artery disorders”, such as myocardial infarction, were the second most 
frequently evaluated AE (n=14). Risk for occurrence of “coagulopathies and bleeding 
diathesis (excl thrombocytopenic)”, such as bleeding events, and the “embolism and 
thrombosis”, such as stroke or venous thromboembolism, were evaluated by nine meta-
analyses. Some meta-analyses evaluated more than one specific AE as primary outcome. 
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Figure II.2 - Pharmacological interventions classification according to therapeutic subgroup (2nd level) 
of the ATC code. 
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Figure II.3 - Meta-analyses adverse events’ primary outcome(s) classification according to the 
MedDRA dictionary, High Level Group Term (HLGT). 
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II.4.1. EVALUATION OF THE SAME CLINICAL QUESTIONS 
 
 Some meta-analyses addressed the same clinical question. In Table II.1, research 
questions and studied interventions are presented. According to the results, nine clinical 
questions were evaluated by more than one meta-analysis. All but one meta-analysis included 
RCTs. Four meta-analysis studied cardiovascular risk associated with rosiglitazone (all 
RCTs), two studied major bleeding associated with antithrombotic agents (all RCTs), four 
studied death from all causes associated with erythropoiesis-stimulating agents (all RCTs), 
three studied death from all causes associated with drug-eluting stents with sirolimus (all 
RCTs), two studied myocardial infarction associated with non-steroid anti-inflammatory 
drugs (on included RCTs and other observational studies) , two studied suicidal behavior 
associated with antidepressants (all RCTs), and two studied pneumonia associated with 
inhaled corticosteroids (all RCTs). 
 
II.4.1.1. Statistical meta-analytic methods 
 
 We compared the statistical methodology for meta-analyses, which addressed the 
same clinical question. To prevent biased analysis, the majority of meta-analyses compared 
the results obtained from two meta-analytic methodologies (random or fixed effects 
models). Not all the meta-analyses, which evaluated the same clinical question, used the 
same meta-analytic methods. The meta-analytic methodology choice was discussed in all 
meta-analyses. 
 For the majority of the meta-analyses, the choice between a fixed effects model and a 
random effects model was based on the presence of heterogeneity. When between-study 
heterogeneity was not observed, the authors used a fixed effects model. 
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Table II.1 - Same clinical questions evaluated by different meta-analyses. 
Study Clinical question Intervention Common 
outcome 
evaluated 
Studies 
included 
Statistical 
analysis 
A10 – Drugs used in diabetes 
NISSEN and 
WOLSKI, 200729 
“...assess the effects of 
rosiglitazone on cardiovascular 
outcomes...” 
Rosiglitazone Myocardial infarction; 
cardiovascular 
mortality; all-cause 
death 
RCTs Peto OR 
 
SINGH et al, 
20077 
“...review the long-term 
cardiovascular risks of 
rosiglitazone...” 
Rosiglitazone Myocardial infarction; 
cardiovascular 
mortality 
RCTs Fixed-effects 
RR; 
Random-
effects RR 
LAGO et al, 
200723 
“...examine the risk of 
congestive heart failure and of 
cardiac death in patients given 
TZDs.” 
Pioglitazone; 
Rosiglitazone 
Cardiovascular 
mortality 
RCTs Fixed-effects 
RR; 
Random-
effects RR 
NISSEN and 
WOLSKI, 201031 
“...review the effects of 
rosiglitazone therapy on MI and 
mortality (CV and all-cause)” 
Rosiglitazone Myocardial infarction; 
cardiovascular 
mortality; all-cause 
death 
RCTs Peto OR; 
Fixed-effects 
OR 
B01 – Antithrombotic agents 
COOPER et al, 
200638 
“...identify different stroke 
prevention treatments for atrial 
fibrillation assessed in 
randomized controlled trials 
and to compare them within a 
single evidence synthesis 
framework.” 
Warfarin; 
Ximelagatran; 
Indobufen; Triflusal; 
Acenocoumarol 
Aspirin; 
Major bleedings RCTs Random-
effects 
Poisson 
regression RR 
HART et al, 
200743 
“To characterize the efficacy 
and safety of antithrombotic 
agents for stroke prevention in 
patients who have atrial 
fibrillation...” 
Warfarin; Aspirin; 
Dipyridamole 
Major bleedings RCTs Random-
effects RRR 
and ARR 
B03 – Antianemic preparations 
BENNET et al, 
20086 
“To evaluate VTE and mortality 
rates associated with ESA 
administration for the 
treatment of anemia among 
patients with cancer.” 
Erythropoietin; 
Darbepoetin. 
All-cause death RCTs Random-
effects HR 
and RR 
 
BOHLIUS et al, 
200921 
“...to examine the effects of 
these drugs on the survival of 
patients with cancer and to 
identify factors that might 
modify such effects.” 
Erythropoietin-alfa; 
Erythropoietin-beta; 
Darbepoetin. 
All-cause death RCTs Fixed-effects 
meta-
regression 
analysis HR; 
Random-
effects meta-
regression 
analysis HR 
PHROMMINTIKUL 
et al, 200725 
“...to determine whether 
targeting different haemoglobin 
concentrations when treating 
anaemic patients with chronic 
kidney disease with 
erythropoiesis-stimulating 
agents is associated with altered 
all-cause mortality and 
cardiovascular events.” 
Erythropoietin-alfa; 
Erythropoietin-beta; 
Darbepoetin. 
All-cause death RCTs Fixed-effects 
RR; 
Random-
effects RR 
PALMER et al, 
201041 
“To summarize the effects of 
ESA treatment on clinical 
outcomes in patients with 
anemia and CKD.” 
Erythropoietin-alfa; 
Erythropoietin-beta; 
Darbepoetin. 
All-cause death RCTs Random-
effects RR; 
Random-
effects meta-
regression 
analysis 
L01 – Antineoplastic agents & L04 – Immunosuppressants 
KASTRATI et al, “...to assess the long-term Sirolimus-eluting All-cause death RCTs Random-
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200730 outcome after implantation of 
sirolimus-eluting stent...” 
stents; Bare-metal 
stents. 
effects HR; 
Random-
effects meta-
regression 
analysis 
STETTLER et al, 
200724 
“...to compare the safety and 
effectiveness of these stents.” 
(drug-eluting stents vs. bare-
metal stents or drug-eluting 
stents heat-to-head) 
Paclitaxel-eluting 
stents; Sirolimus-
stents; Bare-metal 
stents. 
All-cause death RCTs Multivariable 
Bayesian 
hierarchial 
random-
effects HR; 
Random-
effects HR 
STETTLER et al, 
200850 
“To compare the effectiveness 
and the safety of three types of 
stents (sirolimus eluting, 
paclitaxel eluting, and bare 
metal) in people with or 
without diabetes mellitus.” 
Paclitaxel-eluting 
stents; Sirolimus-
stents; Bare-metal 
stents. 
All-cause death RCTs Multivariable 
Bayesian 
hierarchial 
random-
effects HR; 
Random-
effects 
Poisson 
regression 
model HR 
M01 – Antiinflammatory and antirheumatic products 
KEARNEY et al, 
200656 
“To assess the effects of 
selective cyclo-oxygenase-2 
(COX 2) inhibitors and 
traditional non-steroidal anti-
inflammatory drugs (NSAIDs) 
on the risk of vascular events.” 
Rofecoxib; 
Celecoxib; 
Etoricoxib; 
Lumiracoxib; 
Valdecoxib; 
Ibuprofen; 
Diclofenac; 
Naproxen. 
Myocardial infarction RCTs Peto “one 
step” 
approximation 
RR (rate 
ratio) 
MCGETTIGAN et 
al, 200612 
“…to compare the risks of 
serious cardiovascular events 
with individual NSAIDs and 
cyclooxygenase 2 inhibitors.” 
Rofecoxib; 
Celecoxib; 
Meloxicam; 
Ibuprofen; 
Diclofenac; 
Naproxen; 
Indomethacin; 
Piroxicam. 
Myocardial infarction Case-
control 
studies; 
Cohort 
studies. 
Random-
effects RR 
N06 – Psychoanaleptics 
BRIDGE et al, 
200710 
“To assess the efficacy and risk 
of reported suicidal 
ideation/suicide attempt of 
antidepressants for treatment 
of pediatric major depressive 
disorder (MDD), obsessive-
compulsive disorder (OCD), 
and non-OCD anxiety 
disorders.” 
Fluoxetine; 
Paroxetine; 
Sertraline; 
Citalopram; 
Escitalopram; 
Venlafaxine; 
Nefazodone; 
Mirtazipine.  
Suicide ideation; 
Suicide attempt; 
Suicide preparatory 
actions; Suicide 
ideation/Suicide 
attempt. 
RCTs Random-
effects RD 
STONE et al, 
200949 
“To examine the risk of suicidal 
behaviour within clinical trials 
of antidepressants in adults.” 
Fluoxetine; 
Fluvoxamine; 
Duloxetine; 
Paroxetine; 
Sertraline; 
Citalopram; 
Escitalopram; 
Venlafaxine; 
Nefazodone; 
Mirtazipine; 
Bupropion; 
Amitriptyline; 
Clomipramine; 
Desipramine; 
Dosulepin; 
Imipramine; 
Trazodone; 
Mianserin 
Suicide ideation; 
Suicide attempt; 
Suicide preparatory 
actions. 
RCTs Random-
effects logistic 
regression 
OR and RD 
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R03 – Drugs for obstructive arway diseases 
DRUMMOND et 
al, 20082 
“...synthesize the effects of 
inhaled corticosteroid therapy 
on mortality and adverse events 
in patients with stable chronic 
obstructive pulmonary disease.” 
Fluticasone; 
Budesonide;  
Any pneumonia RCTs Random-
effects RR 
Fixed-effects 
RR 
SINGH et al, 
200933 
“...to ascertain the risk of 
pneumonia with long-term 
inhaled corticosteroid use 
among patients with chronic 
obstructive pulmonary disease.” 
Fluticasone; 
Budesonide; 
Beclomethasone. 
Any pneumonia RCTs Random-
effects RR 
Fixed-effects 
RR 
 
 
 
II.4.2. DATA SOURCES AND SEARCH STRATEGY 
 
 Nearly all the meta-analyses (n=57; 95%) searched electronic databases (median 3; 
range, 1-7), with a total of 19 different electronic databases reported (Table II.2). MEDLINE 
was the electronic database most frequently searched in meta-analyses (n=51/57; 89%), 
followed by Cochrane Library (n=47/57; 82%), and EMBASE (n=37/57; 65%). One meta-
analysis did not report which electronic databases were searched. Of the 57 meta-analyses 
that searched electronic databases, 13 (23%) meta-analyses completely specified the search 
strategy. Twenty-four meta-analyses (42%) reported the use of medical subject headings in 
their search strategies. 
 Forty-nine (82%) meta-analyses searched at least one additional data source, besides 
electronic databases, such as retrieved trials (n=34/49; 70%) or references from reviews 
(n=24/49; 49%). Other additional data sources were the contact with the manufacturer 
company (n=21/49; 43%), data from scientific societies meetings (n=17/49; 35%) and contact 
with the regulatory agencies (n=17/49; 35%), and relevant websites, such as clinicaltrials.gov 
(n=14/49; 29%). 
 
  
The references of the studies included in this table are presented at Supplemental Data 2. RCT – randomized 
clinical trial; RR – relative risk; OR – odds ratio; HR – hazard ratio 
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Table II.2 - Data sources and search strategy of the meta-analyses studied. 
 n = 60 
Data sources searched   
Reported at least one source 60 100% 
Electronic database 57 95% 
MEDLINE 51 89% 
Cochrane Library 47 82% 
EMBASE 37 65% 
PubMed 7 12% 
Web of Science 6 11% 
CINAHL 3 5% 
OVID 2 4% 
HealthSTAR 1 2% 
EBM 1 2% 
CancerLit 1 2% 
SIGLE 1 2% 
PsycINFO 1 2% 
PsychLit 1 2% 
Cum. Index to Nursing 1 2% 
Int. Pharm. Abstracts 1 2% 
All. Compl. Med 1 2% 
Google Scholar 1 2% 
CRISP 1 2% 
German Inst. Med. Doc. Inf. 1 2% 
Not reported 1 2% 
Searched additional data source 49 82% 
References from retrieved trials 34 70% 
References from reviews 24 49% 
Contact with manufacturer company 21 43% 
Scientific society meetings 17 35% 
Regulatory agencies 17 35% 
Relevant websites 14 29% 
Contact with trial investigator 12 24% 
Contact with experts 11 22% 
Scientific journal in the area 3 6% 
Book chapters 2 4% 
Product information sheet 1 2% 
Helath organizations 1 2% 
 
  
Abbreviations: Cum. Index to Nursing - Cumulative Index to Nursing and Allied Health Literature; 
Int. Pharm. Abstracts – International Pharmaceutical Abstracts; All. Compl. Med – Allied and 
Complementary Medicine; German Inst. Med. Doc. Inf. – German Institute of Medical 
Documentation and Information 
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II.4.3. TYPE OF STUDIES INCLUDED IN META-ANALYSIS AND ANALYSIS OF RESULTS 
 
 Of the meta-analyses included in this study, 25 (42%) assessed both efficacy and safety 
outcomes, whereas 35 (58%) assessed only safety outcomes (Table II.3). Twenty-four (96%) 
of the meta-analyses assessing efficacy and safety included only experimental studies (RCTs), 
and 1 (4%) meta-analysis included both experimental and observational studies (RCTs, non-
RCTs, prospective cohort, retrospective cohort, case-control, and cross-sectional studies). 
 
 
Table II.3 - Meta-analyses design, type of included studies and their publication status, and assessment of 
publication bias. 
 n=60 
Type of study design  
Efficacy and Safety outcomes  25 42% 
Experimental studies 24 96% 
Observational studies -  
Experimental and Observational studies 1 4% 
Safety outcomes 54 58% 
Experimental studies 29 83% 
Observational studies 2 6% 
Experimental and Observational studies 3 9% 
Study design not reported 1 3% 
Publication status of included studies   
Published 31 52% 
Published and Unpublished 21 35% 
Published and Short communications 8 13% 
Publication Bias   
Assessed 25 42% 
Not assessed 35 58% 
 
 
 Of the meta-analyses that assessed safety outcomes, 29 (83%) included only 
experimental studies (RCTs), 3 (9%) included both experimental and observational studies, 2 
(6%) included only observational studies, and 1 (3%) did not report the design of the studies. 
Of the three meta-analyses that comprised experimental and observational studies, one 
included RCTs, post hoc analysis within an RCT, and prospective and retrospective cohort 
studies; 1 included RCTs and prospective and retrospective cohort studies; and 1 included 
RCTs, prospective cohort, and case-control studies. Of the 2 meta-analyses that comprised 
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only observational studies, one included prospective cohort and case-control studies, and 
the other one included prospective cohort, case-control, and cross-sectional studies. 
 According to the publication status, 31 (52%) meta-analyses included only published 
studies, 21 (35%) included published and unpublished studies, and 8 (13 %) meta-analyses 
included published studies and short communications (Table II.3). 
 Less than half (n=25; 42%) of the meta-analyses reported publication bias assessment. 
 
II.4.3.1. Meta-analyses which included different types of studies 
 
 Of the four meta-analyses that comprised experimental and observational studies, we 
evaluated if the pooled results were different and, if so, in which direction. Two meta-
analyses compared the results pooled from RCTs with the results pooled from observational 
studies. Of these, in one meta-analysis, the RCTs’ pooled OR of harms overlapped the OR 
pooled from observational studies. In the other, for one safety outcome (discontinuation of 
the drug due to AEs, mainly because of cough) the observational studies’ pooled OR was 
beyond chance comparing with RCTs’ pooled OR. 
 Two meta-analyses did not compare the results pooled from RCTs with the results 
pooled from observational studies. In one of these, observational studies provided 
information on safety outcomes, which were not reported in RCTs. 
 
II.4.4. QUALITY ASSESSMENT OF THE STUDIES INCLUDED IN META-ANALYSES 
 
 Forty-one (68%) meta-analyses reported the quality assessment of the included 
studies, of which, 30 (73%) were based on published quality assessment instruments (Table 
II.4). Twelve different instruments were used to assess methodological quality of RCTs. Of 
these, Jadad scale (n=10; 24%) and the Cochrane Handbook f or Systematic Reviews of 
Interventions (n=6; 15%) were the most frequently used (JADAD et al., 1996; HIGGINS and 
GREEN, 2011). Four meta-analyses assessed the quality of observational studies included, two 
using the method of Downs and Black (n=2; 5%), one using the Newcastle-Ottawa Scale 
(n=1; 2%), and the other based its assessment on MOOSE guidelines (n=1; 2%) (DOWNS and 
BLACK, 1998; WELLS et al., 2011; STROUP et al., 2000). Five meta-analyses assessed the 
methodological quality of the included studies according to more than one quality 
assessment instrument. The remaining 11 (27%) meta-analyses did not report the use of 
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instruments to assess the methodological quality of the included studies. Instead, they 
described the indicators used for quality assessment. 
 
 
Table II.4 - Quality assessment of the studies included in meta-analyses. 
 n=60 
   
Assessed methodological quality 41 68% 
Based on existing instruments 30 73% 
Jadad scale 10 24% 
Coch. Hand. For Syst. Rev. Interventions 6 15% 
QUOROM 3 7% 
Juni et al, 2001 3 7% 
Schulz  et al, 1995 3 7% 
Meade and Richardson, 2007 2 5% 
Moher et al, 1998 1 2% 
US Preventive Task Force 1 2% 
NHS Centre for Reviews and Dissemination 1 2% 
CONSORT 1 2% 
Schulz, KF 1 2% 
Altman and Schulz, 2001 1 2% 
Detsky et al, 1992 1 2% 
Downs and Black, 1998 2 5% 
Newcastle-Ottawa Scale 1 2% 
MOOSE 1 2% 
Not based on existing instruments 11 27% 
Not assessed 19 32% 
 
 
 Of the 41 meta-analyses that assessed the methodological quality of the studies, 35 
(85%) reported the results of this assessment. Nine (22%) meta-analyses evaluated the effect 
of the different quality scored studies on the results, by performing a sensitivity analysis. The 
methodological quality assessment was used as inclusion criterion in seven (17%) meta-
analyses, of which, three used the Cochrane Handbook for Systematic reviews of 
Interventions to assess the quality reporting of AEs reported (LOKE, PRICE and HERXHEIMER, 
2011). 
 
II.4.5. GUIDELINES DESCRIBED AS USED IN THE ELABORATION OF META-ANALYSES 
 
 In 11 (18%) meta-analyses, the authors said they used established recommended 
statements to elaborate meta-analyses: seven (64%) according to QUOROM guidelines; two 
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(18%) using the Cochrane Handbook for Systematic reviews of Interventions guidelines; and 
PRISMA, MOOSE, and Agency for Healthcare Research and Quality guidelines were used to 
report one meta-analysis each (Table II.5) (HIGGINS and GREEN, 2011; STROUP et al., 2000; 
MOHER et al., 1999; MOHER et al., 2009; MATCHAR et al., 2007). Of the 11 meta-analyses, one 
was reported according to both QUOROM and Cochrane Handbook guidelines. 
 
 
Table II.5 - Reporting guidelines used by meta-analyses. 
 n=60 
   
Reported using existing guidelines 11 18% 
QUOROM 7 64% 
Coch. Hand. For Syst. Rev. Interventions 2 18% 
PRISMA 1 9% 
AHRQ 1 9% 
MOOSE 1 9% 
Use not reported 49 82% 
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II.5. DISCUSSION 
 
 This study provides evidence on the use of meta-analysis to evaluate the safety of 
pharmacological interventions published in eight medical journals from 2005 to 2010, 
selected according to their impact factor on the area of general/internal medicine. 
 We identified 438 meta-analyses published during the studied period, of which, 60 
(14%) assessed drug safety as a primary outcome. The majority was designed to assess drug 
efficacy and to evaluate non-pharmacological interventions. This result supports our previous 
concerns that only a limited number of published meta-analyses are currently devoted to 
monitor safety profile of pharmacological interventions. We also found that several meta-
analyses evaluated the same clinical question during the studied period (e.g., risk of 
cardiovascular events associated with rosiglitazone therapy). This was expected because, 
during the studied period, some pharmacological interventions were under evaluation 
because of doubts about their safety profile. 
 The 60 meta-analyses assessing AEs included experimental studies, observational 
studies, and both simultaneously. Experimental studies were the predominant source of 
information in this sample. Experimental studies are accepted to be the gold standard to 
evaluate drug efficacy, mainly because randomized allocation protects against bias and 
confounding effects that can threaten the validity of the study. Experimental designs to 
evaluate drug safety are difficult to carry out, often because of ethical reasons. However, 
experimental designs that evaluate drug efficacy use rigorous criteria for patient selection 
and use efficacy end points to estimate sample size and follow-up time. Thus, data on 
frequent and acute AEs may be observed in these studies, but unknown, rare, and/or long-
term latency AEs are difficult to be identified. 
 Most evidence on harms is more likely to be obtained from pharmacovigilance 
activities, particularly by using observational studies. Although these studies are more prone 
to bias and confounding, they offer the advantage of a naturalistic observation, more likely to 
include a broad representation of the population at risk. However, as it can be found in the 
present study, meta-analyses including observational studies aiming at drug safety monitoring 
are relatively few, although there are a vast number of observational studies published, some 
with remarkable contributions on the study of drug safety (LACROIX et al., 2003; TROMP et al., 
2001; VAN STAA, LEUFKENS and COOPER, 2001; SCOLNIK et al., 1994). 
 The assessment of the methodological quality was reported for the majority of the 
studies included in the identified meta-analyses. However, for the purpose of quality 
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assessments, different instruments have been developed and applied, giving place for 
heterogeneity in such evaluations. The use of different instruments can lead to different 
considerations in terms of weight assigned to key domains. In our study, different scores 
from quality assessments were not weighted on the overall results in several meta-analyses, 
therefore not reflecting the impact of poor quality studies on the presented findings. 
Although it is widely recommended that epidemiologic studies undergo some type of quality 
review, the method of assessing and incorporating the quality scores is a matter of ongoing 
debate (JÜNI et al., 1999). Assessing the influence of specific relevant methodological aspects 
on effects sizes has been a preferred approach recently (JÜNI et al., 1999). 
 Few meta-analyses included unpublished studies and assessed publication bias. This 
has been documented as an essential effort in meta-analyses studies because it can influence 
the accuracy of data and lead to misleading results. The potential consequences of 
publication bias have been debated for some time (STERNE, EGGER and SMITH, 2001; BAX and 
MOONS, 2010). 
 The choice of the selected journals probably shaped what we found because 
numerous other journals devoted to specific clinical areas or covering the disciplines of 
pharmacoepidemiology and pharmacovigilance have published relevant meta-analyses, some 
of those including different studies designs as data sources (HENNESSY et al., 2001; GAGNE, 
GRIESDALE and SCHNEEWEISS, 2009; LOKE, JEEVANANTHAM and SINGH, 2009; TOH and 
HERNÁNDEZ-DÍAZ, 2007; CHEN and ASHCROFT, 2006). These journals were selected because 
they are the most widely read and quoted and, thus, are the most likely to influence clinical 
practice. Safety is a matter of concern in the use of medicines. To identify if the selected 
journals highlight safety in the same extent that efficacy is expected to be highlighted was a 
selected objective of this study. Although this fact may be considered a limitation, its 
intention was to explore the possibility of imbalance in equal terms of safety and efficacy, 
therefore modulating clinicians’ judgments toward efficacy. The present study only included 
published meta-analyses. Therefore, eventually existing non-published relevant meta-analyses 
are not represented. 
 Despite that we had found meta-analyses devoted to evaluate the safety of 
pharmacological interventions, they included mostly experimental studies. In 60 meta-
analyses, 6 (10%) included observational studies. The usefulness of the observational studies 
is the detection of rare and long-term latency AEs and the study of minority populations. 
The evaluation of rare AEs is recognized to be challenging (BRADBURN et al., 2007). The 
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inclusion of different study designs in meta-analyses should be properly planned, depending 
on the type of outcome, which is being evaluated. 
 The Safety Planning, Evaluation and Reporting Team formed in 2006 recommend that 
sponsors develop a program safety analysis plan beginning with first clinical studies, as a tool 
to proactively plan for meta-analyses at regular intervals during marketed use of a product 
(CROWE et al., 2009). The ICH E9 guideline also states that meta-analyses should be 
prospectively planned with the RCTs program in the development of a new treatment 
(INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR 
REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE, 1998). 
 Meta-analysis is recognized as a valuable method to address safety questions, either 
defined prospectively or those that are retrospectively addressed. However, the 
combination of information across all studies is facilitated by the use of consistent 
approaches in the definitions, data collection, processing, and analysis during drug 
development and postmarketing (IOANNIDIS et al., 2004; BEHRMAN et al., 2011). The role of 
meta-analysis in pharmacovigilance is a matter of ongoing debate, and efforts are being made 
to develop guidelines on the use of meta-analysis in drug safety assessments (DRUG 
INFORMATION ASSOCIATION, 2011; THE COCHRANE COLLABORATION, 2014). 
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II.7. SUPPLEMENTAL DATA II 
 
II.7.1. SUPPLEMENTAL DATA II.1 - SEARCH STRATEGY 
 
 
Supplemental Table II.1 - Search Strategy. 
Search  PubMed Results 
1 
“N Engl J Med” [journal] 
Limits: meta-analysis; date range 2005/10/01 – 2010/09/30 
10 
2 
“Lancet” [journal] 
Limits: meta-analysis; date range 2005/10/01 – 2010/09/30 
81 
3 
“JAMA” [journal] 
Limits: meta-analysis; date range 2005/10/01 – 2010/09/30 
71 
4 
“BMJ” [journal] 
Limits: meta-analysis; date range 2005/10/01 – 2010/09/30 
133 
5 
“Arch Intern Med” [journal] 
Limits: meta-analysis; date range 2005/10/01 – 2010/09/30 
59 
6 
“Ann Intern Med” [journal] 
Limits: meta-analysis; date range 2005/10/01 – 2010/09/30 
73 
7 
“PLoS Med” [journal] 
Limits: meta-analysis; date range 2005/10/01 – 2010/09/30 
32 
8 
“Annu Rev Med” [journal] 
Limits: meta-analysis; date range 2005/10/01 – 2010/09/30 
0 
9 Total 459 
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III. APIXABAN AND RIVAROXABAN SAFETY AFTER HIP AND KNEE ARTHROPLASTY: 
A META-ANALYSIS 
 
III.1. ABSTRACT 
 
 Direct experimental safety comparisons of Xa coagulation factor direct inhibitors, 
apixaban and rivaroxaban, on their approved therapeutic indications have not been 
identified. Due to recently raised safety concerns, a meta-analysis was carried out pooling 
data from studies identified on a MEDLINE and Cochrane Library search in order to better 
evaluate the safety profile of both drugs. Abstracts from scientific meetings were also 
searched from 2003 to 2011. Primary and secondary outcome measures were major 
bleeding and total bleeding, respectively. Relative risks were estimated using random effects 
models and statistical heterogeneity was estimated with I2 statistics. Of the 160 screened 
publications, 12 RCTs were included in which enoxaparin was the active control. For knee 
arthroplasty, apixaban was associated with significantly fewer major bleeding events (6496 
patients, RR 0.56, 95% CI 0.32-0.96) and fewer total bleeding events (6496 patients, RR 0.81, 
95% CI 0.67-0.97). There were no significant differences in the incidence of major bleeding 
events (5699 patients, RR 1.40, 95% CI 0.56-3.52) or in the incidence of total bleeding events 
for rivaroxaban (5699 patients, RR 1.09, 95% CI 0.91-1.30). No differences were found when 
thromboprophylaxis after hip replacement was the case. Apixaban seems to be associated 
with a lower risk of the incidence of hemorrhagic events after total knee arthroplasty. For 
hip arthroplasty, no differences were found between the studied drugs. 
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III.2. INTRODUCTION 
 
 Patients submitted to major orthopedic surgery, such as elective total knee or hip 
arthroplasty, represent a group at high risk of venous thromboembolism (VTE) (WARWICK, 
2004). Almost half of the patients who underwent arthroplasty are affected by asymptomatic 
deep venous thrombosis (DVT), although most of these thrombi resolve without long-term 
complications (GEERTS et al., 2008; HILL and TREASURE, 2010; RASHID et al., 2010). For some 
patients, propagation of the existing thrombus can cause symptoms as a result of venous 
occlusion (GINSBERG et al., 2000). Symptomatic VTE is common after discharge from hospital 
(DOUKETIS et al., 2002; BJORNARA, GUDMUNDSEN and DAHL, 2006). The most frequent cause 
for readmission to the hospital following total knee arthroplasty is VTE (SEAGROATT et al., 
1991). 
 The provision of thromboprophylaxis during hospitalization has been established as 
standard of care for the last 2 decades (ANONYMOUS, 1986). With anticoagulant therapy, 
incidence of fatal pulmonary embolism (PE) decreased to 0.2%, although symptomatic VTE 
continues to be reported in 1.3% to 10% of patients within 3 months after surgery (GEERTS 
et al., 2008; SHARROCK et al., 2008). Low molecular weight heparins (LMWHs), fondaparinux, 
and vitamin K antagonists have been used as pharmacological agents for VTE prophylaxis. 
Although these therapies have shown to be effective, they are associated with some practical 
limitations (HIRSH et al., 2008). Low molecular weight heparin and fondaparinux have the 
inconvenience of subcutaneous administration, which also can increase the risk of injection 
site hematomas (LASSEN et al., 2010a; JANG and HURSTING, 2005). Furthermore, 
subcutaneous administration of anticoagulants is difficult to provide after hospital discharge. 
Vitamin K antagonists are being abandoned in Europe due to concerns about their delayed 
onset of action, unpredictable pharmacokinetic and pharmacodynamic effects, and need for 
frequent monitoring (LEVY, KEY and AZRAN, 2010; ANSELL et al., 2008). Mechanical VTE 
prophylaxis is known to be cumbersome, and its efficacy is found to be lower when 
compared with anticoagulant therapy, especially after hip arthroplasty (GEERTS et al., 2008).  
 The specific limitations of the currently available anticoagulant agents led to the 
development of new therapies for preventing VTE (WEITZ, 2010; BECATTINI, LIGNANI and 
AGNELLI, 2010; GROSS and WEITZ, 2008). The direct thrombin inhibitor, dabigatran (Pradaxa, 
Boehringer Ingelheim, Ingelheim am Rheim, Germany), and the oral direct inhibitors of 
coagulation factor Xa, rivaroxaban (Xarelto, Bayer, Berlin, Germany) and apixaban (Eliquis, 
Bristol-Myers Squibb/Pfizer EEIG, Uxbridge, UK), were recently approved by the EMA for 
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thromboprophylaxis after total knee and hip arthroplasty (NATIONAL INSTITUTE FOR HEALTH 
AND CARE EXCELLENCE, 2008; NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE, 
2009). Both oral coagulation factorXa direct inhibitors were approved based on evidence 
provided by phase III RCTs using once daily 40 mg enoxaparin (European regimen) or twice 
daily 30 mg enoxaparin (North American regimen) as the active control (LASSEN et al., 2009; 
LASSEN et al., 2010b; ERIKSSON et al., 2008; TURPIE et al., 2009). These studies found that oral 
coagulation factor Xa direct inhibitors are effective in VTE prevention. However, safety 
concerns have been raised regarding thromboprophylaxis with rivaroxaban (JENSEN et al., 
2011; LOTKE, 2008; CAO et al., 2010; GÓMEZ-OUTES et al., 2009). One study has shown an 
increased risk of wound complications associated with rivaroxaban (JENSEN et al., 2011). 
Since the prevalence of fatal PE after total knee arthroplasty is 0.1% and the risk of major 
and clinically relevant bleeding events with thromboprophylaxis is 3.0%, risk and benefits 
should be balanced before starting anticoagulation therapies (JOHANSON et al., 2009). The 
safety of Xa coagulation factor direct inhibitors holding a European market authorization, 
apixaban and rivaroxaban, have never been evaluated by direct comparisons in RCTs. 
 The aim of this study was to carry out a meta-analysis in order to comparatively 
evaluate the safety profile of the direct inhibitors of coagulation factor Xa, apixaban and 
rivaroxaban, as thromboprophylaxis agents after total knee or hip arthroplasty. 
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III.3. METHODS 
 
 We searched EMA Web site for direct inhibitors of coagulation factor Xa which had 
been already approved (EUROPEAN MEDICINES AGENCY, 2008; EUROPEAN MEDICINES AGENCY, 
2011). Data search and safety analysis were performed according to the therapeutic 
indication approved by EMA. 
 
 
III.3.1. SEARCH STRATEGY 
 
 MEDLINE and the Cochrane Library were searched from its inception until June 27, 
2011 in order to identify relevant studies comparing direct factor Xa inhibitors with 
enoxaparin. Search terms related with knee and hip arthroplasty (eg ‘knee operation’, ‘knee 
surgery’, ‘knee arthroplasty’, ‘hip arthroplasty’, ‘hip replacement’, and ‘hip surgery’) were 
combined with thromboembolism prophylaxis terms, such as ‘thrombosis prophylaxis’, ‘deep 
venous thrombosis prophylaxis’, and ‘PE prophylaxis’. Text words, brand names, and 
manufacturer’s coded designations were used to identify both factor Xa inhibitors. All 
languages were considered in the search strategy. The bibliographic list of all relevant RCTs 
was hand searched in order to identify additional eligible studies. Study lists from systematic 
reviews and meta-analysis identified during the search process were also considered. The 
databases of the American Society of Haematology (starting on the 2004 issue) and the 
International Society on Thrombosis and Haemostasis (starting on the 2003 issue) were 
searched in order to identify relevant studies published as abstracts. FDA and EMA publicly 
available records were searched in order to identify studies that met our inclusion criteria. 
Articles that were not available were requested to the authors. The electronic databases 
search strategy is available in the Supplemental Data III.1. 
 
III.3.2. STUDY SELECTION 
 
 Literature was searched and relevant studies were examined for further assessment. 
The studies inclusion criteria were (1) RCTs, (2) patients of all ages undergoing total hip or 
knee arthroplasty, (3) comparison of safety of factor Xa direct inhibitors with enoxaparin for 
thromboprophylaxis. Only the oral direct inhibitors of factor Xa holding marketing 
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authorizations in the EU were evaluated. Both trials with blinded and unblinded design were 
included. Studies focusing on pharmacokinetic or pharmacodynamic variables were excluded. 
 
III.3.3. QUALITY ASSESSMENT 
 
 Quality assessment of studies was based on the recommendations of the Cochrane 
Handbook of Systematic Review of Interventions on assessing adverse effects (LOKE, PRICE 
and HERXHEIMER, 2011). The value of trial data on adverse effects relies on 2 major 
characteristics: the rigor of monitoring for the adverse effects during the study and the 
completeness of reporting. Allocation concealment and the withdrawal rates were also 
evaluated. 
 
III.3.4. DATA EXTRACTION 
  
 Two reviewers independently extracted data from the included studies. Any 
disagreements were resolved by consensus or arbitration by a third reviewer. We contacted 
the authors of studies for missing data when necessary. Data on study characteristics 
(methodology, included population, study design, and drugs evaluated) and outcomes 
(bleeding and AEs) during treatment were extracted. 
 
III.3.5. OUTCOME ASSESSED 
  
 The primary outcome of this meta-analysis was the incidence of major bleeding 
beginning after the first dose of the study drug and up to 2 days after the last dose of the 
study drug (on-treatment period). Major bleeding was defined as bleeding that was fatal, 
involved a critical organ (eg, retroperitoneal, intracranial, intraocular, and intraspinal), 
required reoperation or that was clinically overt, extra-surgical site bleeding associated with 
a fall in hemoglobin level of at least 2 g/dL, calculated from the day 1 postoperative baseline 
value, or requiring infusion of 2 or more units of whole blood or packed cells. Other safety 
outcomes included any on-treatment bleeding, any on-treatment clinically relevant nonmajor 
bleeding, drug-related AEs, drug-related serious AEs, and wound complications. Wound 
complications outcome is the composite of major and/or nonmajor wound bleedings. 
Chapter III 
 
146 
Clinically relevant nonmajor bleeding was defined according to the RCTs that evaluated 
apixaban and rivaroxaban (LASSEN et al., 2009). 
 
III.3.6. STATISTICAL ANALYSIS 
  
 Review Manager (RevMan) version 5.1.2 (Cochrane Collaboration, Oxford, UK) was 
used to calculate RR and 95% CIs for all the primary and secondary outcomes throughout 
the meta-analysis. All reported P values are 2-sided with significance set at <.05. Statistical 
heterogeneity was assessed by calculating a chi-square test and the I2 measure of 
inconsistency (HIGGINS et al., 2003). Statistical heterogeneity was considered low when 0%< 
I2 < 25%, moderate when 25%< I2 < 50%, and high when I2 > 50%. We planned to pool data 
across studies using the DerSimonian and Laird random effects model (DERSIMONIAN and 
LAIRD, 1986). The publication bias was assessed by examining the funnel plot (BORENSTEIN et 
al., 2009). We performed a sensitivity analysis to explore the influence on effect size of 
blinding of outcome assessment and the methodological quality of included trials. For each 
Xa coagulation factor direct inhibitor, the results of total hip or knee arthroplasty subgroups 
were compared with the overall meta-analysis. For the sensitivity analysis, RCTs using twice 
daily enoxaparin 30 mg (North American regimen) as active control were excluded. 
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III.4. RESULTS 
 
III.4.1. STUDY SELECTION 
 
 Figure III.1 presents the flow of the search strategy criteria. The electronic databases 
searches returned 165 potentially relevant articles. After review of the titles and abstracts, 
142 citations were refused; 16 articles were duplicates; 23 articles were selected for further 
evaluation. After application of inclusion criteria, 12 studies were eligible for inclusion 
(LASSEN et al., 2009; LASSEN et al., 2010b; ERIKSSON et al., 2008; TURPIE et al., 2009; LASSEN et 
al., 2007; TURPIE et al., 2005; ERIKSSON et al., 2006a; ERIKSSON et al., 2006b ERIKSSON et al., 
2007; KAKKAR et al., 2008; LASSEN et al., 2008). The review of reference lists scientific 
society’s databases did not find any other relevant studies. No further studies were identified 
in the FDA and EMA publicly available records. 
 
III.4.2. CHARACTERISTICS OF THE INCLUDED STUDIES 
 
 The main characteristics of the studies are presented in Table III.1. Study design, 
duration of treatment, demographic characteristics of patients, drugs under evaluation, and 
number of participants are described. A total of 12 RCTs were found, of which 8 evaluated 
the efficacy and safety of rivaroxaban versus enoxaparin and 4 evaluated the efficacy and 
safety of apixaban versus enoxaparin. These RCTs included 28 483 patients, in which 15 586 
were randomized to receive rivaroxaban or enoxaparin, and 12 897 were randomized to 
receive apixaban or enoxaparin. All the RCTs were performed in adult patients undergoing 
total knee or hip arthroplasty. Five RCTs evaluated rivaroxaban for thromboprophylaxis in 
patients undergoing total hip replacement and 3 RCTs evaluated rivaroxaban for 
thromboprophylaxis in patients undergoing total knee replacement. Apixaban was evaluated 
as thromboprophylaxis agent after total knee arthroplasty in 3 RCTs and 1 RCT evaluated 
apixaban as thromboprophylaxis agent in patients undergoing total hip replacement. 
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Figure III.1 - Flow diagram of identification of studies for inclusion. 
 
  
23 articles reviewed 
142 citations excluded at title and 
abstract review stage: 
 16 were duplicates 
 29 were presentations of the same 
study 
 16 were comments or letters 
 75 were reviews or meta-analysis 
 4 interventions evaluated in other 
therapeutic indication 
 1 evaluated a diagnostic technique 
11 studies excluded: 
5 focused on pharmacokinetic and/or 
pharmacodynamic variables 
5 evaluated different outcomes 
1 retrospective cohort study 
comparing rivaroxaban versus 
tinzaparin 
12 studies included: 
Rivaroxaban: 8 RCT 
Apixaban: 4 RCT 
165 articles retrieved 
0 relevant studies found 
by hand search of 
reference lists, reviews, 
meta-analysis and at the 
FDA, EMA and scientific 
society’s databases  
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Table III.1 - Characteristics of the studies included in the meta-analysis. 
Study Study 
design 
Nº 
participants 
Age, 
mean 
Female, 
% 
Population Drugs tested 
      Intervention Enoxaparin 
Apixaban 
APROPOS36 RCT, 
double-
blind, 
multicenter 
1238 Apix:67.6 
Enox:66.5 
Apix:68.0 
Enox:61.8 
Adults, ≥ 18 years 
old, submitted to 
total knee 
arthroplasty. 
Apixaban 2.5, 
5 or 10 mg, 2 
id, or 5, 10 or 
20 mg id, p.o., 
starting 12 to 
24h after 
wound 
closure, for 
10-14 days. 
Enoxaparin 30 
mg, s.c., every 
12h, starting 12 
to 24h after 
wound closure, 
for 10-14 days. 
ADVANCE-
121 
RCT, 
double-
blind, 
multicenter 
3195 Apix:62.4 
Enox:61.8 
Apix:62.4 
Enox:61.8 
Adults, ≥ 18 years 
old, submitted to 
total knee 
arthroplasty. 
Apixaban 2.5 
mg, 2 id, p.o., 
starting 12 to 
24h after 
surgery, for 
10-14 days. 
Enoxaparin 30 
mg, s.c., every 
12h, starting 12 
to 24h after 
surgery, for 10-
14 days. 
ADVANCE-
222 
RCT, 
double-
blind, 
multicenter 
3057 Apix:65.6 
Enox:65.9 
Apix:71.0 
Enox:74.0 
Adults, ≥ 18 years 
old, submitted to 
total knee 
arthroplasty. 
Apixaban 2.5 
mg, 2 id, p.o., 
starting 12 to 
24h after 
wound 
closure, for 
10-14 days. 
Enoxaparin 40 
mg, s.c., daily, 
starting 12h 
before surgery 
and restarted 
according 
investigators 
standard of 
care, for 10-14 
days. 
ADVANCE-
312 
RCT, 
double-
blind, 
multicenter 
5407 Apix:60.9 
Enox:60.6 
Apix:52.8 
Enox:53.8 
Adults, ≥ 18 years 
old, submitted to 
total hip 
arthroplasty. 
Apixaban 2.5 
mg, 2 id, p.o., 
starting 12 to 
24h after 
wound 
closure, for 
31-39 days. 
Enoxaparin 40 
mg, s.c., daily, 
starting 12h 
before surgery 
and restarted 
according 
investigators 
standard of 
care, for 31-39 
days. 
Rivaroxaban 
RECORD123 RCT, 
double-
blind, 
multicenter 
4541 Riva:63.1 
Enox:63.3 
Riva:55.2 
Enox:55.8 
Adults, ≥ 18 years 
old, submitted to 
total hip 
arthroplasty. 
Rivaroxaban 
10 mg, 1 id, 
p.o., starting 6 
to 8h after 
wound 
closure, for 
31-39 days. 
Enoxaparin 40 
mg, once daily, 
starting 12h 
before surgery, 
restarting 6 to 
8h after wound 
closure, for 31-
39 days. 
RECORD241 RCT, 
double-
blind, 
multicenter 
2509 Riva:61.4 
Enox:61.6 
Riva:54.3 
Enox:53.0 
Adults, ≥ 18 years 
old, submitted to 
total hip 
arthroplasty. 
Rivaroxaban 
10 mg, 1 id, 
p.o., starting 6 
to 8h after 
wound 
closure, for 
31-39 days. 
Enoxaparin 40 
mg, once daily, 
starting 12h 
before surgery, 
restarting 6 to 
8h after wound 
closure, for 10-
14 days. 
RECORD342 RCT, 
double-
blind, 
multicenter 
2531 Riva:67.6 
Enox:67.6 
Riva:70.2 
Enox:66.3 
Adults, ≥ 18 years 
old, submitted to 
total knee 
arthroplasty. 
Rivaroxaban 
10 mg, 1 id, 
p.o., starting 6 
to 8h after 
wound 
closure, for 
10-14 days. 
Enoxaparin 40 
mg, once daily, 
starting 12h 
before surgery, 
restarting 6 to 
8h after wound 
closure, for 10-
14 days. 
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RECORD424 RCT, 
double-
blind, 
multicenter 
3148 Riva:64.4 
Enox:64.7 
Riva:66.0 
Enox:64.1 
Adults, ≥ 18 years 
old, submitted to 
total knee 
arthroplasty. 
Rivaroxaban 
10 mg, 1 id, 
p.o., starting 6 
to 8h after 
wound 
closure, for 
10-14 days. 
Enoxaparin 30 
mg, s.c., every 
12h, starting 12 
to 24h after 
wound closure, 
for 10-14 days. 
Eriksson et al. 
(2007)40 
RCT, open-
label, 
multicenter 
641 Riva:67.0 
Enox:64.0 
Riva:51.0 
Enox:88.0 
Men aged   ≥ 18 
years old and 
postmenopausal 
women submitted 
to elective, primary 
total hip 
arthroplasty. 
Rivaroxaban 
2.5, 5, 10, 20, 
and 30 mg, 
every 12 h, 
p.o., starting 6 
to 8h after 
wound 
closure, and 
30 mg, every 
24h, starting 6 
– 8h after 
wound 
closure, for 5 -
9 days. 
Enoxaparin 40 
mg, once daily, 
starting in the 
evening before 
surgery, 
restarting 6 to 
8h after wound 
closure, for 5-9 
days. 
Eriksson et al. 
(2) (2006)39 
RCT, 
double-
blind, 
multicenter 
873 Riva:64.0 
Enox:65.6 
Riva:63.0 
Enox:64.0 
Men aged   ≥ 18 
years old and 
postmenopausal 
women submitted 
to elective, primary 
total hip 
arthroplasty. 
Rivaroxaban 5, 
10, 20, 30 and 
40 mg id, p.o., 
starting 6 to 
8h after 
wound 
closure, for 5 -
9 days. 
Enoxaparin 40 
mg, once daily, 
starting in the 
evening before 
surgery, 
restarting 6 to 
8h after wound 
closure, for 5-9 
days. 
Eriksson et al. 
(1) (2006)38 
RCT, 
double-
blind, 
multicenter 
722 Riva:64.0 
Enox:65.0 
Riva:54.0 
Enox:59.0 
Men aged   ≥ 18 
years old and 
postmenopausal 
women submitted 
to elective, primary 
total hip 
arthroplasty. 
Rivaroxaban 
2.5, 5, 10, 20, 
and 30 mg, 
every 12 h, 
p.o., starting 6 
to 8h after 
wound 
closure, for 5 -
9 days. 
Enoxaparin 40 
mg, once daily, 
starting in the 
evening before 
surgery, 
restarting 6 to 
8h after wound 
closure, for 5-9 
days. 
Turpie et al. 
(2005)37 
RCT, 
double-
blind, 
multicenter 
621 Riva:66.0 
Enox:66.0 
Riva:64.0 
Enox:55.0 
Men aged   ≥ 18 
years old and 
postmenopausal 
women submitted 
to elective, primary 
total knee 
arthroplasty. 
Rivaroxaban 
2.5, 5, 10, 20, 
and 30 mg, 
every 12 h, 
p.o., starting 6 
to 8h 
postsurgery, 
for 5 -9 days. 
Enoxaparin 30 
mg, s.c., every 
12h, starting on 
the morning 
after surgery, 
for 5-9 days. 
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 Rivaroxaban treatment schedules for thromboprophylaxis were comparable among 
the included RCTs. The patients of the rivaroxaban group received the first dose 6 to 8 
hours after skin wound closure. To avoid clinical heterogeneity, for the dose-ranging studies, 
only the patients that received a total daily dose of 10 mg were included in the analysis. In 
our study, all the patients received 10 mg/d of rivaroxaban (single dose or 5 mg twice day). 
 In the 4 apixaban RCT, the apixaban treatment group received the first dose 12 to 24 
hours after wound closure. In the apixaban dose-ranging study, only the patients that 
received 2.5 mg twice daily were included in the analysis. All the patients included in our 
study treated with apixaban received 2.5 mg twice a day. 
 The included treatment arms of apixaban and rivaroxaban correspond to the 
approved total daily dosage for thromboprophylaxis after total hip or knee arthroplasty, 
which is 5 mg for apixaban, given 2.5 mg twice daily, and 10 mg for rivaroxaban, given once 
daily or 5 mg twice daily. 
 Clinical trials included in the meta-analysis used either the enoxaparin dose and 
regimen approved for use in Europe (40 mg once daily, first dose received 12 hours or the 
evening before the surgery and medication resumed 6-8 hours after wound closure) or the 
regimen approved for use in North America (30 mg twice daily, first dose received on the 
morning after surgery or 12 or 24 hours after wound closure). The enoxaparin European 
regimen was administrated in 6 RCTs that evaluated rivaroxaban and in 2 RCTs that 
evaluated apixaban. The enoxaparin (North American regimen) was administrated in 2 RCTs 
that evaluated rivaroxaban and in 2 RCTs that evaluated apixaban. 
 
III.4.3. QUALITY ASSESSMENT OF THE INCLUDED STUDIES 
 
 The quality assessment of the included trials is presented in Table III.2. All but 1 RCT 
were double blind. Allocation concealment was adequate in 9 trials. In 3 trials, allocation 
concealment was unclear. Information on withdrawal rates was available for all trials and 
ranged from 9.5% to 44.1%. The monitoring of bleeding events was performed in all trials. 
Besides bleeding events, few adverse effects were specifically monitored. All trials used an 
independent adjudication committee masked to allocation to assess the outcomes. 
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III.4.4. PUBLICATION BIAS 
  
 We examined the funnel plot (standard error [SE] of log RR plotted against RR) and 
did not find evidence of publication bias. 
 
III.4.5. SAFETY EVALUATION RESULTS 
  
 Results of the meta-analysis comparing apixaban and rivaroxaban with enoxaparin are 
shown in Table III.3 and Table III.4. 
 According to the results, apixaban presented a more favorable safety profile 
compared with enoxaparin in the following outcomes: major bleeding events, all bleeding 
events, and clinically relevant nonmajor bleeding events for thromboprophylaxis after total 
knee arthroplasty. No significant differences were found when thromboprophylaxis after 
total hip arthroplasty was the case. For rivaroxaban, no statistically significant differences in 
safety profile were found when compared with enoxaparin. 
 
III.4.6. SENSITIVITY ANALYSIS 
  
 The sensitivity analysis limited to double-blind RCTs did not change the results. After 
removing a phase II, dose-ranging RCT, there were no significant differences for the 
incidence of clinically relevant nonmajor bleeding events between apixaban and enoxaparin 
thromboprophylaxis after total knee arthroplasty (6193 patients, RR: 0.75, 95% CI: 0.56-
1.00, P = 0.05). For all other outcomes in knee or hip arthroplasty thromboprophylaxis, the 
removing of any other phase II, dose-ranging, study did not change the results. 
 For the sensitivity analysis, studies that compared direct inhibitor of coagulation 
factor Xa with twice daily enoxaparin 30 mg were excluded (Supplmental Data III.2). The 
removal of RCTs using enoxaparin on the North American regimen as active control did not 
significantly affect any outcome with rivaroxaban after total hip arthroplasty. One RCT 
compared rivaroxaban and enoxaparin on European regimen for thromboprophylaxis after 
total knee arthroplasty (LASSEN et al., 2008). The results of that RCT were similar to those 
obtained in this meta-analysis, for all outcomes. One RCT compared apixaban with 
enoxaparin European regimen for thromboprophylaxis after total knee arthroplasty (LASSEN 
et al., 2010). The results of this RCT were different from those obtained in this meta-
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analysis. According to the results of that RCT, there were no significant differences in the 
incidence of bleeding outcomes when apixaban was compared with once daily enoxaparin 40 
mg (major bleeding events: 3009 patients, RR: 0.65, 95% CI: 0.28-1.49, P = 0.30; all bleeding 
events: 3009 patients, RR: 0.83, 95% CI: 0.65-1.06, P = 0.14; clinically relevant nonmajor 
bleeding events: 3009 patients, RR: 0.76, 95% CI: 0.52-1.12, P = 0.17). After removing the 
RCTs that used enoxaparin on North American regimen as active control, no statistically 
significant differences were observed for wound bleeding rates, drug-related AE rates, and 
drug-related serious AE rates for both apixaban and rivaroxaban. 
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Table III.2 - Quality assessment of included studies. 
Study Design Allocation 
concealment 
Adverse event monitoring Adjudication of 
adverse events 
Withdrawal 
rate, % 
ADVANCE-121 Double-
blind 
Adequate Primary safety outcome was bleeding 
during treatment (major, clinically 
relev. nonmajor, minor). Other 
outcomes were elevated liver 
enzymes, arterial thromboembolic 
events during treatment and f-up. 
Independent central 
adjudication committee 
unaware of patient’s 
assigned treatment. 
 
Apixaban  27.6% 
Enoxaparin  29.2% 
ADVANCE-222 Double-
blind 
Adequate Primary safety outcome was bleeding 
during treatment (major, clinically 
relev. nonmajor, minor). Other 
outcomes were elevated liver 
enzymes, arterial thromboembolic 
events during treatment and f-up. 
Independent central 
committee unaware of 
patient’s assigned 
treatment. Patients 
screened daily while in 
hospital. 
 
Apixaban  36.0% 
Enoxaparin  35.0% 
ADVANCE-312 Double-
blind 
Adequate Primary safety outcome was bleeding 
during treatment (major, clinically 
relev. nonmajor, minor). Other 
outcomes were elevated liver 
enzymes, arterial thromboembolic 
events and thrombocytopenia during 
treatment and f-up. 
Independent central 
committee unaware of 
patient’s assigned 
treatment. Patients 
screened daily while in 
hospital. 
 
Apixaban  28.0% 
Enoxaparin  29.0% 
APROPOS36 Double-
blind 
Adequate Primary safety outcome was major 
bleeding during treatment. Minor 
bleeding, any bleeding, potentially 
significant non-overt bleeding, and 
AEs during treatment were also 
assessed. 
Independent central 
committee unaware of 
patient’s assigned 
treatment. Patients 
screened daily while in 
hospital. Safety was 
assessed via the review 
of all reported AEs, 
laboratory test results, 
and adjudicated bleeding 
events. 
 
Apixaban  27.4% 
Enoxaparin  28.3% 
RECORD123 Double-
blind 
Adequate Primary safety outcome was major 
bleeding during treatment. Other 
safety outcomes were any bleeding, 
nonmajor bleeding, hemorrhagic 
wound complications, AEs and death 
during treatment. During treatment 
and f-up were assessed laboratory 
variables and cardiovascular events.  
Independent central 
adjudication committee 
unaware of patient’s 
assigned treatment. 
 
Rivaroxaban  29.6% 
Enoxaparin  31.5% 
RECORD241 Double-
blind 
Adequate Primary safety outcome was major 
bleeding during treatment. Other 
safety outcomes were any bleeding, 
nonmajor bleeding, hemorrhagic 
wound complications, AEs and death 
during treatment. During treatment 
and f-up were assessed laboratory 
variables and cardiovascular events. 
Independent central 
adjudication committee 
unaware of patient’s 
assigned treatment. 
Cardiovascular events 
were independently and 
blindly adjudicated. 
 
Rivaroxaban  23.2% 
Enoxaparin  23.5% 
RECORD342 Double-
blind 
Adequate Primary safety outcome was major 
bleeding during treatment. Other 
safety outcomes were any bleeding, 
nonmajor bleeding, hemorrhagic 
wound complications, AEs and death 
during treatment. During treatment 
and f-up were assessed laboratory 
variables and cardiovascular events. 
Independent central 
adjudication committee 
unaware of patient’s 
assigned treatment. 
 
Rivaroxaban  27.6% 
Enoxaparin  27.6% 
RECORD424 Double-
blind 
Adequate Primary safety outcome was major 
bleeding during treatment. Secondary 
outcome was clinically relev. 
nonmajor bleeding. Other safety 
outcomes were any bleeding, any 
nonmajor bleeding, hemorrhagic 
wound complications, AEs and death 
during treatment. During treatment 
and f-up were assessed laboratory 
variables and cardiovascular events. 
Central independent 
adjudication committees 
masked to allocation 
assessed all outcomes. 
 
Rivaroxaban  29.2% 
Enoxaparin  28.9% 
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Eriksson et al. 
(2007)40 
Open-
label 
Unclear Primary safety outcome was major, 
post-operative bleeding during 
treatment. Secondary outcome was 
clinically relev. nonmajor bleeding. 
Other safety outcomes were any 
bleeding, any nonmajor bleeding, 
hemorrhagic wound complications, 
AEs and death during treatment. 
During treatment and f-up were 
assessed laboratory variables and 
cardiovascular events. 
Study drug allocation was 
not revealed to the 
adjudication committees, 
who performed their 
assessments in a blinded 
manner. 
 
Rivaroxaban  9.5% 
Enoxaparin  25% 
Eriksson et 
al.(2) (2006)39 
Double-
blind 
Unclear Primary safety outcome was major, 
post-operative bleeding during 
treatment. Other safety outcomes 
were clinically relev. nonmajor 
bleeding events and minor bleeding 
events, hematology and clinical 
chemistry laboratory tests, including 
liver function and coagulation tests. 
Post-operative blood loss and 
transfusion volumes were 
documented during treatment period.  
All bleeding events were 
assessed centrally by the 
Bleeding Event 
Adjudication Committee. 
All adjudication 
committees were 
independent and blinded 
to treatment allocation. 
 
Rivaroxaban 20.5% 
Enoxaparin 31.8% 
Eriksson et 
al.(1) (2006)38 
Double-
blind 
Unclear Primary safety outcome was major, 
postoperative bleeding during 
treatment. Other safety outcomes 
were clinically relev. nonmajor 
bleeding events and minor bleeding 
events, hematology and clinical 
chemistry laboratory tests, including 
liver function and coagulation tests, 
and serious treatment emergent AEs. 
Post-operative blood loss and 
transfusion volumes were 
documented during treatment period. 
All bleeding events were 
assessed centrally by the 
Bleeding Event 
Adjudication Committee. 
All adjudication 
committees were 
independent and blinded 
to treatment allocation. 
 
Rivaroxaban 44.1% 
Enoxaparin 32.6% 
Turpie et al. 
(2005)37 
Double-
blind 
Adequate Primary safety outcome was major, 
postoperative bleeding during 
treatment. Other safety outcomes 
were clinically relev. nonmajor 
bleeding events and minor bleeding 
events. Post-operative blood loss and 
transfusion volumes were 
documented during treatment period. 
All bleeding events were 
assessed centrally by a 
blinded independent 
bleeding event 
committee. 
 
Rivaroxaban 19.8% 
Enoxaparin 19.7% 
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Table III.3 - Outcomes of meta-analysis comparing apixaban and enoxaparin. 
 
RCTs Apixaban Enoxaparin Heterogeneity RR 
Outcomes n n/N (%) n/N (%) P I2 I.C. 95% P 
Major bleeding events  
  
    
Knee 3 20/3251 (0.65%) 36/3245 (1.11%) 0.64 0% 0.56 [0.32-0.96] 0.03 
Hip 1 22/2673 (0.82%) 18/2659 (0.68%) - - 1.22 [0.65-2.26] 0.54 
All bleeding events  
  
    
Knee 3 195/3251 (5.99%) 242/3245 (7.46%) 0.94 0% 0.81 [0.67-0.97] 0.02 
Hip 1 323/2673 (12.08%) 334/2659 (12.56%) - - 0.93 [0.81-1.08] 0.34 
Clinically relevant 
nonmajor bleeding events 
 
  
    
Knee 3 79/3251 (2.43%) 107/3245 (3.30%) 0.68 0% 0.74 [0.56-0.99] 0.04 
Hip 1 109/2673 (4.08%) 120/2659 (4.51%) - - 0.90 [0.70-1.16] 0.43 
Drug-related AEs 2 534/3097 (17.24%) 558/3096 (18.02%) 0.81 0% 0.96 [0.86-1.06] 0.40 
Drug-related serious AEs 2 27/3097 (0.87%) 41/3096 (1.32%) 0.50 0% 0.66 [0.41-1.07] 0.09 
Wound bleedings 3 167/5770 (2.89%) 208/5755 (3.61%) 0.25 27% 0.78 [0.61-1.00] 0.05 
 
 
Table III.4 - Outcomes of meta-analysis comparing rivaroxaban and enoxaparin. 
 
RCTs Rivaroxaban Enoxaparin Heterogeneity RR 
Outcomes n n/N (%) n/N (%) P I2 I.C. 95% P 
Major bleeding  events  
  
    
Knee 3 17/2848 (0.60%) 12/2851 (0.42%) 0.28 22% 1.40 [0.56-3.52] 0.47 
Hip 5 13/3795 (0.34%) 8/3904 (0.20%) 0.44 0% 1.70 [0.67-4.32] 0.27 
All bleeding events  
  
    
Knee 3 229/2848 (8.04%) 210/2851 (7.37%) 0.90 0% 1.09 [0.91-1.30] 0.36 
Hip 5 247/3795 (6.51%) 232/3904 (5.94%) 0.38 5% 1.10[0.92-1.33] 0.30 
Clinically relevant 
nonmajor bleeding events 
 
  
    
Knee 3 75/2848 (2.63%) 61/2851 (2.14%) 0.95 0% 1.23 [0.88-1.72] 0.22 
Hip 5 117/3795 (3.08%) 95/3904 (2.43%) 0.37 7% 1.20[0.89-1.63] 0.23 
Drug-related AEs 4 971/6183 (1.57%) 970/6200 (15.65%) 0.50 0% 1.00 [0.92-1.09] 0.95 
Drug-related serious AEs 2 39/2448 (1.59%) 36/2468 (1.46%) 0.21 37% 1.07 [0.60-1.91] 0.82 
Wound bleedings 6 105/6399 (1.64%) 106/6494 (1.63%) 0.64 0% 0.99 [0.76-1.29] 0.94 
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III.5. DISCUSSION 
 
 Clinical guidelines recommend pharmacological prophylaxis for patients undergoing 
total knee and hip arthroplasty for at least 10 days after the surgery (GEERTS et al., 2008; HILL 
et al., 2010; JOHANSON et al., 2009). New oral anticoagulants, such as apixaban and 
rivaroxaban, may provide a more suitable antithrombotic therapy and increase patient 
compliance, when compared with available alternatives (LMWH and vitamin K antagonists). 
 Several RCTs compared rivaroxaban versus enoxaparin for thromboprophylaxis after 
total knee or hip arthroplasty, reporting higher efficacy of rivaroxaban when compared with 
both European and North American enoxaparin regimens (ERIKSSON et al., 2008; TURPIE et 
al., 2009; KAKKAR et al., 2008; LASSEN et al., 2008). A previous meta-analysis confirmed that 
rivaroxaban was superior to enoxaparin as a thromboprophylaxis agent after total hip and 
knee surgery (CAO et al., 2010). However, a higher number of bleeding events associated 
with rivaroxaban was identified. As a consequence, the authors do not recommend the use 
of rivaroxaban in patients susceptible to hemorrhage. 
 Apixaban was proven to be at least as effective as enoxaparin for 
thromboprophylaxis after total knee or hip arthroplasty (LASSEN et al., 2010a; LASSEN et al., 
2009; LASSEN et al., 2010b). Although in ADVANCE 1 study apixaban was not shown to be 
superior to enoxaparin (North American regimen) after knee arthroplasty, it was associated 
with a lower bleeding risk (LASSEN et al., 2009). When compared with enoxaparin European 
regimen, apixaban was superior in preventing thromboembolism after knee and hip 
arthroplasty without increased bleeding risk (LASSEN et al., 2010a; LASSEN et al., 2010b). 
Another published meta-analysis points out apixaban as effective as enoxaparin for 
thromboprophylaxis after total knee arthroplasty (HUANG et al., 2011). In this study, 
apixaban is associated with significantly fewer major bleeding events. These findings raised 
the need to comparatively evaluate the safety profiles of apixaban and rivaroxaban, once 
both the drugs were proven to be efficacious in preventing VTE events. 
 Our meta-analysis included enoxaparin RCTs, in the absence of studies comparing 
directly both drugs. The results suggest that thromboprophylaxis with apixaban after total 
knee arthroplasty is associated with a lower risk of major, clinically relevant nonmajor, and 
total bleeding events, when compared with rivaroxaban. No differences were observed 
when apixaban and rivaroxaban were compared for thromboprophylaxis after total hip 
arthroplasty. 
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 In order to avoid clinical heterogeneity of the studies, 2 subgroup meta-analyses were 
carried out according to the approved therapeutic indications (hip and knee surgery). A 
sensitivity analysis was also performed aiming at preventing erroneous interpretations of the 
results. The removing of phase II, dose-ranging, RCTs from the meta-analysis did not 
significantly altered the results. Eight RCTs (2 with apixaban and 6 with rivaroxaban) used 
enoxaparin according to the European regimen (40 mg, once daily) and 4 RCTs (2 with 
apixaban and 2 with rivaroxaban) used enoxaparin according to the North American 
regimen (30 mg, twice daily). The indirect comparison of apixaban with rivaroxaban based on 
the enoxaparin European regimen significantly altered the results. These findings could 
suggest that twice daily enoxaparin 30 mg is associated with a higher risk of bleeding. 
Although both the enoxaparin regimens have never been directly compared, this risk was 
also observed in a previous meta-analysis (HUANG et al., 2011). Nonetheless, indirect 
comparisons between the 2 inhibitors of coagulation factor Xa based on both enoxaparin 
regimens (European and North American) consistently present the trend for lower bleeding 
risk in patients treated with apixaban. 
 The overall incidence of drug-related adverse reactions of any cause was similar for 
both drugs. Apixaban was found to be less associated with wound hemorrhages, although 
this difference did not reach statistical significance. However, when major and nonmajor 
wound hemorrhages are observed separately, such difference was no longer observed. 
 Preclinical studies have shown that both rivaroxaban and apixaban are highly selective 
for factor Xa (BECATTINI, LIGNANI and AGNELLI, 2010). Although it is suggested that 
rivaroxaban could be associated with an increased factor Xa inhibitory potential (BARRET et 
al., 2010), this may cause differences in the efficacy and safety profile of both drugs. 
Therefore, there is a rationale to compare both rivaroxaban and apixaban safety profiles, 
since differences in the incidence of PE and major bleeding events can change benefit-risk 
balance that supports therapeutic decisions. 
 For the phase II dose-ranging studies, both apixaban and rivaroxaban were compared 
with enoxaparin regimens (LASSEN et al., 2007; TURPIE et al., 2005; ERIKSSON et al., 2006a; 
ERIKSSON et al., 2006b; ERIKSSON et al., 2007). Based on their phase II programs, rivaroxaban 
10 mg once daily and apixaban 2.5 mg twice daily have proven to have similar efficacy and 
safety to enoxaparin. Therefore, an indirect comparison can be established between 
rivaroxaban and apixaban safety profile based on their approved daily doses. 
 The findings of the present study are based on a pooled analysis of 28 483 patients. 
Safety outcomes considered in this meta-analysis were those defined in the included RCTs. 
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To our knowledge, this is the first study comparing the safety of the 2 marketed direct 
inhibitors of coagulation factor Xa. The findings of this meta-analysis may be useful to more 
accurately establish benefit-risk ratios of both drugs and in the individualization of drug 
therapy. 
 The present study has limitations. First, although it includes the results of well-
designed RCTs with a large number of patients, some relevant clinical outcomes such as 
rates of wound infection and wound healing were not assessed in all the included RCTs 
(JENSEN et al., 2011). Second, only 1 RCT evaluated the safety of apixaban in the 
thromboprophylaxis after total hip arthroplasty (LASSEN et al., 2010a). Although the RCT 
included a large number of patients, the availability of more studies would strength the 
analysis. Third, some heterogeneity between RCTs was found. Such differences could be due 
to differences in prophylactic treatment duration but also to different enoxaparin regimens 
(North American and European) used as active control. However, heterogeneity should 
always be taken into account since each RCT included different populations. Fourth, the 
number of eligible studies to perform a sensitivity analysis is few. Although an indirect 
comparison between apixaban and rivaroxaban had been done based on the enoxaparin 
European regimen, the sample of both included trials could not be powered enough to 
detect significant differences. 
 Bleeding is a major concern in patients submitted to thromboprophylaxis after hip or 
knee arthroplasty after hospital discharge (GEERTS et al., 2008; HILL et al., 2010; JOHANSON et 
al., 2009). New direct inhibitors of the coagulation factor Xa have proved to be effective in 
reducing the risk of TVE in a single, unmonitored dose, given orally, which can lead to a 
more effective anticoagulant therapy. The results of this study suggest that apixaban may be 
a safer alternative than rivaroxaban for thromboprophylaxis, when total knee arthroplasty is 
the case. However, more studies are needed, in particular with direct comparisons, in order 
to better establish the risk profile of these 2 therapeutic agents. 
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III.7. SUPPLEMENTAL DATA III 
 
III.7.1. SUPPLEMENTAL DATA III.1 - SEARCH STRATEGY 
 
 
Supplemental Table III.1 - Search strategy performed at MEDLINE and Cochrane Library at June 27, 2011. 
Search  PubMed Results 
1 
(thrombosis prophylaxis) OR (deep venous thrombosis prophylaxis) OR (thromboembolism prophylaxis) 
OR (DVT prophylaxis) OR (pulmonary embolism prophylaxis) OR (venous thromboembolism prophylaxis) 
OR (prevention of venous thromboembolism) OR (thromboprophylaxis) OR (prevention of 
thromboembolic events) 
32247 
2 
(knee operation) OR (knee surgery) OR (knee arthroplasty) OR (arthroplasty of knee) OR (knee total 
replacement) OR (total knee replacement) OR (total replacement of knee) 
49694 
3 
(hip arthroplasty) OR (arthroplasty of hip) OR (hip replacement) OR (hip total replacement) OR (total 
hip replacement) OR (hip surgery) OR (hip operation) 
49530 
4 apixaban OR (BMS 562247) OR eliquis 158 
5 rivaroxaban OR (BAY 59 7939) OR xarelto 349 
6 (((#3 OR #2) AND #1) AND #4) 26 
7 (((#3 OR #2) AND #1) AND #5) 93 
8 #6 OR #7 102 
Search Cochrane Library Results 
1 
((((knee operation) OR (knee surgery) OR (knee arthroplasty) OR (arthroplasty of knee) OR (knee total 
replacement) OR (total knee replacement) OR (total replacement of knee)) OR ((hip arthroplasty) OR 
(arthroplasty of hip) OR (hip replacement) OR (hip total replacement) OR (total hip replacement) OR 
(hip surgery) OR (hip operation))) OR ((thrombosis prophylaxis) OR (deep venous thrombosis 
prophylaxis) OR (thromboembolism prophylaxis) OR (DVT prophylaxis) OR (pulmonary embolism 
prophylaxis) OR (venous thromboembolism prophylaxis) OR (prevention of venous thromboembolism) OR 
(thromboprophylaxis) OR (prevention of thromboembolic events))) AND (rivaroxaban OR (BAY 59-
7939) OR xarelto) 
Reviews: 
10 
Clinical 
trials: 44 
2 
((((knee operation) OR (knee surgery) OR (knee arthroplasty) OR (arthroplasty of knee) OR (knee total 
replacement) OR (total knee replacement) OR (total replacement of knee)) OR ((hip arthroplasty) OR 
(arthroplasty of hip) OR (hip replacement) OR (hip total replacement) OR (total hip replacement) OR 
(hip surgery) OR (hip operation))) OR ((thrombosis prophylaxis) OR (deep venous thrombosis 
prophylaxis) OR (thromboembolism prophylaxis) OR (DVT prophylaxis) OR (pulmonary embolism 
prophylaxis) OR (venous thromboembolism prophylaxis) OR (prevention of venous thromboembolism) OR 
(thromboprophylaxis) OR (prevention of thromboembolic events))) AND (apixaban OR (BMS 562247) 
OR eliquis) 
Reviews: 
8 
Clinical 
trials: 9 
3 #1 OR #2 
Reviews: 
10 
Clinical 
trials: 53 
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III.7.2. SUPPLEMENTAL DATA III.2 - RESULTS OF SENSITIVITY ANALYSIS 
 
 
 
Supplemental Table III.2 - Results of the sensitivity analysis comparing apixaban and enoxaparin (40 mg 
once daily) for thromboprophylaxis after total knee arthroplasty (ADVANCE-2 study results). 
 
RCTs Apixaban Enoxaparin Heterogeneity RR 
Outcomes n n/N (%) n/N (%) P I2 I.C. 95% P 
Major bleeding events 1 9/1501 (0.60%) 14/1508 (0.93%) - - 0.65 [0.28-1.49] 0.30 
All bleeding events 1 104/1501 (6.93%) 126/1508 (8.36%) - - 0.83 [0.65-1.06] 0.14 
Clinically relevant 
nonmajor bleeding events 
1 44/1501 (2.93%) 58/1508 (3.85%) - - 0.76 [0.52-1.12] 0.17 
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IV. A META-ANALYSIS OF SERIOUS ADVERSE EVENTS REPORTED WITH EXENATIDE 
AND LIRAGLUTIDE: ACUTE PANCREATITIS AND CANCER 
 
IV.1. ABSTRACT 
 
The association between Glucagon-like peptide-1 (GLP-1) agonists, acute pancreatitis (AP), 
any cancer and thyroid cancer is discussed. This meta-analysis was aimed at evaluating the 
risk of those serious AEs associated with GLP-1 agonists in patients with type 2 diabetes. 
MEDLINE, EMBASE, Cochrane Library and clinicaltrials.gov were searched in order to 
identify longitudinal studies evaluating exenatide or liraglutide use and reporting data on AP 
or cancer. ORs were pooled using a random-effects model. I2 statistics assessed 
heterogeneity. Twenty-five studies were included. Neither exenatide (OR 0.84 [95% CI 
0.58–1.22], I2 = 30%) nor liraglutide (OR 0.97 [95% CI 0.21–4.39], I2 = 0%) were associated 
with an in-creased risk of AP, independent of baseline comparator. The pooled OR for 
cancer associated with exenatide was 0.86 (95% CI 0.29, 2.60, I2 = 0%) and for liraglutide 
was 1.35 (95% CI 0.70, 2.59, I2 = 0%). Liraglutide was not associated with an increased risk 
for thyroid cancer (OR 1.54 [95% CI 0.40–6.02], I2 = 0%). For exenatide, no thyroid 
malignancies were reported. Current available published evidence is insufficient to support 
an increased risk of AP or cancer associated with GLP-1 agonists. These rare and long-term 
AEs deserve properly monitoring in future studies evaluating GLP-1 agonists. 
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IV.2. INTRODUCTION 
 
 Pharmacological treatment of type 2 diabetes mellitus usually requires the sequential 
addition of antihyperglycemic agents (NATHAN et al., 2009). Both the American Diabetes 
Association (ADA) and the European Association for the Study of Diabetes (EASD) 
consensus algorithm for the treatment of type 2 diabetes mellitus recommends the initiation 
of metformin and a lifestyle modification program at the time of diagnosis (NATHAN et al., 
2009). Sulphonylureas, thiazolidinediones and insulin can be subsequently added to the 
therapy (NATHAN et al., 2009). 
 Glucagon-like peptide-1 agonists are a new class of blood-glucose lowering drugs 
indicated for the treatment of type 2 diabetes mellitus (DRUCKER et al., 2008; MADSBAD et al., 
2004). The first in class, exenatide twice-daily (BID) (ByettaTM, Amylin Pharmaceuticals, San 
Diego, CA, USA/Eli Lilly and Company, Indianapolis, IN, USA), was approved by the FDA and 
by the EMA in 2005 and 2006, respectively (US FOOD AND DRUG ADMINISTRATION, 2005; 
EUROPEAN MEDICINES AGENCY, 2006). Lately, a once-weekly (QW) presentation of exenatide 
(BydureonTM) received a market authorization in Europe (2011) and in the United States 
(2012) (US FOOD AND DRUG ADMINISTRATION, 2012; EUROPEAN MEDICINES AGENCY, 2011). 
Liraglutide (VictozaTM, Novo Nordisk A/S, Bagsværd, Denmark) was authorized by EMA and 
FDA in 2009 and 2010, respectively (US FOOD AND DRUG ADMINISTRATION, 2010; EUROPEAN 
MEDICINES AGENCY, 2009). During the clinical development programmes, the GLP-1 agonists 
have demonstrated the potential to address fasting and postprandial glucose control with 
weight loss and low risk of hypoglycaemia (EUROPEAN MEDICINES AGENCY, 2006; EUROPEAN 
MEDICINES AGENCY, 2009; EUROPEAN MEDICINES AGENCY, 2011). However, this new class of 
antihyperglycaemic drugs has demanded some attention since potentially, although rare, 
serious AEs have been associated with their use (DRUCKER et al., 2010). 
 Post-marketing spontaneous reports of acute pancreatitis among patients treated 
with exenatide BID have been submitted to FDA’s Adverse Event Reporting System (FDA-
AERS) since 2005 (US FOOD AND DRUG ADMINISTRATION, 2007). Signal generation analyses of 
this database identified an increased risk for acute pancreatitis associated with exenatide 
(ELASHOFF et al., 2011; RASCHI et al., 2013). However, further observational longitudinal 
studies did not confirm such findings (DORE, SEEGER and CHAN, 2009; GARG, CHEN, and 
PENDERGRASS, 2010; DORE et al., 2011). The post-marketing case reports led to an update of 
the exenatide’ product labeling, on request of FDA (US FOOD AND DRUG ADMINISTRATION, 
A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer 
171 
2009). Acute pancreatitis was also reported in RCTs with liraglutide (PARKS and 
ROSENBRAUGH, 2010). 
 Benign thyroid C-cell adenomas were observed in rodents treated with exenatide 
BID but no carcinomas were reported (EUROPEAN MEDICINES AGENCY, 2006; DRUCKER et al., 
2010). Thyroid tumors occurred in rats administered with exenatide QW in carcinogenicity 
studies (EUROPEAN MEDICINES AGENCY, 2011). During RCTs, unspecified neoplasms have 
been reported in patients treated with exenatide BID (EUROPEAN MEDICINES AGENCY, 2006). 
For liraglutide, C-cell hyperplasia and thyroid cancer were observed in pre-clinical toxicology 
studies (EUROPEAN MEDICINES AGENCY, 2009; BJERRE KNUDSEN et al., 2010). Several cases of 
thyroid cancer were also reported during the liraglutide clinical development programme 
(EUROPEAN MEDICINES AGENCY, 2009; PARKS and ROSENBRAUGH, 2010). When approved by 
FDA, liraglutide label carries a Black Box warning regarding the risk of thyroid c-cell cancer 
(US FOOD AND DRUG ADMINISTRATION, 2010). 
 This study was aimed at evaluating the risk of acute pancreatitis, any cancer or 
thyroid cancer, associated with GLP-1 agonists, exenatide and liraglutide, by carrying out a 
meta-analysis based on both experimental and observational published studies. 
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IV.3. METHODS 
 
IV.3.1. LITERATURE SEARCH 
 
 MEDLINE and Cochrane Library were searched from its inception until May 24, 2012 
in order to identify relevant studies which evaluated GLP-1 agonists holding a market 
authorization (US FOOD AND DRUG ADMINISTRATION, 2005; EUROPEAN MEDICINES AGENCY, 
2006; US FOOD AND DRUG ADMINISTRATION, 2012; EUROPEAN MEDICINES AGENCY, 2011; US 
FOOD AND DRUG ADMINISTRATION, 2010; EUROPEAN MEDICINES AGENCY, 2009]. Text words, 
brand names and manufacturer’s coded designations were used to identify the medicines. 
Only literature published in the English language was considered for inclusion in this analysis. 
In order to ensure that all studies were identified, a second electronic search in the Medline 
and EMBASE was performed. Search terms related with pancreatitis and with cancer were 
combined with the medicines designations priori stated. The search terms were identified by 
consulting the MedDRA dictionary (MEDICAL DICTIONARY FOR REGULATORY ACTIVITIES, 2011). 
Bibliographic references list of all relevant studies, meta-analyses and reviews were hand 
searched in order to identify additional eligible articles. The registration site clinicaltrials.gov 
was searched in order to identify all studies with available results that evaluated exenatide or 
liraglutide in type 2 diabetes mellitus. We did not seek to identify safety information of GLP-
1 agonists beyond published studies. All the studies reporting zero events in the treatment 
and/or control group were included. The electronic databases search strategy is available in 
Supplemental Data IV.I. 
 
IV.3.2. STUDY SELECTION AND QUALITY ASSESSMENT 
 
 Literature was searched and relevant studies were selected for further assessment. 
The studies inclusion criteria were: 1 - published in English language; 2 - RCTs or longitudinal 
observational studies (case-control or cohort studies); 3 - patients of all ages with type 2 
diabetes mellitus; 4 - comparison of GLP-1 agonists with a placebo or active control (oral 
hypoglycaemic agents or insulin) and 5 - effect estimates on acute pancreatitis or cancer 
associated with GLP-1 agonists use. Only studies with duration of at least 12 weeks were 
included. 
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 The quality of the retrieved studies was assessed using the checklist proposed by 
Downs and Black (DOWNS and BLACK, 1998). Studies’ methodological quality was assessed 
as high, moderate or low when the total score was ≥ 20, from 10 to 19, and < 10, 
respectively. When more than one reference was found for the same study, methodological 
quality evaluation was based on the total set of information. Two investigators scored the 
studies independently. Disagreement was resolved by discussion and consensus with a third 
investigator. 
 
IV.3.3. DATA EXTRACTION AND OUTCOMES ASSESSED 
 
 Data on study design, study duration, characteristics of participants, 
antihyperglycaemic therapy (dosage and treatment duration) and estimated effect measures 
or specified outcomes was extracted. 
 The following outcomes were considered: acute pancreatitis, any cancer and thyroid 
cancer. For any cancer as an outcome, all the events defined as ‘Neoplasms benign, malignant 
and unspecified (including cysts and polyps)’ according to the MedDRA dictionary were 
considered (MEDICAL DICTIONARY FOR REGULATORY ACTIVITIES, 2011). For thyroid cancer, all 
terms were considered as those defined in the MedDRA dictionary were taking into 
consideration (MEDICAL DICTIONARY FOR REGULATORY ACTIVITIES, 2011). 
 
IV.3.4. STATISTICAL ANALYSIS 
 
 A meta-analysis was performed by pooling ORs with their 95% confidence intervals 
CIs, using the DerSimonian and Laird random-effects model and assuming that OR was an 
unbiased estimate of the RR (DERSIMONIAN and LAIRD, 1986). This model was chosen since 
the validity of tests of heterogeneity can be limited with a small number of component 
studies and it is more conservative than a fixed-effect model in the presence of between-
studies heterogeneity. When more than one adjusted effect estimate was reported, the most 
adjusted estimate was used. For studies with more than one intervention-arm, the number 
of events and the number of exposures were added. The same was applied when studies 
with multiple controls were the case. Between-studies heterogeneity was assessed by 
calculating a chi-square test and the I2 measure of inconsistency (HIGGINS et al., 2003). When 
no events were reported in one or both groups, a continuity correction of 0.5 was added to 
each cell. 
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 The publication bias was visually examined by a funnel plot and statistically evaluated 
by Egger’s regression asymmetry test (BORENSTEIN et al., 2009; EGGER et al., 1997). 
 A sensitivity analysis was conducted to explore the influence of the following 
variables on the summary estimates: studies’ design, studies’ methodological quality scores, 
the nature of the comparators (placebo or active control) and different GLP-1 agonists dose 
regimens (weekly or daily). All reported P values are 2-sided with significance being set as 
less than 0.05. 
 Review Manager (RevMan) version 5.1.6 (Cochrane Collaboration, Oxford, UK) and 
Comprehensive Meta-analysis Version 2 (Biostat, Englewood, NJ, USA) were used for all 
statistical analysis. 
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IV.4. RESULTS 
 
 The flowchart of the search strategy criteria is presented in Figure IV.1. The 
electronic databases searches returned 4373 possible eligible references. After excluding for 
duplicates and screening the titles and abstracts, 179 bibliographic references were selected 
and full reports were obtained and evaluated in detail against inclusion criteria. A final sample 
of 40 references was eligible for inclusion, corresponding to 25 studies. No further studies 
meeting the inclusion criteria were identified throughout the studies back references lists’. 
Of the included studies in the analysis, 3 were retrospective cohorts and the remaining were 
RCTs. Two studies directly compared exenatide and liraglutide (Supplemental IV.2 
References 13,14,21).  
 The main characteristics of the studies and their methodological quality are 
presented in Table IV.1. More than one article can be referred to one study. For some 
studies, the information from the public database clinicaltrials.gov complemented that 
reported in published papers (e.g., length of follow-up). The methodological quality was 
considered ‘‘high’’ for 15 studies and ‘‘moderate’’ for the other 10 studies. 
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Figure IV.1 - Flow diagram of identification of studies for inclusion. 
 
 
2379 articles screened 
1994 duplicates 
139 full-text articles excluded: 
5 evaluated obese patients 
6 evaluated type 1 diabetes patients 
10 evaluated healthy patients 
1 evaluated metabolic syndrome 
31 < 12 weeks interventional period 
8 interin analysis of RCTs 
2 analysis of disproportion 
54 no relevant outcomes 
22 uncontrolled studies 
40 references included: 
Exenatide: 19 references; 12 studies 
Liraglutide: 18 references; 11 studies 
Exenatide + Liraglutide: 3 references; 
2 study 
4373 references retrieved 
- 0 relevant studies found by 
hand search of reference lists, 
reviews or meta-analysis 
164 full-text articles 
assessed for eligibility 
2215 articles excluded after 
titles and abstracts review 
15 references from 
clinicaltrials.gov 
4 studies not published as 
full-papers 
11 duplicates  
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Table IV.1 - Characteristics of the studies included in the meta-analysis. 
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IV.4.1. ACUTE PANCREATITIS 
 
 Thirteen studies of exenatide reported acute pancreatitis outcomes (Figure IV.2a). 
Pooling their estimates yielded an OR of 0.84 (95% CI 0.58–1.22). Similar results were found 
in the subgroup analysis according to study design for both RCTs (OR 1.70, 95% CI 0.35–
8.29) and retrospective cohorts (OR 0.79, 95% CI 0.49–1.27) (Table IV.2). Between-studies 
heterogeneity accounted for 30% (P = 0.20) of variation in treatment effect, mainly among 
observational studies (I2 = 70%, P = 0.03) than between RCTs (I2 = 0%, P = 0.76). The results 
did not significantly change from the initial estimates when stratification according to 
different controls, exenatide dose regimens or when only high methodological quality studies 
were considered. Non-significant between-studies heterogeneity was observed (Table IV.2). 
 Twelve liraglutide RCTs reported acute pancreatitis as an outcome (Figure IV.2a). 
The estimated OR for liraglutide and acute pancreatitis was 0.97 (95% CI 0.21 - 4.39). No 
significant between-studies heterogeneity was observed. The sensitivity analysis according to 
different controls and the methodological quality of the studies did not significantly change 
the results (Table IV.2).  
 No significant risk reduction was observed in acute pancreatitis for both GLP-1 
agonists (OR 0.87, 95% CI 0.64 -1.17). 
 
IV.4.2. ANY CANCER 
 
 Ten RCTs studying exenatide reported cancer outcomes (Figure IV.2b). Exenatide 
was not associated with a significant risk of cancer development (OR 0.86, 95% CI 0.29 - 
2.60). The sensitivity analysis according to the different controls, therapeutic regimen and 
the methodological quality of the studies did not significantly change the results (Table IV.2). 
 Ten RCTs with liraglutide in type 2 diabetes mellitus reported cancer outcomes 
(Figure IV.2b). Liraglutide was associated with a statistically non-significant 35% increased risk 
for any cancer development (OR 1.35, 95% CI 0.70 - 2.59). When liraglutide was compared 
with different controls, the results did not become statistically significant. However, the 
stratification of the results becomes statistically significant when only methodological studies 
of high quality were considered (OR 2.60, 95% CI 1.08 - 6.27) (Table IV.2). 
 No significant risk reduction was observed in cancer for both GLP-1 agonists (OR 
1.24, 95% CI 0.68 - 2.27) and no significant heterogeneity was observed in any of the 
comparisons (Table IV.2). 
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IV.4.3. THYROID CANCER 
 
 None of the studies evaluating exenatide reported cases of thyroid cancer. Of the 
studies evaluating liraglutide, five reported cases of thyroid cancer. Nine patients treated 
with liraglutide were diagnosed with thyroid cancer comparing to one patient who 
developed this type of cancer and was treated with glimepiride (Supplemental Data IV.2 
References 4-6, 9, 10, 13, 14, 16-18). The OR for thyroid cancer occurrence associated with 
liraglutide treatment was 1.54 (95% CI 0.40-6.02, P = 0.53, I2 = 0%). 
 
IV.4.4. PUBLICATION BIAS ASSESSMENT 
  
 Egger’s asymmetry test was not statistically significant for the primary or and most 
subgroup analyses but was significant for the analysis among exenatide RCTs (P = 0.01) and 
for once- weekly exenatide regimen studies (P = 0.01) (Table IV.2). Subjective evaluation of 
publication bias was based on the visual inspection of funnel plot. Few studies were 
considered for both the analyses, not allowing firm conclusions about the potential 
publication bias. Regarding cancer risk assessment, large studies are possibly absent for both 
exenatide and liraglutide. 
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Figure IV.2 - Pooled ORs and 95% CIs of (a) acute pancreatitis and (b) overall cancer associated with GLP-1 
agonists. 
Note: * For GLP-1 receptor agonists overall pooled results, LEAD-6 and NCT01029886 studies were not 
included 
 
a) 
* 
b) * 
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Table IV.2 - Pooled ORs and 95% CIs of acute pancreatitis and cancer associated with GLP-1 agonists. 
GLP-1 receptor 
agonists 
Studies Odds Ratio (OR) Heterogeneity Publication 
bias* 
N 95% IC P P I2 P 
Acute pancreatitis 
Exenatide 
All studies 13 0.84 [0.58, 1.22] 0.37 0.20 30% 0.94 
RCTs 10 1.70 [0.35, 8.29] 0.51 0.76 0% 0.01 
Retrospective cohorts 3 0.79 [0.49, 1.27] 0.32 0.03 70% 0.22 
vs Insulin 3 2.86 [0.29, 27.86] 0.37 0.99 0% - 
vs OADs 2 0.82 [0.51, 1.33] 0.43 0.65 9% - 
Twice-daily 10 0.81 [0.51, 1.27] 0.36 0.06 59% 0.64 
Once weekly 3 1.45 [0.24, 8.90] 0.69 0.60 0% 0.01 
High quality 7 1.42 [0.23, 8.81] 0.70 0.61 0% 0.09 
Liraglutide 
All studies 12 0.97 [0.21, 4.39] 0.97 0.70 0% 0.97 
vs Placebo 6 0.51 [0.02, 12.54] 0.68 - - - 
vs OADs 3 1.12 [0.20, 6.23] 0.89 0.50 0% 0.58 
High quality 3 1.31 [0.24, 7.24] 0.76 0.63 0% 0.63 
GLP-1 Agonists 21 0.87 [0.64, 1.17] 0.34 0.34 12% 0.93 
Cancer 
Exenatide 
All studies 10 0.86 [0.29, 2.60] 0.79 0.48 0% 0.33 
vs Placebo 3 0.24 [0.01, 3.90] 0.31 - - - 
vs OADs 1 0.69 [0.03, 16.94] 0.82 - - - 
vs Insulin 4 1.48 [0.29, 7.52] 0.64 0.46 0% 0.22 
Twice-daily 7 0.50 [0.12, 2.05] 0.34 0.38 3% 0.78 
Once weekly 3 2.20 [0.36, 13.53] 0.40 0.67 0% 0.49 
High quality 7 0.56 [0.13, 2.37] 0.43 0.60 0% 0.67 
Liraglutide 
All studies 10 1.35 [0.70, 2.59] 0.37 0.60 0% 0.27 
vs Placebo 4 0.53 [0.17, 1.65] 0.28 0.86 0% 0.72 
vs OADs 6 1.56 [0.74, 3.32] 0.24 0.76 0% 0.82 
High quality 5 2.60 [1.08, 6.27] 0.03 0.90 0% 0.84 
GLP-1 Agonists 16 1.24 [0.68, 2.27] 0.49 0.80 0% 0.23 
 
Note: * Egger’s regression asymmetry test. For GLP-1 agonists pooled results, both LEAD-6 and 
NCT01029886 studies weren’t included. 
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IV.5. DISCUSSION 
 
 The results of this meta-analysis suggest that neither exenatide nor liraglutide 
increase the risk for acute pancreatitis, when used in the treatment of type 2 diabetes 
mellitus. However, no conclusions can be drawn since the analysis is based on small studies, 
possibly underpowered to detect rare AEs. 
 Our findings are in line with those reported in longitudinal observational studies 
which evaluated the risk for acute pancreatitis associated with exenatide (DORE, SEEGER and 
CHAN, 2009; GARG, CHEN, and PENDERGRASS, 2010; DORE et al., 2011). The rates of acute 
pancreatitis in those studies were less than 0.5%, indicating that this is a rare AE. Our search 
did not find post-market observational studies for liraglutide. 
 Although evidence of association has not been established between GLP-1 agonists 
and acute pancreatitis, a few potentially confounding factors should be considered. Nausea, 
abdominal discomfort and vomiting are adverse drug reac-tions known to be associated with 
GLP-1 agonists use (EUROPEAN MEDICINES AGENCY, 2006; EUROPEAN MEDICINES AGENCY, 
2009; EUROPEAN MEDICINES AGENCY, 2011). Since these events are also symptoms of acute 
pancreatitis, its recognition and appropriately diagnose may become difficult (BALANI and 
GRENDELL, 2008). We only included studies with patients diagnosed with type 2 diabetes 
mellitus. It was recently documented that having type 2 diabetes puts patients in a higher risk 
of developing acute pancreatitis, independently of the drug therapy (NOEL et al., 2009). This 
may raise the question of whether the cases of acute pancreatitis are due to GLP-1 agonists 
therapy, to type 2 diabetes or to risk factors commonly seen in patients with type 2 diabetes 
- hypertriglyceridaemia, hyperlipidaemia, obesity, or concomitant medicines (ANDERSON and 
TRUJILLO, 2010). Considering that GLP-1 agonists were initially approved as type 2 diabetes 
add-on therapy and the recommendations of clinical guide-lines, patients receiving GLP-1 
agonists are more likely to be at more advanced stages of the disease, which increases the 
risk for pancreatitis, the potential for confounding by indication may be increased, 
particularly when observational studies are the case (NATHAN et al., 2009; GARG, CHEN, and 
PENDERGRASS, 2010). Based on spontaneous reports of adverse drug reactions, FDA 
recommended that the prescribing information of exenatide should include a warning about 
the risk of acute pancreatitis (US FOOD AND DRUG ADMINISTRATION, 2009). Liraglutide’ 
prescribing information also includes a warning about the risk of pancreatitis, without a 
specific mention to its onset, type or severity (US FOOD AND DRUG ADMINISTRATION, 2011). 
This meta-analysis did not find any increased risk for acute pancreatitis associated with both 
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GLP-1 agonists. Labeling change of exenatide regarding acute pancreatitis required by FDA 
was supported by spontaneous reports. Therefore, if the increased risk exists, the meta-
analysis is unable to identify such risk, since spontaneous reporting data is not considered in 
the meta-analysis methodology. Similarly the FDA required the market authorization holder 
of liraglutide to conduct post-approval mechanistic animal studies along with a 
pharmacoepidemiologic study in order to better assess the risk of acute pancreatitis (PARKS 
and ROSENBRAUGH, 2010). 
 Several studies were conducted aiming to explain the mechanisms by which acute 
pancreatitis could be developed. Butler et al. presented a theoretical model on which GLP-1 
agonists could amplify the pancreatic ductal replication already increased by type 2 diabetes 
mellitus or obesity (BUTLER, DRY and ELASHOFF, 2010; BUTLER et al., 2010). This would 
increase the risk for low grade chronic pancreatitis that predisposes to acute pancreatitis or 
pancreatic carcinoma. However, the results of preclinical studies were contradictory, 
remaining unknown if GLP-1 agonists are associated with a specific pharmacological 
mechanism that may cause pancreatitis (KOEHLER et al., 2009; NACHNANI et al., 2010; VRANG 
et al., 2012). In order to avoid misclassification bias, and since the results of pre-clinical 
studies have shown to be contradictory, only cases reported as acute pancreatitis were 
included in this meta-analysis. 
 The possible carcinogenic effect of GLP-1 agonists observed during the pre-clinical 
studies should be properly evaluated. Moreover, the analysis of disproportion of the FDA-
AERS database performed by Elashoff and colleagues (2011) demonstrated an increased risk 
for thyroid cancer associated with exenatide. This meta-analysis did not identify an increased 
risk for any cancer associated with exenatide. The risk remained unchanged when the 
analysis was stratified according to the therapeutic regimens or different comparators. 
Regarding liraglutide exposure, no difference was observed when data from all studies was 
integrated or when the results were stratified according to the type of comparator. 
However, sensitivity analysis restricted to five high methodological quality studies showed an 
increased risk of cancer from all causes in patients treated with liraglutide. Caution should 
be taken when interpreting this result, since is the only significant association found, 
suggesting a possible chance of finding. Several instruments have been developed in order to 
assess the methodological quality of the studies (JÜNI et al., 1999). The scale of Downs and 
Black was chosen since it is able to assess both experimental and observational studies 
(DOWNS and BLACK, 1998).  
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 Although the total number of cancer events was found to be low, a divergence 
between the risk of cancer associated with exenatide and liraglutide was identified (-14% for 
exenatide and 35% for liraglutide, both non-significant) (Table 12). Such findings deserve 
further careful attention. Moreover, when only high quality studies were considered, this 
difference increases. The present evaluation is based only in data from RCTs since 
observational studies were not identified in our search strategy. Clinical trials are able to 
identify the most frequent and common AEs that occurred during the intervention 
administration. However, considering cancer as a long-latency event, the duration of RCTs 
and the short period between initial liraglutide exposure and malignancies diagnosis do not 
allow the establishment of a reliable causality between liraglutide exposure and cancer. No 
cases of C-cell lesions in thyroid have been documented in patients treated with exenatide. 
An increased proportion of thyroid carcinomas in patients treated with liraglutide have been 
reported in the included studies when compared with controls. However, the increased risk 
was non-statistically significant. As Drucker and colleagues (2010) previously stated, the 
small number of cases and the lack of biological plausibility raise some doubts between the 
use of GLP-1 agonists, namely liraglutide, and thyroid cancer occurrence. Moreover, the 
effects of this drug in humans, particularly in the human thyroid gland, are unknown and 
difficult to be extrapolated from pre-clinical studies, despite the C-cell hyperplasia in rats 
(PAROLA, 2009). The findings of this meta-analysis enhance the need for long-term well-
designed epidemiological studies devoted to assess the risk for cancer associated with GLP-1 
agonists, including thyroid cancer during liraglutide exposure. Additional studies in animals 
and the establishment of a cancer registry database to monitor the incidence of medullary 
thyroid cancer associated with liraglutide was required by the FDA (PARKS and ROSENBAUGH, 
2010). 
 This meta-analysis may be subject to several limitations. Of the 22 RCT included, only 
one included the clinical evaluation of pancreatitis. Despite two RCTs have evaluated the 
calcitonin levels, none of them were designed to prospectively monitor for malignancies. 
Pancreatitis and cancer were not defined as an initially outcome measure of RCTs. These 
events were recorded as serious AEs. The absence of malignancies and/or pancreatitis pre-
defined diagnostic criteria can lead to missing events. Moreover, patients enrolled in the 
RCTs are usually younger and with less comorbidities, being at a lower risk for developing 
the AEs studied in this meta-analysis when compared with the average patients with type 2 
diabetes observed on routine clinical practice. Residual confounding in the included 
observational studies may extend to the results of this meta-analysis. 
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 Different controls were identified in the RCTs included in this meta-analysis and they 
might be associated with different risks for acute pancreatitis or cancer, such the case of 
gliptins or pioglitazone. Because of the heterogeneity of comparators and the relatively small 
number of acute pancreatitis and cancer events reported in the studies, the stratification of 
the results at this level is difficult. 
 Publication bias with regard to acute pancreatitis and cancer is difficult to assess with 
few studies. In two acute pancreatitis analyses, the results were significant. This may be the 
case of RCTs unpowered to detect rare events and subsequently creating difficulties in AEs 
assessments. The European Public Assessment Report (EPAR) of exenatide BID reports that 
several neoplasms occurred in patients treated with exenatide BID during the clinical 
development programme, without specifying its type (EUROPEAN MEDICINES AGENCY, 2006). 
We were unable to find such data in published studies (DEFRONZO et al., 2005; KENDALL et 
al., 2005; BUSE et al., 2004). This suggests that publication bias may be present in our meta-
analysis despites non-significant results observed for this outcome in the Egger’s regression 
asymmetry test. We did not seek to collect data beyond that which is published. However, 
non-publication of events of such severity turns difficult the correct benefit/risk ratio 
assessment, and in particular the assessment of the risk for cancer and its subtypes. 
 Current available published evidence is insufficient to support an increased risk of 
acute pancreatitis or an increased risk of cancer from all causes associated with GLP-1 
agonists. However, there is a growing body of evidence from postmarketing spontaneous 
reports. Physicians and patients should remain vigilant for episodes of acute pancreatitis or 
cancer and report any events to the correspondent pharmacovigilance system. Since trials’ 
size, duration and design may not be appropriate to accurately assess the risk of rare or 
long-term AEs, such acute pancreatitis or cancer, and it is unlikely that randomized trials of 
GLP-1 agonists designed to detect malignancies will ever exist, clinicians should rely on 
observational studies in future assessment of the risk of cancer. A rigorous monitoring of 
these outcomes should be implemented in the future studies since current evidence was not 
adequately designed to address this issue, precluding any definitive conclusion. 
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IV.7. SUPPLEMENTAL DATA IV 
 
IV.7.1. SUPPLEMENTAL DATA IV.1 - SEARCH STRATEGY 
 
Supplemental Table IV.1 - Search strategy performed at MEDLINE, EMBASE, Cochrane Library and 
ClinicalTrials.gov at May 24, 2012. 
Search  Medline 1st search strategy Results 
1 
(liraglutide) OR  (victoza) OR (NN2211) OR (NN 2211) OR (GLP-1 receptor 
agonists) OR (GLP-1 analogues) OR (GLP-1 agonists) 
1308 
2 
(exenatide) OR (byetta) OR (bydureon) OR (AC2993) OR (AC002993) OR 
(AC2993A) OR (AC 2993) OR (GLP-1 receptor agonists) OR (GLP-1 analogues) 
OR (GLP-1 agonists) 
1883 
Search  Medline 2nd search strategy Results 
1 
(neoplasm) OR (neoplasms) OR (cancer) OR (carcinoma) OR (tumour) OR 
(tumours) OR (neoplasia) OR (neoplasias) 
2956013 
2 
(pancreatitis) OR (pancreatitis NOS) OR (toxic pancreatitis) OR (acute pancreatitis) 
OR (pancreatitis acute) 
50663 
3 
(liraglutide) OR  (victoza) OR (NN2211) OR (NN 2211) OR (GLP-1 receptor 
agonists) OR (GLP-1 analogues) OR (GLP-1 agonists) 
1308 
4 
(exenatide) OR (byetta) OR (bydureon) OR (AC2993) OR (AC002993) OR 
(AC2993A) OR (AC 2993) OR (GLP-1 receptor agonists) OR (GLP-1 analogues) 
OR (GLP-1 agonists) 
1883 
5 1 AND 3 79 
6 1 AND 4 115 
7 2 AND 3 31 
8 2 AND 4 49 
Search EMBASE Results 
1 (neoplas* OR cancer OR carcinoma OR tumour).mp. [mp=title, abstract, subject 
headings, heading word, drug trade name, original title, device manufacturer, drug 
manufacturer, device trade name, keyword] 
2527903 
2 exp acute pancreatitis/ OR pancreatitis/ OR toxic pancreatitis.mp. OR pancreatitis 
NOS.mp. [mp=title, abstract, subject headings, heading word, drug trade name, 
original title, device manufacturer, drug manufacturer, device trade name, keyword] 
79073 
3 (liraglutide OR victoza OR NN2211 OR NN 2211 OR "GLP-1 receptor agonists" 
OR "GLP-1 analogues" OR "GLP-1 agonists").mp. [mp=title, abstract, subject 
headings, heading word, drug trade name, original title, device manufacturer, drug 
manufacturer, device trade name, keyword] 
2048 
4 (exenatide OR byetta OR bydureon OR AC2993 OR AC002993 OR AC2993A OR 
AC 2993 OR "GLP-1 receptor agonists" OR "GLP-1 analogues" OR "GLP-1 
agonists").mp. [mp=title, abstract, subject headings, heading word, drug trade name, 
original title, device manufacturer, drug manufacturer, device trade name, keyword] 
2320 
5 1 OR 2 2593671 
6 3 OR 4 3290 
7 5 AND 6 536 
Search Cochrane Library Results 
1 
(liraglutide) OR  (victoza) OR (NN2211) OR (NN 2211) OR (GLP-1 receptor 
agonists) OR (GLP-1 analogues) OR (GLP-1 agonists) 
Reviews: 
18 
Clinical 
trials: 133 
2 
(exenatide) OR (byetta) OR (bydureon) OR (AC2993) OR (AC002993) OR 
(AC2993A) OR (AC 2993) OR (GLP-1 receptor agonists) OR (GLP-1 analogues) 
OR (GLP-1 agonists) 
Reviews: 
33 
Clinical 
trials: 192 
Search ClinicalTrials.gov Results 
1 (liraglutide) OR  (victoza) OR (NN2211) OR (NN 2211) OR (GLP-1 receptor 179 
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agonists) OR (GLP-1 analogues) OR (GLP-1 agonists) 
2 
(exenatide) OR (byetta) OR (bydureon) OR (AC2993) OR (AC002993) OR 
(AC2993A) OR (AC 2993) OR (GLP-1 receptor agonists) OR (GLP-1 analogues) 
OR (GLP-1 agonists) 
238 
3 
(liraglutide) OR  (victoza) OR (NN2211) OR (NN 2211) OR (GLP-1 receptor 
agonists) OR (GLP-1 analogues) OR (GLP-1 agonists) 
Limits: Studies with results 
14 
4 
(exenatide) OR (byetta) OR (bydureon) OR (AC2993) OR (AC002993) OR 
(AC2993A) OR (AC 2993) OR (GLP-1 receptor agonists) OR (GLP-1 analogues) 
OR (GLP-1 agonists) 
Limits: Studies with results 
22 
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V. SOURCES OF INFORMATION USED BY REGULATORY AGENCIES ON THE 
GENERATION OF DRUG SAFETY ALERTS 
 
V.1. ABSTRACT 
 
 The study of the grounds on which data regulatory authorities base their decisions on 
drug safety evaluations is an important clinical and public health issue. The aim of this study 
was to review the type and publication status of data sources supporting benefit/risk ratio 
reevaluations conducted by the major regulatory authorities on safety issues. A website 
search was carried out to identify all safety alerts published by the FDA, Health Canada, 
EMA and the Australian Therapeutics Goods Administration (TGA). Safety alerts were 
included if the causal relation between a suspected drug exposure and the occurrence of an 
AE was evaluated for the first time between 2010 and 2012. Type of data sources evaluated 
by these regulatory authorities, publication status of the data sources and status of the drug 
label section with respect to updating were evaluated. A total of 59 safety alerts were 
included in this study. Of these, 33 (56%) were supported by postmarketing spontaneous 
reports, 24 (41%) evaluated RCTs, 16 evaluated cohort studies (27%), 13 were case-control 
studies (22%) and 11 evaluated case report/case-series (17%). Twenty-three safety alerts 
(39%) were issued based. on unpublished evidence, corresponding mainly to postmarketing 
spontaneous reports. The “Warnings and precautions section” was the drug label section 
most frequently updated (n=40; 68%). Despite the different lengths of time taken by the 
different regulatory authorities to come to similar decisions on the same issues - an issue 
which would seem to deserve further harmonization - post-marketing spontaneous reports 
have supported most of the benefit/risk ratio reevaluations, thereby confirming the value of 
such method in detecting unknown AEs. 
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V.2. INTRODUCTION 
 
 Assessment of the benefit/risk relation is conducted throughout the entire life cycle 
of a drug, starting from its clinical development and continuing during the post-licensing 
phase (US FOOD AND DRUG ADMINISTRATION, 2012). Before a market authorization is 
granted, drugs are studied for a defined therapeutic indication in RCTs with a limited 
duration and with strict inclusion/exclusion criteria for a relatively small number of patients 
(MADRE et al., 2006). These are accepted limitations to RCTs, one of which is that not all 
harmful effects can be easily anticipated (WYSOWSKI and SWARTZ, 2005). Some AEs can only 
be detected after marketing authorization, and these may be sufficiently serious to require a 
change in the established benefit/risk relation profile of a particular drug, leading to its label 
change or even market removal (MOORE, SINGH and FURBERG, 2012). 
 Post-marketing spontaneous reporting systems are useful to identify rare and/or 
serious AEs which could not be anticipated during the pre-approval stage (Wysowski and 
SWARTZ, 2005; AHMAD, MARKS and GOETSCH, 2006). Spontaneous reporting of AEs covers all 
drugs during their entire life cycle, both the whole population and special subgroups 
(EDWARDS et al., 2006). However, regulatory authorities recognize that this surveillance 
system may have limitations, such as underreporting or lack of data on the number of 
exposed individuals (US FOOD AND DRUG ADMINISTRATION, 2008). 
 Additional studies are usually needed to confirm safety signals identified through 
spontaneous reports (EDWARDS et al., 2006; US FOOD AND DRUG ADMINISTRATION, 2008). 
Indeed, observational studies may better reflect the nature of AEs occurring in clinical 
practice since they include populations usually underrepresented in RCTs, such as the 
elderly, pregnant women or patients with comorbidities (MADRE et al., 2006; ROTHWELL et 
al., 2005; PAPANIKOLAOU, CHRISTIDI and IOANNIDIS, 2006). 
 Safety signals represent findings and results from “reported information on a possible 
causal relationship between an AE and a drug, being the relationship unknown or 
incompletely documented at that time” (EDWARDS and BIRIELL, 1994). A safety signal can also 
be generated from other sources than post-marketing spontaneous reports, such as pre-
clinical data, observational longitudinal studies or even from information on other drugs of 
the same pharmacological class (BULL, 2007). Therefore, postmarketing data collection and 
risk assessment are critical steps in characterizing a drug’s safety profile and lead to better 
decisions on which regulatory actions should be implemented (BULL, 2007; US FOOD AND 
DRUG ADMINISTRATION, 2011). As a consequence, the study of the grounds on which 
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supporting data have been reviewed by regulatory authorities on clinical safety evaluations is 
an important public health issue. 
 The aim of this study was to review the type and publication status of data sources 
supporting benefit/risk ratio reevaluations conducted by four major regulatory authorities on 
safety issues evaluated between January 2010 and December 2012. 
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V.3. METHODS 
 
 The websites of four health regulatory authorities and reference data sources were 
reviewed to identify safety alerts. Data were extracted from the following publicly accessible 
addresses: the FDA “Drug Safety Communications”, “Advisories, warnings and recalls” of 
Health Canada, EMA “News, press release and public statement archive”, monthly reports of 
the “CHMP’ Pharmacovigilance Working Party” and “Pharmacovigilance Risk Assessment 
Committee”, and the TGA “All alerts” and “All recalls” (US FOOD AND DRUG 
ADMINISTRATION , 2014; HEALTH CANADA, 2013; EUROPEAN MEDICINES AGENCY, 2014; 
EUROPEAN MEDICINES AGENCY, 2013; THERAPEUTIC GOODS ADMINISTRATION, 2014; 
THERAPEUTIC GOODS ADMINISTRATION, 2014). Safety alerts were included if the causal 
relation between a suspected drug exposure and the occurrence of an AE was evaluated for 
the first time between January 2010 and December 2012. Natural and healthcare products, 
medical devices, contrast agents, drug-drug interactions, drug-food interactions, medication 
errors, evaluations of lack of efficacy and AEs occurring during off-label use were not 
considered for inclusion. 
 Only safety alerts on drugs with market authorization and simultaneously included in 
one of the 30 most prescribed drug classes worldwide used in the ambulatory setting were 
considered for inclusion (Supplemental Data V.1). Drug classes were considered as the 
second level therapeutic subgroup of the ATC classification system (WHO COLLABORATION 
CENTRE FOR DRUG STATISTICS METHODOLOGY, 2014). Data on sales of drug classes were 
requested from IMS (Intercontinental Marketing Services) Health. The bibliographic lists of 
all relevant safety alerts were hand searched in order to identify additional eligible safety 
alerts. The website search and the safety alerts selection were conducted by one researcher 
(Carlos Alves). A second researcher scanned the included safety alerts (Ana Filipa Macedo). 
Discrepancies were resolved by majority (two out of three) decision involving a third 
investigator (Francisco Batel Marques). 
 The following information from each safety alert was extracted: (1) date of first 
publication; (2) regulatory authority issuing the safety alert; (3) suspected drug(s); (4) AE of 
interest; (5) type of data source supporting the evaluation, namely: (I) study design; (ii) 
results for the outcome of interest; (iii) publication status; (6) drug label’ section(s) updated. 
“Drug remains under revision” or “benefit/risk ratio unchanged” were considered when any 
label change was performed. 
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 Regarding the publication status of the data sources, postmarketing spontaneous 
reports and studies consulted by regulatory authorities which had not been published at the 
time of the safety alert disclosure were considered to be unpublished data. Updates of the 
same safety alert were revised in order to retrieve further information on the regulatory 
authority decision and/or other data sources evaluated. Two safety alerts were considered 
to be evaluating the same clinical question when they assessed the same AE for the same 
suspected drug(s). Each safety alert could have been supported by more than one type of 
data source. More than one section of the drug label could have been updated. Regulatory 
authorities could have decided to keep the suspected drug(s) under revision despite labeling 
changes having been carried out. 
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V.4. RESULTS 
 
 The results of our search of the regulatory authorities’ websites are displayed in 
Figure V.1. A total of 1,204 publications were initially identified, of which 953 were excluded 
after further review of the titles, subjects and publication dates. This resulted in 251 safety 
alerts identified as “possibly eligible” for inclusion. After confirming the drug class as one of 
the 30 most consumed worldwide in ambulatory care, 59 safety alerts were included in the 
study, of which five were published by TGA, 13 by Health Canada, 16 by FDA and 25 by 
EMA. 
 Table V.1 describes the characteristics of the eligible safety alerts. Forty-two different 
clinical questions were evaluated in the 59 safety alerts, of which 28 clinical questions were 
evaluated by only one regulatory authority and the remaining 14 by at least two regulatory 
authorities. Thirty-two different drugs or drug classes were evaluated. 
 
V.4.1. SCIENTIFIC INFORMATION SOURCES EVALUATED IN SAFETY ALERTS 
 
 Table V.2 presents the different scientific information sources evaluated by the 
regulatory authorities. Thirty-three (56 %) safety alerts issued by authorities supported their 
regulatory decisions on post-marketing spontaneous reports, of which 18 (20%) were based 
exclusively on this data source. Twenty four (41%) safety alerts evaluated RCTs, eight (14%) 
of them exclusively. Cohort studies supported 16 (27 %) regulatory decisions, followed by 
case-control studies (n=13; 22 %) and case report/case-series (n=11; 17 %). Meta-analyses of 
RCTs, meta-analyses of observational studies, retrospective cohorts and surveys supported 
regulatory decisions on six (11 %) safety alerts each. Health Canada and EMA did not 
provide the scientific evidence supporting two evaluations. 
 The design of studies supporting the review of three safety alerts (5 %) by authorities 
was not specified. 
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Figure V.1 - Flow diagram of identification of safety alerts for inclusion. 
 
  
 
251 Safety alerts fully reviewed 
59 Safety alerts included 
5 issued by TGA 
13 issued by Health Canada 
16 issued by FDA 
25 issued by EMA 
1204 Safety alerts issued by regulatory authorities 
661 issued by EMA 
221 issued by Health Canada 
188 issued by TGA 
134 issued by FDA 
192 Excluded safety alerts 
Drugs not included in the 30 most 
prescribed drug classes in the ambulatory 
setting 
953 Excluded safety alerts: 
News/press releases or announcements 
not considering drugs: 524  
Medical device: 125 
Natural/health product: 81 
Quality control: 61 
Issued before 2010: 45 
Repeated: 43 
Lack of efficacy: 16 
Interaction: 12 
Medication error: 11 
Off-label use: 7 
Toxicity/overdose: 7 
Contrast agent: 6 
Stock/availability: 6 
Pharmacokinetic issue: 3 
Counterfeiting: 2 
New drug approval: 2 
Guideline update: 1 
Risk management plan evaluation: 1 
 
Chapter V 
 
210 
 
Table V.1 - Safety alerts, data sources evaluated and decisions taken by the regulatory authorities. 
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V.4.2. PUBLICATION STATUS OF DATA SOURCES 
 
 The publication status of data sources evaluated by regulatory authorities is 
presented in Table V.2. Twenty-two (37 %) safety alerts were supported by published and 
unpublished evidence. Most of the unpublished evidence evaluated by the authorities 
consisted of postmarketing spontaneous reports (17/22). At the date of their release, the 
regulatory decisions on four safety alerts were supported by studies (cohort, case-control 
and meta-analysis of RCTs) subsequently published as full papers. 
 Twenty-one (36 %) safety alerts were issued based solely on unpublished scientific 
evidence. The majority of these alerts (16/21) were based on postmarketing spontaneous 
reports, followed by the results of RCTs (7/21). The regulatory decisions on citalopram and 
escitalopram and the risk for arrhythmia (QT interval prolongation) were based on 
postmarketing spontaneous reports and unpublished data from RCTs. Clinical trials 
supporting regulatory decisions on tinzaparin had not been published when the respective 
safety alerts were issued. 
 Fourteen safety alerts were supported exclusively on scientific evidence already 
published. Observational studies were revised by regulatory authorities in the majority of 
these alerts (8/14). A safety alert on Atomoxetine was issued by three regulatory authorities 
which relayed their decision on RCTs sponsored by the drug’ market owner but did not 
provide references. 
 
V.4.3. REGULATORY ACTIONS 
 
 Table V.3 describes the different safety regulatory actions and the frequency by which 
they were applied. The most commonly updated drug label section was the 
Warnings/Precautions section (n=40; 68 %), followed by the update of the Contraindications 
section (n=17; 29 %). Updates of the Dosage section due to new recommendations were 
made in eight evaluations (14 %). New boxed warnings were issued on two occasions (3%). 
The marketing authorization of an association of drugs was preventively suspended. In eight 
safety alerts (14 %) the authorities announced that the benefit/risk ratio of the drug 
remained positive. The safety profile of nine (14 %) drugs/drug classes remains under 
revision.  
 The Australian TGA took a regulatory decision upon the evaluation conducted by US 
FDA on statins and the risk for increased blood sugar and cognitive side effects. 
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Table V.2 - Data sources and its publication status. 
 n = 59 
Type of data sources reviewed  Exclusive 
Reported at least one data source 57 97% - - 
Post-marketing spontenous reports 33 56% 12 20% 
RCT 24 41% 8 14% 
Cohort 16 27% - - 
Case-control 13 22% - - 
Case report/case series 11 17% - - 
Meta-analysis of RCTs 6 10% - - 
Meta-analysis of observational studies 6 10% - - 
Retrospective cohort 6 10% - - 
Survey (prospective or retrospective) 6 10% - - 
Systematic review 5 9% - - 
Prospective, non-comparative studies 3 5% - - 
Cross-sectional 3 5% - - 
Pregnancy registers database 2 3% 2 3% 
Retrospective, non-comparative studies 2 3% - - 
Revision of post-marketing spontaneous reports database 2 3% - - 
Pre-clinical studies 1 2% - - 
Unpublished/references not provided 18 31% - - 
Unspecified design 3 5% - - 
Based on other regulatory authority warning 1 2% - - 
Type of data sources not clarified 2 3% - - 
Publication status of data sources on safety alerts n=57*   
Published and unpublished 22 37% - - 
Unpublished  21 36% - - 
Published 14 24% - - 
     
 
 
 
Table V.3 - Drug label sections updated by regulatory authorities 
 n=59 
Regulatory actions  
Warnings/precautions 40 68% 
Contraindications 17 29% 
Dosage recommendations 8 14% 
Pregnancy section updated 4 7% 
Adverse events section updated 2 3% 
Boxed warning 2 3% 
Patient counseling information 1 2% 
Pediatric section 1 2% 
Suspension 1 2% 
Remains under revision 9 15% 
Benefit/Risk ratio remains positive 8 14% 
Additional studies required 1 2% 
 
* - For the analysis of the publication status of data sources on safety alerts, only those which reported the 
type of data sources were considered (n=57). Each safety alert could have been supported by more than one 
type of data source. 
More than one section of the drug label could have been updated. Regulatory authorities could 
have decided to remain the suspected drug(s) under revision despite labeling changes have been 
carried out. 
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V.5. DISCUSSION 
 
 The results of this study provide evidence that in the cases of the safety alerts 
assessed herein regulatory authorities reviewed, either isolated or in combination, several 
sources of information to support their decisions on safety issues associated with the most 
widely consumed drug classes in ambulatory care, including published and non-published 
data. Such sources of information mainly comprised post-marketing spontaneous reports and 
experimental and observational clinical studies. 
 Spontaneously notified reports of cases were present in the majority of the 
benefit/risk ratio reassessments, with a considerable proportion (20%) of safety evaluations 
conducted exclusively on this source of evidence. This seems to be the case for rare and 
previously unsuspected situations (WYSOWSKI and SWARTZ, 2005). Such events are prone to 
be reported by healthcare professionals or patients when they occur within a relatively short 
period of time after the initiation of the treatment or following a dose increment (MADRE et 
al., 2006). 
 The results of this study are similar to those found in other studies, thereby 
confirming the value of the pharmacovigilance spontaneous reporting systems in providing 
evidence on iatrogenic risk (MOORE, SINGH and FURBERG, 2012; LESTER et al., 2013). One 
previous study demonstrated that the results from this surveillance system have provided 
evidence of serious safety problems, leading not only label changes but also to the 
withdrawal of drugs from the market (WYSOWSKI and SWARTZ, 2005). Reports of cases may 
be the only available evidence suggesting an association between a suspected drug and an AE, 
since no further studies may have been conducted or, if conducted, their results may 
preclude any definitive conclusions (US FOOD AND DRUG ADMINISTRATION, 2009; DORE, 
SEEGER and CHAN, 2009; GARG, CHEN, and PENDERGRASS, 2010; DORE et al., 2011). In such 
cases, regulatory authorities may require risk minimization programmes to prevent more 
patients from being exposed to unnecessary risk (US FOOD AND DRUG ADMINISTRATION, 
2009). However, voluntary reports of suspected adverse drug reactions have limitations. The 
quality of the data reported may be low, and some events may be more frequently reported 
than others, such as those which are rare and serious. Additionally, a drug may be subject to 
an increased number of reports in the early years after being granted a market authorization 
(AHMAD, MARKS and GOETSCH, 2006). Such limitations lead post-marketing spontaneous 
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reports to be considered as generating hypotheses rather than confirming them, and 
additional analytic studies may be required to better assess the safety profile of a drug. 
 In this study, evidence from RCTs supported a significant number of regulatory 
decisions. When RCTs constituted the only source of evidence, it was not uncommon that 
the AE was an end-point of interest of the study (e.g. QT interval prolongation, bleeding, 
mortality). Clinical trials are considered to be the most reliable source of scientific evidence 
that can support healthcare policies and clinical practice (GUYATT et al., 2008). However, the 
majority of RCTs are designed to evaluate the most common AEs occurring early on the 
treatment. 
 Observational studies are more likely to be involved in the detection of long-term 
latency AEs. Moreover, this type of data may better represent the frequency of harmful 
effects experienced in actual clinical practice (PAPANIKOLAOU, CHRISTIDI and IOANNIDIS, 2006; 
VANDENBROUCKE and PSATY, 2008). Several regulatory decisions on AEs occurring with a 
long-latency time from the initiation of the treatment, such as fractures, cardiovascular 
events or malignancies, were found to be based on observational designs, the majority being 
cohort and case-control studies. Despite a considerable proportion of the safety alerts being 
supported by RCTs (41%), this study found that observational data made a relevant 
contribution towards supporting safety issues, not only in postmarketing reports of cases 
(56%) but also in longitudinal studies [cohort (27 %) case-control (22 %)] and case 
reports/case-series (17 %). Since only the most consumed classes of medicines were 
included in this work, the probability of these drugs being the subject of observational 
studies is high. Moreover, it is expected that the contribution of observational data to label 
updates due to safety issues may increase due to the adoption of electronic health records 
(LESTER et al., 2013).  
 The quality of the evidence supporting regulatory decisions on drug safety has been 
discussed (MOORE, SINGH and FURBERG, 2012; WOLFE, 2012; DAL PAN and TEMPLE, 2012). 
Methodological limitations of the studies may impair causality assessment; this was the 
conclusion of the EMA on the association between antiepileptic drugs and bone disorders. 
Most of the regulatory decisions presented in this work were based on the evaluation of 
evidence which was not immediately published in the scientific literature or which is difficult 
to access by the scientific community, such as the post-marketing spontaneous reports or 
studies requested from market authorization holders. As such, the regulatory authority is in 
an unmatched position to conduct critical analyses. However, access to unpublished data 
may allow independent investigators to conduct secondary assessments on specific safety 
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issues and to clarify important questions, as it was the case for selective serotonin reuptake 
inhibitors in the treatment of depression in children (WHITTINGTON et al., 2004). Moreover, 
analyses of postmarketing spontaneous reports compiled in databases of regulatory 
authorities, such as the FDA, by other investigators have led to the generation of safety 
signals and the production of scientific literature, thereby proving to be a good strategy in 
drug safety monitoring (POWERS and COOK, 2012). 
 Surprisingly, only three of the 59 safety signals studied, were simultaneously raised 
and evaluated by all four regulatory agencies assessed in this study: pioglitazone and bladder 
cancer, combined hormonal contraceptives containing drospirenone and venous 
thromboembolism and citalopram and QT interval prolongation. The vast majority of these 
drugs were approved in the countries regulated by the four authorities, with the exception 
of tinzaparin and ketoprofen containing drugs used topically. Since a given alert, which leads 
to a further regulatory action, can be considered a safety issue by one agency and not by 
another agency, similar populations may be at different levels of risk due to regulatory 
decisions. Moreover, when the same safety issues were simultaneously evaluated by more 
than one agency, decisions were taken within different time frames, as was the case for 
proton pump inhibitors and bone fractures or hypomagnesemia, pioglitazone or 
escitalopram, with a difference of several months. A study conducted by Hirst and colleagues 
(2006) described some examples of different regulatory actions conducted for the same 
medicines in different countries - however, in this study discrepancies in label changes were 
rare. 
 Although guidelines have been developed to harmonize pharmacovigilance activities 
worldwide, differences in healthcare systems, regulatory procedures and even in culture may 
contribute to risk management strategies varying across countries (HIRST et al., 2006; US 
FOOD AND DRUG ADMINISTRATION, 2013; PFISTERMEISTER et al., 2013). Additionally, 
surveillance of all approved drugs and their potential adverse reactions in an active way may 
not be feasible due to restrictions in human resources and/or budget (WYSOWSKI and 
SWARTZ, 2005; HIRST et al., 2006). Cooperative agreements may be established between 
regulatory authorities to monitor various activities, including discussions of safety issues, 
exchange of pharmacovigilance information and collaboration in conducting studies to clarify 
safety issues (EUROPEAN MEDICINES AGENCY, 2013a; EUROPEAN MEDICINES AGENCY, 2013b; 
STANG, M.; WYSOWSKI, D.K.; BUTLER-JONES, 1999). Despite guidance and cooperation, 
differences in safety regulation between major regulatory authorities still exist, such as the 
discrepancies in drug label updates conducted by FDA and EMA on the cardiovascular safety 
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of non-selective non-steroids anti-inflammatory drugs - decisions which were based on the 
same scientific evidence (FURBERG, 2007). As Hirst and colleagues (2006) previously stated, 
since the methods applied for evaluating benefit/risk ratio may not be comparable, 
inconsistent regulatory action around the world may be inevitable.  
 Most of the label changes identified in our study resulted in an update of the 
Warnings and precautions section, with only two boxed warnings being added and a 
marketing authorization being suspended. Similar studies on this subject identified more 
boxed warnings added to labels (MOORE, SINGH and FURBERG, 2012; LESTER et al., 2013). The 
majority of the drugs included in this study have been marketed for several years almost 
worldwide and have thus been used to treat millions of people. Recently approved drugs 
may be more likely to be associated with unknown and serious adverse drug reactions. A 
previous study found that half of drug withdrawals occur within 2 years after a market 
authorization has been granted and that half of major label changes (defined as “drug 
withdrawal” or “black box warning inclusion”) occur within 7 years after drug approval 
(LASSER et al., 2012). Additionally, changes in drug development that have led to important 
safety issues being taken into consideration may also have led to drug withdrawal due to 
common causes, such as hepatotoxicity or cardiovascular toxicity, to have become less likely 
(TEMPLE and HIMMEL, 2002). 
 This study has a number of limitations. Regulatory agencies other than FDA, Health 
Canada, EMA and Australian TGA were not searched. Websites posted in languages other 
than English were not considered, which could have resulted in the exclusion of important 
information. We analysed safety alerts and communications which included early notices on 
safety issues and, therefore, some of these continue to be under revision at this time, 
without as yet any final decision by the authorities; additionally, information on data sources 
and regulatory actions may not be published in their entirety. Safety signals generated 
through the analysis of postmarketing spontaneous reports databases were not specifically 
searched since such information should be confirmed by the authorities due to its 
uncertainties.  
 Regulatory authorities continuously review the benefit/risk ratio of a drug throughout 
its entire life time, taking into account that data sources which are available will differ 
substantially. During the post-marketing phase, once an AE is possibly associated with drug 
treatment, regulatory authorities assess the extent to which it may be a threat to public 
health (MADRE et al., 2006). Postmarketing spontaneous reporting systems have been shown 
to be a valuable resource by which to identify suspected adverse drug reactions, especially 
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those which are rare and serious. Harmonization between regulatory authorities of different 
regions should be the subject of further efforts in order to expedite the decision-making 
process and to understand the reason(s) for the differences in the length of time involved in 
the regulatory safety decision process. 
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V.7. SUPPLEMENTAL DATA V 
 
V.7.1. SUPPLEMENTAL DATA V.1 - WORLDWIDE MOST CONSUMED DRUG CLASSES IN 
AMBULATORY CARE FROM 2010 UNTIL SEPTEMBER 2012 
 
Supplemental Table V.1 - Worldwide most consumed drug classes in ambulatory care from 2010 until 
September 2012. 
ATC 2nd level 
Worldwide Ambulatory setting 
Units* 
September 2012 
Units* 
Year 2011 
Units* 
Year 2010 
TOTAL 86.705.920 85.303.455 81.295.783 
J1 (SYSTEMIC ANTIBACTERIALS)  7.338.442 7.202.647 7.058.254 
N2 (ANALGESICS)  6.341.166 6.267.979 6.040.099 
A2 (A-ACID A-FLAT A-ULCERANT)  5.399.376 5.217.473 4.763.242 
R5 (COUGH,COLD PREPARATIONS)  4.750.842 4.867.359 4.628.154 
M1 (ANTIRHEUMATIC SYSTEM)  3.931.491 3.920.386 3.756.272 
A11 (VITAMINS) 3.824.783 3.714.156 3.614.190 
A10 (DRUGS USED IN DIABETES) 3.005.279 2.865.126 2.569.084 
R3 (ANTI-ASTHMA & COPD PROD)  2.743.511 2.772.934 2.606.099 
C9 (RENIN-ANGIOTEN SYS AGENT)  2.502.718 2.428.457 2.242.174 
A7 (A-DIAR ORAL ELEC+A-INFLA)  2.339.231 2.222.082 2.128.853 
N5 (PSYCHOLEPTICS)  2.112.611 2.152.871 2.130.181 
H2 (SYSTEMIC CORTICOSTEROIDS)  1.953.957 1.927.224 1.859.051 
S1 (OPHTHALMOLOGICALS)  1.941.345 1.917.163 1.894.804 
D7 (TOPICAL CORTICOSTEROIDS)  1.660.655 1.589.325 1.476.307 
A3 (GAST-INTEST DISORD DRUG)  1.557.979 1.570.617 1.474.761 
R6 (ANTIHISTAMINES SYSTEMIC)  1.429.452 1.419.120 1.349.397 
R1 (NASAL PREPARATIONS)  1.405.983 1.389.094 1.332.254 
C8 (CALCIUM ANTAGONISTS)  1.401.255 1.371.635 1.307.215 
N6 (PSYCHOANALEPTICS)  1.374.850 1.342.811 1.261.624 
B1 (ANTITHROMBOTIC AGENTS)  1.355.129 1.342.219 1.274.782 
C7 (BETA BLOCKING AGENTS)  1.352.113 1.317.395 1.238.400 
C10 (LIP.REG./ANTI-ATH. PREPS) 1.336.965 1.305.105 1.218.968 
P1 (ANTIPROTOZOALS & ANTHELMIN)  1.268.085 1.275.381 1.278.451 
G3 (SEX HORMONES-SYSTEMIC)  1.235.709 1.216.392 1.162.638 
N3 (ANTI-EPILEPTICS)  1.188.892 1.128.611 1.029.457 
M2 (ANTIRHEUMATICS TOPICAL)  1.017.346 984.034 942.144 
B3 (ANTIANAEMICS)  1.002.198 987.989 937.067 
V6 (GENERAL NUTRIENTS)  906.938 880.395 822.031 
 
  
* Thousands of units. 
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VI. DRUG-SAFETY ALERTS ISSUED BY REGULATORY AUTHORITIES: USEFULNESS OF 
META-ANALYSIS IN PREDICTING EARLIER RISKS 
 
VI.1. ABSTRACT 
 
To evaluate how risk estimates generated from cumulative meta-analysis performs over time 
for drugs having their benefit/risk ratio reevaluated due to safety issues and, additionally, 
assess if the results are consistent with regulatory authorities’ conclusions. Four major 
regulatory authorities were searched for their issued safety alerts which have been 
supported by longitudinal, comparative studies (experimentals and/or observationals). 
Random-effects model was used to pooled ORs over time, by including studies according to 
the year they first became available. Seventeen safety alerts were included in this study. In 
2008, proton pump inhibitors were associated with an increased risk for bone fractures (OR 
1.25, 95% CI 1.00-1.55, P=0.049); FDA issued a safety alert in 2010 and added warnings to 
label. An increased risk for Clostridium difficile associated diarrhea was pooled for proton 
pump inhibitors in 2004 (OR 1.89, 1.19-3.02, P=0.007); FDA issued a safety alert in 2012, 
adding warnings to label. Proton pump inhibitors were associated with pneumonia in 2009 
(OR 1.40, 1.06-1.85, P=0.017); FDA issued an alert in 2012 but concluded that B/R ratio 
remains positive. Statins were associated to an increased risk for diabetes (OR 1.07, 1.01-
1.15, P=0.033) in 2008. EMA issued an alert in 2012, including warnings to label. The 
remaining cumulative meta-analyses have not estimated increased risks in advance to 
regulatory decisions. This study demonstrates that meta-analysis may help predicting 
iatrogenic risks. However, between-studies heterogeneity can considerably affect the 
estimated results and, therefore, this technique should not replace further assessments 
during benefit/risk ratio reevaluations.  
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VI.2. INTRODUCTION 
 
 After a medicine has been issued a market authorization and became available, 
unknown ADRs can arise from the everyday practice (MADRE et al., 2006). This additional 
knowledge of the safety profile deserves to be carefully evaluated for the protection of 
patients (MADRE et al., 2006). Some ADRs are serious enough to change the benefit/risk 
profile of a particular drug, leading to restriction on its use or even market withdrawal 
(MOORE, SINGH and FURBERG, 2012). In order to keep the patients and health care 
professionals updated, authorities frequently issue drug safety alerts informing about 
benefit/risk ratio reevaluations being conducted and subsequent regulatory decisions (US 
FOOD AND DRUG ADMINISTRATION, 2013; EUROPEAN MEDICINES AGENCY, 2013). 
 Clinical trials provide the best design to evaluate the efficacy of drug and its most 
common adverse effects (WYSOWSKI and SWARTZ, 2005; MEDICINES AND HEALTHCARE 
PRODUCTS REGULATORY AGENCY, 2011). However, not all harmfull effects can be easily 
anticipated in RCTs, and even if measured their reporting is usually inadequate. 
Observational studies usually support regulatory decisions on rare and/or long latency AEs, 
such as fractures, cardiovascular events or malignancies (VAN STAA, LEUFKENS and COOPER, 
2001). 
 Different types of epidemiological data support pharmacovigilance activities, and its 
collection and evaluation are crucial steps for regulatory authorities in order to establish the 
most accurate benefit/risk ratio (PAPANIKOLAOU, CHRISTIDI and IOANNIDIS, 2006; US FOOD 
AND DRUG ADMINISTRATION, 2012). Post-marketing drug safety surveillance can be 
considered a dynamic prospective process that requires timelier ascertainment of drug risks 
together with higher quality and better documented scientific evidence (MADRE et al., 2006). 
Therefore, a considerable period of time can separate the arising of evidence supporting the 
association between a new AE and a drug exposure, leading to a decision from regulatory 
authorities. 
 Meta-analysis provides the conceptual and quantitative framework for rigorous 
literature review, combining effect measures when appropriate and allowing an objective 
presentation and analysis of the available data (KIM and BERLIN, 2006). This technique has 
been commonly used to pool data from RCTs mainly to evaluate efficacy endpoints (ALVES, 
BATEL-MARQUES and MACEDO, 2012a) Despite not frequently used to evaluate safety issues, 
the meta-analytic cumulative analysis of evidence has demonstrated that appropriate and 
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timely decisions could have been taken concerning cardiovascular events associated with 
rofecoxib (JÜNI et al., 2004). 
 This study is aimed to evaluate how risk estimates generated from cumulative meta-
analysis performs over time for drugs having their benefit/risk ratio reevaluated due to safety 
issues and, additionally, assess if the results are consistent with regulatory authorities’ 
conclusions.   
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VI.3. METHODS 
 
VI.3.1. SAFETY ALERTS SELECTION 
  
 A previous study reviewed the type and publication status of data sources supporting 
benefit/risk ratio reevaluations conducted by FDA, Health Canada, EMA and Australian TGA 
(ALVES, MACEDO and BATEL MARQUES, 2013). A total of 59 safety alerts were evaluated. Only 
safety alerts regarding the evaluation of a causal relation between a suspected drug exposure 
and the occurrence of an AE which have been issued for the first time between January 2010 
and December 2012 were considered for inclusion. Natural and healthcare products, 
medical devices, contrast agents, drug-drug interactions, drug-food interactions, medication 
errors, evaluations of lack of efficacy and AEs occurring during off-label use were not 
considered for inclusion. Only safety alerts concerning drugs with market authorization and 
simultaneously included in one of the thirty most prescribed drug classes worldwide used in 
the ambulatory setting were considered for inclusion. The complete methodology by which 
the safety alerts have been selected is described in the previous study (ALVES, MACEDO and 
BATEL MARQUES, 2013). 
 This study only included safety alerts in which regulatory authorities’ decisions were 
supported by longitudinal, comparative studies [RCTs and/or observational studies (cohort 
or case-control)]. Studies included in meta-analyses used to support regulatory decisions 
were retrieved and pooled in the respective cumulative meta-analyses. No further 
bibliographic references were requested to regulatory authorities beyond those published in 
the websites. Bibliographic electronic searches were not conducted. 
 The following information from each safety alert was extracted: (1) date of first 
publication; (2) regulatory authority issuing the safety alert; (3) suspected drug(s); (4) AE; (5) 
type of studies supporting the evaluation; (6) drug label’ section(s) updated. “Benefit/risk 
ratio unchanged” was considered when no change was performed. 
 Updates of the same safety alert were reviewed in order to retrieve further 
information. Two safety alerts were considered to be evaluating the same clinical question 
when they assessed the same AE for the same suspected drug(s). Clinical question is 
referring to the investigational hypothesis evaluated by a regulatory authority. Regulatory 
authorities could have decided to remain the suspected drug(s) under revision despite 
labelling changes have been carried out.  
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VI.3.2. META-ANALYSIS 
 
 For each clinical question, a cumulative meta-analysis was performed for the outcome 
of interest to display the pooled evidence over time. In the cumulative meta-analysis the 
studies were included according to the year they first became available – i.e., the earliest of: 
online publication date (Epub ahead of print date) or the correspondent journal issue 
publication date. Studies must have provided risk estimates (RR, OR, or HR) for patients 
treated with the suspected drug compared with a control group, or data allowing calculation 
of such risk estimates. The most adjusted estimate was used for studies presenting more 
than one risk estimate. A minimum of three studies was needed in order to carry on a 
cumulative meta-analysis. 
 Meta-analyses were conducted using the DerSimonian and Laird random-effects 
model in order to pool the OR with their 95% CIs (DERSIMONIAN and LAIRD, 1986). It was 
assumed that OR was an unbiased estimate of the RR. This model was chosen since it is 
more conservative than a fixed-effect model in the presence of between-studies 
heterogeneity. Between-studies heterogeneity was assessed by calculating a chi-square test 
and the I2 measure of inconsistency (HIGGINS et al., 2003). The influence of studies’ 
publication date over the primary outcomes’ risk considered in each safety alert was 
assessed by means of a meta-regression, according to the method of moments. The 
publication bias was visually examined by a funnel plot and statistically evaluated by Egger’s 
regression asymmetry test (BORENSTEIN et al., 2009; EGGER et al., 1997). A sensitivity analysis 
was performed to explore the influence of studies’ design in the summary estimates. 
 All statistical analyses were performed using the Comprehensive Meta-analysis 
Version 2 (Biostat, Englewood, NJ, USA). 
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VI.4. RESULTS 
 
 Figure VI.1 summarizes the selection process of the safety alerts. Of the 59 safety 
alerts, 39 were excluded since they were not supported by longitudinal, comparative studies. 
Twenty safety alerts were selected for further revision, of which three were excluded: 
valproate and impaired cognitive development since the revised studies did not provide data 
to calculate RR estimates; lamotrigine and increased risk of sudden unexpected death since 
any death occurred in studies where patients were treated with lamotrigine; and 
antiepileptics and bone disorders since a considerable proportion of studies compared 
patients with epilepsy receiving treatment with healthy individuals. 
 The characteristics of the safety alerts included are described in Table VI.1. The 17 
safety alerts evaluated 9 different clinical questions. Two clinical questions (statins and 
increased blood sugar; statins and cognitive side effects) were evaluated by FDA in the same 
safety alert released on 28-02-2012. Four clinical questions were evaluated by only one 
regulatory authority. Five clinical questions were evaluated by at least two regulatory 
authorities.      
 Table VI.2 describes the results of cumulative meta-analyses over time according to 
the year of publication of each study, the meta-regression estimates and publication bias 
assessment. 
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Figure VI.1 - Flow diagram of identification of safety alerts selected for cumulative meta-analysis 
 
 
 
20 Safety alerts fully reviewed 
17 Safety alerts included 
2 issued by TGA 
2 issued by Health Canada 
6 issued by FDA 
7 issued by EMA 
59 Safety alerts reviewed in Alves et al. 
2013 
5 issued by TGA 
13 issued by Health Canada 
16 issued by FDA 
25 issued by EMA 
3 Excluded safety alert 
Studies did not provide risk estimates: 
valproate and impaired cognitive 
development 
Any event occurred in patients treated 
with the suspected drug: lamotrigine 
and increased risk of sudden unexpected 
death 
Heterogeneity between study designs: 
antiepileptics and bone disorders 
39 Initially excluded safety alerts: 
Supported by post-marketing 
spontaneous reports and/or case 
reports and/or case series: 15 
Supported by less than three 
longitudinal, comparative studies: 10 
Supported by post-marketing 
spontaneous reports and/or case 
reports and/or case series and by 
less than three longitudinal, 
comparative studies: 7 
Supported by post-marketing 
spontaneous reports and/or case 
reports and/or case series and 
supported by non-comparative 
studies: 3 
Supported by pregnancy register 
databases studies: 2 
Supporting data sources not provided: 
2 
Based upon other regulatory 
authority evaluation: 1 
References not provided: 1 
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Table VI.1 - Safety alerts, data sources evaluated, studies included in cumulative meta-analyses and decisions 
taken by the regulatory authorities. 
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Fluoxetine and cardiovascular birth defects 
 Fluoxetine was not associated with a significant risk for cardiovascular birth defects 
development (final result OR 1.19; 95% CI 0.86-1.65, P=0.304; I2=28.3%, P=0.21). Only two 
studies reported an increased risk (Supplemental Data VI.1 References 1,4).  
 
Protons pump inhibitors and bone fractures 
 A statistically significant increased risk for bone fractures associated with proton 
pump inhibitors was initially identified in 2006 by pooling data from 2 studies (OR 1.31, 95% 
CI 1.08-1.59, P=0.007). In 2008, the risk became not statistically significant (OR 1.18, 95% CI 
0.93-1.48, P=0.169) with the publication of Kaye et al. (2008) (Supplemental Data VI.1 
Reference 15). In the same year, a statistically significant association could be pooled from 
studies after the publication of Targownik et al. (2008) (Supplemental Data VI.1 Reference 
16) (OR 1.25, 955 CI 1.00-1.55, P=0.049) as well as to the final result (OR 1.27, 95% CI 
1.17-1.37, P<0.001; I2=77.0%, P<0.001). 
 
Angiotensin receptor blockers and cancer 
 Angiotensin receptor blockers are not associated with an increased risk for cancer 
(final result OR 0.99, 95% CI 0.95-1.05, P=0.674; I2=0%, P=0.49). Meta-regression showed 
that the results were stable over time [Estimate (SE) 0.001 (0.006); P=0.85]. 
 
Pioglitazone and bladder cancer 
 A statistically significant risk for bladder cancer associated with pioglitazone was 
identified after the publication of the first study on 2012 (OR 1.24, 95% CI 1.04-1.48, 
P=0.012) and remained significant when the results of all studies were pooled (OR 1.32, 95% 
CI 1.08-1.62, P=0.020; I2=37.4%, P=0.19).  
 
Combined hormonal contraceptives containing drospirenone and venous thromboembolism 
 Two early studies published in 2007 didn’t report an increase in the risk between 
combined hormonal contraceptives containing drospirenone venous thromboembolism. 
Later studies established an increased risk which is confirmed in 2011 by meta-analysis [OR 
1.70, 95% CI 1.13-2.57, P=0.011; I2=81.0%, P<0.001; meta-regression estimate (SE) = 0.22 
(0.12); P=0.06].  
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Statins and increased blood sugar 
 The outcome of interest evaluated was “newly-diagnosed diabetes mellitus”. The 
cumulative meta-analysis of studies in 2008 associated statins with an increased risk for 
diabetes mellitus (OR 1.07, 95% CI 1.01-1.15, P=0.034). The result became statistically non-
significant after data from a cohort study being pooled (OR 1.11, 95% CI 0.99-1.23, P=0.055; 
I2=72.7%, P<0.001) [meta-regression estimate (SE) = 0.02 (0.006); P<0.001] (Supplemental 
Data VI.1 Reference 73). 
 
Protons pump inhibitors and Clostridium difficile associated diarrhea 
 Cumulative meta-analysis showed that statistically significant increased risk for 
Clostridium difficile associated diarrhea with proton pump inhibitors became evident when 
the fifth study was published in 2005 (OR 1.89, 95% CI 1.19-3.02, P=0.007). Final OR 
estimates was 1.94 (95% CI 1.61-2.37, P<0.001; I2=87.9%, P<0.001).  
 
Statins and cognitive side effects 
 A protective effect of statins on dementia and cognitive impairment was found (OR 
0.65, 95% CI 0.43-0.98, P=0.039; I2=75.9%, P<0.001). Meta-regression showed that the 
results were stable over time [Estimate (SE) -0.0008 (0.06), P=0.99]. 
 
Proton pump inhibitors and pneumonia 
 Cumulative meta-analysis showed that statistically significant increased risk for 
pneumonia associated with proton pump inhibitors became evident when the third study 
was published in 2007 (OR 1.56, 95% CI 1.31-1.87, P<0.001). However, when the study of 
Roughead et al. was published in 2009, the result became statistically non-significant (OR 
1.37, 95% CI 0.99-1.89, P=0.055) (Supplemental Data VI.1 Reference 154). Following the 
publication of Myles et al. (2009) an increased risk was observed again (OR 1.40, 95% CI 
1.06-1.85, P=0.017) (Supplemental Data VI.1 Reference 150). The final OR for cumulative 
meta-analysis was 1.35 (95% CI 1.13-1.61, P=0.001; I2=95.7%, P< 0.001).   
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Table VI.2 - Cumulative ORs and 95% CIs. 
Safety alerts Studies Design Year Cumulative OR Heterogeneity Meta-regression PBa 
    OR (95% CI) P I2 P Estimate (SE) P P 
Fluoxetine and 
cardiovascular birth 
defects  
EMA 25-02-2010 
Chambers et al. Cohort 1996 4.19 (0.43-40.78) 0.217      
Malm et al. Case-control 2005 1.78 (0.78-4.05) 0.172      
Källén et al. Case-control 2007 1.27 (0.79-2.03) 0.308      
Alwan et al. Case-control 2007 1.24 (0.87-1.77) 0.231      
Louik et al. Case-control 2007 1.10 (0.83-1.46) 0.503      
Oberlander et al. R. cohort 2008 1.06 (0.82-1.39) 0.652      
Diav-Citrin et al. Cohort 2008 1.19 (0.86-1.65) 0.304 28.3% 0.21 -0.102 (0.097) 0.29 0.06 
Proton pump 
inhibitors and bone 
fractures  
US FDA 25-05-2010 
EMA 22-03-2012 
Vestergaard et al. Case-control 2006 1.18 (1.04-1.33) 0.008      
Yang et al. Case-control 2006 1.31 (1.08-1.59) 0.007      
Kaye et al. Case-control 2008 1.18 (0.93-1.48) 0.169      
Targownik et al. Cohort 2008 1.25 (1.00-1.55) 0.049      
Yu et al. Cohort 2008 1.25 (1.06-1.48) 0.007      
Roux et al. Cohort 2008 1.29 (1.08-1.53) 0.004      
de Vries et al. R. cohort 2009 1.25 (1.09-1.41) 0.001      
Gray et al. Cohort 2010 1.24 (1.13-1.37) <0.001      
Corley et al. Case-control 2010 1.25 (1.15-1.36) <0.001      
Pouwels et al. Case-control 2010 1.24 (1.15-1.34) <0.001      
Chiu et al. Case-control 2010 1.27 (1.17-1.37) <0.001 77.0% < 0.001 -0.0002 (0.027) 0.99 0.12 
Angiotensin 
receptor blockers 
and cancer 
US FDA 15-07-2010 
EMA 20-10-2011 
IRMA 2 RCT 2001 1.27 (0.26-6.13) 0.767      
RENAAL RCT 2001 1.31 (0.44-3.91) 0.627      
IDNT RCT 2001 0.86 (0.53-1.40) 0.556      
Val-HeFT RCT 2001 0.89 (0.72-1.11) 0.313      
LIFE RCT 2002 1.04 (0.92-1.18) 0.556      
ALPINE RCT 2003 1.04 (0.92-1.18) 0.557      
CHARM Alternative RCT 2003 1.04 (0.92-1.17) 0.578      
VALIANT RCT 2003 1.02 (0.91-1.14) 0.759      
CHARM RCT 2004 1.02 (0.93-1.13) 0.654      
VALUE RCT 2006 0.96 (0.88-1.03) 0.255      
TROPHY RCT 2006 0.95 (0.88-1.03) 0.221      
SCOPE RCT 2007 0.97 (0.90-1.04) 0.365      
JIKEI RCT 2007 0.97 (0.90-1.04) 0.366      
ONTARGET (vs ACEi) RCT 2008 0.99 (0.93-1.05) 0.736      
PROFESS RCT 2008 0.99 (0.93-1.04) 0.619      
TRANSCEND RCT 2008 1.00 (0.95-1.05) 0.986      
DIRECT (Overall) RCT 2008 1.01 (0.95-1.08) 0.726      
I-PRESERVE RCT 2008 1.01 (0.95-1.07) 0.828      
GISSI-AF RCT 2009 1.01 (0.95-1.07) 0,846      
HIJ-CREATE RCT 2009 1.00 (0.95-1.06) 0.900      
KYOTO RCT 2009 1.00 (0.95-1.06) 0.939      
NAVIGATOR RCT 2010 1.01 (0.96-1.06) 0.749      
ACTIVE-I RCT 2011 0.99 (0.95-1.05) 0.943      
Pasternak et al. Cohort 2011 0.99 (0.96-1.02) 0.674 0% 0.49 0.001 (0.006) 0.85 0.56 
Pioglitazone and 
bladder cancer 
EMA 17-09-2010 
US FDA 16-03-2011 
Health Canada 17-
06-2011 
TGA 18-07-2011 
Dormandy et al. RCT 2005 2.84 (1.02-7.89) 0.045      
Lewis et al. Cohort 2011 1.59 (0.72-3.52) 0.162      
Neumann et al. Cohort 2012 1.24 (1.04-1.48) 0.012      
Azoulay et al. Case-control 2012 1.32 (1.08-1.62) 0.020 37.4% 0.19 -0.09 (0.08) 0.23 0.07 
Combined 
hormonal 
contraceptives 
containing 
drospirenone and 
venous 
thromboembolism 
EMA 27-05-2011 
US FDA 31-05-2011 
Health Canada 07-
06-2011 
TGA 06-07-2011 
Dinger et al. Cohort 2007 0.90 (0.57-1.42) 0.652      
Seeger et al. R. cohort 2007 0.90 (0.63-1.29) 0.566      
Lidegaard et al. Cohort 2009 1.15 (0.73-1.82) 0.544      
van Hylckama Vieg et al. Case-control 2009 1.61 (0.85-3.02) 0.143      
Dinger et al. Case-control 2010 1.45 (0.87-2.43) 0.158      
Parkin et al. Case-control 2011 1.62 (0.99-2.63) 0.053      
Jick et al. Case-control 2011 1.70 (1.13-2.57) 0.011 81.0% < 0.001 0.22 (0.12) 0.06 0.78 
Statins and 
increased blood 
sugar 
EMA 10-01-2012 
US FDA 28-02-
2012* 
Pravastatin MSG RCT 1993 3.02 (0.12-75.11) 0.500      
4S RCT 1994 1.04 (0,84-1.28) 0.750      
AFCAPS/TEXCAPS RCT 1998 1.02 (0,85-1.22) 0.834      
GISSI PREVENZIONE RCT 2000 0,98 (0,84-1.14) 0.817      
WOSCOPS RCT 2001 0.94 (0.82-1.08) 0.407      
PROSPER RCT 2002 1.01 (0.85-1.19) 0.914      
ALLHAT RCT 2002 1.04 (0.91-1.19) 0.551      
ASCOT-LLA RCT 2003 1.06 (0.95-1.19) 0.325      
HPS RCT 2003 1.08 (0.98-1.19) 0.110      
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LIPID RCT 2003 1.06 (0.97-1.16) 0.216      
PROVE-IT TIMI 22 RCT 2004 1.06 (0.97-1.15) 0.183      
ATHEROMA RCT 2005 1.06 (0.98-1.15) 0.154      
MEGA RCT 2006 1.07 (0.99-1.15) 0.091      
CORONA RCT 2007 1.07 (1.00-1.15) 0.051      
GISSI HF RCT 2008 1.07 (1.01-1.15) 0.033      
JUPITER RCT 2008 1.09 (1.03-1.16) 0.006      
Culver et al. Cohort 2012 1.11 (0.99-1.23) 0.051 71.08% < 0.001 0.02 (0.006) <0.001 0.003 
Proton pump 
inhibitors and 
Clostridium difficile 
associated diarrhea 
US FDA 08-02-2012 
Shah et al. Case-control 2000 0.86 (0.47-1.59) 0.625      
Yip et al. Case-control 2001 1.61 (0.37-7.06) 0.530      
Kyne et al. Cohort 2002 1.67 (0.69-4.04) 0.253      
Cunningham et al. Case-control 2003 1.87 (0.97-3.60) 0.060      
Dial et al.  Cohort 2004 1.89 (1.19-3.02) 0.007      
Dial et al.  Case-control 2004 2.01 (1.36-2.99) 0.001      
Al-Tureihi et al. Case-control 2005 2.08 (1.45-2.99) <0.001      
Dial et al. Case-control 2005 2.26 (1.66-3.08) <0.001      
Loo et al. Case-control 2005 2.01 (1.37-2.95) <0.001      
Pepin et al. R. cohort 2005 1.85 (1.23-2.78) 0.003      
Modena et al. Case-control 2005 1.95 (1.33-2.87) 0.001      
Muto et al. Case-control 2005 1.98 (1.38-2.84) <0.001      
Gillis et al. Case-control 2006 1.92 (1.37-2.70) <0.001      
Kazakova et al. Case-control 2006 1.98 (1.43-2.75) <0.001      
Lowe et al. Case-control 2006 1.86 (1.33-2.60) <0.001      
Dial et al. Case-control 2006 1.82 (1.34-2.46) <0.001      
Yearsley et al. Case-control 2006 1.82 (1.37-2.43) <0.001      
Akhtar et al. Case-control 2007 1.83 (1.40-2.39) <0.001      
Beaulieu et al. R. cohort 2007 1.75 (1.35-2.27) <0.001      
Cadle et al. Case-control 2007 1.81 (1.40-2.39) <0.001      
Dubberke et al. R. cohort 2007 1.90 (1.46-2.49) <0.001      
Jayatilaka et al. Case-control 2007 1.94 (1.49-2.51) <0.001      
Aseeri et al. Case-control 2008 1.98 (1.54-2.56) <0.001      
Baxter et al. Case-control 2008 1.92 (1.52-2.44) <0.001      
Dial et al. Case-control 2008 1.90 (1.52-2.37) <0.001      
Dalton et al. R. cohort 2009 1.90 (1.54-2.35) <0.001      
Debast et al. Case-control 2009 1.89 (1.53-2.32) <0.001      
Turco et al. Case-control 2010 1.92 (1.56-2.36) <0.001      
Bajaj et al. Case-control 2010 1.95 (1.59-2.39) <0.001      
Howell et al. Cohort 2010 1.94 (1.60-2.34) <0.001      
Kim et al. Case-control 2010 1.96 (1.63-2.37) <0.001      
Linsky et al. R. cohort 2010 1.94 (1.61-2.32) <0.001 87.9% < 0.001 0.02 (0.04) 0.59 0.14 
Statins and 
cognitive side 
effects 
US FDA 28-02-
2012* 
Jick et al. Case-control 2000 0.29 (0.13-0.64) 0.002      
Rodriguez et al. Cohort 2002 0.41 (0.21-0.82) 0.011      
Rockwood et al. Case-control 2002 0.38 (0.23-0.63) <0.001      
Li et al. Cohort 2004 0.52 (0.24-1.16) 0.111      
Rea et al. Cohort 2005 0.67 (0.39-1.15) 0.144      
Zandi et al. Cohort 2005 0.75 (0.47-1.19) 0.216      
Beydoun et al. Cohort 2011 0.67 (0.42-1.07) 0.091      
Betterman et al. Cohort 2012 0.65 (0.43-0.98) 0.039 75.9% < 0.001 -0.0008 (0.06) 0.99 0.15 
Proton pump 
inhibitors and 
pneumonia 
EMA 26-07-2012 
Mallow et al. Cohort 2004 1.00 (0.38-2.60) 0.999      
Laheij et al. Case-control 2004 1.62 (0.95-2.77) 0.076      
Gulmez et al. Case-control 2007 1.56 (1.31-1.87) <0.001      
Sarkar et al. Case-control 2008 1.74 (1.37-2.21) <0.001      
Beaulieu et al. R. cohort 2008 1.45 (1.08-1.95) 0.015      
Marciniak et al. Case-control 2009 1.46 (1.10-1.95) 0.009      
Roughead et al. R. cohort 2009 1.37 (0.99-1.89) 0.055      
Myles et al. Case-control 2009 1.40 (1.06-1.85) 0.017      
Herzig et al. Cohort 2009 1.39 (1.09-1.78) 0.008      
Miano et al. R. cohort 2009 1.43 (1.13-1.82) 0.003      
Myles et al.(2) Cohort 2009 1.36 (1.08-1.71) 0.008      
Rodriguez et al. Case-control 2009 1.34 (1.08-1.66) 0.007      
Gau et al. Case-control 2010 1.34 (1.08-1.63) 0.006      
Eurich et al. Case-control 2010 1.30 (1.07-1.59) 0.009      
Dublin et al. Case-control 2010 1.29 (1.07-1.55) 0.009      
Redelmeier et al. R. cohort 2010 1.26 (1.05-1.51) 0.015      
Kasuya et al. R. cohort 2010 1.28 (1.07-1.54) 0.008      
Meijvis et al. Case-control 2011 1.32 (1.13-1.61) 0.003      
Laheij et al. Cohort 2011 1.35 (1.13-1.61) 0.001 95.7% < 0.001 -0.02 (0.04) 0.62 0.47 
 
 
  
Notes: * - issued in the same safety alert;  
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VI.4.1. PUBLICATION BIAS 
 
 Egger’s asymmetry test was not statistically significant for most of the analyses but 
was significant for the analysis of statins and increased blood sugar (P=0.003) (Table 2). After 
the exclusion of the cohort study, no statistically significant asymmetry was found (P=0.773) 
(Supplemental Data VI.1 Reference 73). Few studies were considered for pioglitazone and 
bladder cancer analysis, which may not allow firm conclusions despite the non-statistically 
significant Egger’s asymmetry test (P=0.07). Subjective evaluation of publication bias was 
based on the visual inspection of funnel plot. 
 
VI.4.2. SENSITIVITY ANALYSIS 
 
 The sensitivity analysis according to different study designs did not significantly change 
the results with respect to the observed between-studies heterogeneity (Supplemental Data 
VI.2). Regarding the sub-group analysis according to the studies design, three pooled risk 
estimates changed their timing. When only RCTs were considered to estimate the risk for 
increased blood sugar (newly-diagnosed diabetes mellitus) associated with statins, the 
estimate yielded a statistically significant increased OR (1.07, 95% CI 1.01-1.15, P=0.034). 
The same increased risk was observed in the cohort study, although the final pooled 
estimate of different study designs was non-significant (Supplemental Data VI.1 Reference 
73). For the risk estimate considering only cohort designs, the ultimate increased risk for 
diarrhea due to Clostridium difficile associated with proton pump inhibitors was only 
observed in 2009 (OR 1.75, 1.00-3.07, P=0.05). The definitive increased risk for fractures 
associated with proton pump inhibitors was observed in 2010 (OR 1.23, 1.07-1.40, P=0.003) 
when only case-control studies were considered. 
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VI.5. DISCUSSION 
 
 The findings of this study show that, for the majority of case scenarios (7/9), the 
results yielded by meta-analysis were in line with the conclusions of the regulatory 
authorities. Warnings could have been added to the label of proton pump inhibitors in 2004 
for Clostridium difficile associated diarrhea and in 2008 for bone fractures. The label of 
proton pump inhibitors was subject of first updates in 2012 and 2010 regarding those AEs, 
respectively. These two decisions were supported by observational data only.  Increased 
blood sugar was associated with statins in 2008 after pooling data from RCTs. The inclusion 
of a cohort study in the estimate returned a final result which is statistically non-significant 
and associated with considerable heterogeneity. Statins’ label was updated to properly advise 
users for the risk of diabetes.  
 However, caution is needed when interpreting these risk estimates since they could 
be biased by the inherent confounding variables of the included studies (KIM and BERLIN, 
2006). According to the results of the sensitivity analysis, meta-analyses exclusively 
integrating data from RCTs had their results characterized by low heterogeneity. Frequent 
and acute AEs are regularly identified from RCTs, in particular when they are pre-established 
endpoints of interest. When regulatory authorities and investigators are dealing with rare 
AEs which may be present in RCTs, it is frequent to pool data using meta-analysis. This was 
the case when AEs as cancer and increased blood sugar were evaluated using meta-analytic 
technique (BANGALORE et al., 2011; SATTAR et al., 2010; SIPAHI et al., 2010). 
 All the safety issues studied in this work were evaluated by at least one type of 
observational methodology when regulatory authorities reviewed their benefit/risk ratio. 
This could be due to the fact that most of these AEs being considered as rare and/or long-
latency events, such as malignancies, cardiovascular events or diabetes, which are prone to 
be better evaluated in post-authorization safety studies. These studies offer the advantage of 
a naturalistic observation, which may better represent the incidence of iatrogenic events 
occurred in the clinical practice (PAPANIKOLAOU, CHRISTIDI and IOANNIDIS, 2006; 
VANDENBROUCKE and PSATY, 2008).  
 The final conclusion of benefit/risk reevaluations conducted by the regulatory 
authorities may contradict risk estimates pooled by meta-analytic technique. Additional data 
sources supporting a causal relation between an AE and a drug can be used to substantiate 
regulatory decisions. In cases like this meta-analyses of the existing evidence can return 
inconclusive results, as it was when the authorities decided to include warnings in the label 
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of GLP-1 receptor agonists due to acute pancreatitis risk (ALVES, BATEL-MARQUES and 
MACEDO, 2012b). In this study, an increased risk of pneumonia associated with proton pump 
inhibitors was estimated in 2009. This is in line with the results of previous meta-analyses 
which yielded increased risk estimates and were subsequently reviewed by EMA (EOM et al., 
2011; GIULIANIO, WILHELM and KALE-PRADHAN, 2012; JOHNSTONE, NERENBERG and LOEB, 
2010). However, EMA recommended that no risk minimization activities should be taken at 
the moment and kept this class under review. The authority considered that evidence from 
observational studies of an association between proton pump inhibitors as a class and 
pneumonia was inconsistent and might be subject to residual confounding (EUROPEAN 
MEDICINES AGENCY, 2012). Methodological differences may also be responsible for delays in 
meta-analysis to yield a statistical significant result, as it was for venous thromboembolism 
associated with oral contraceptives containing drospirenone. Differences between venous 
thromboembolism definition, risk factor of included patients and type of contraceptives used 
as control group may explain why the first two studies published in 2007 reported a null 
association (JICK and HERNANDEZ, 2011). Latter studies took these methodological and 
clinical issues into consideration and reported increased risks (JICK and HERNANDEZ, 2011). 
This may help to explain why only in 2011 an increased risk was pooled by cumulative meta-
analysis, the same year that all regulatory authorities suggested labels’ updates.      
 According to meta-regression results, most of the risk estimates were stable over 
time. The exception was statins and increased blood sugar for which the risk progressively 
increased. This may suggest that conducting cumulative meta-analysis of evidence could have 
help regulatory authorities to take more timely decisions. Previous studies estimated that 
drug withdrawals from market occur in the first 2 years and that label changes take, on 
average, between 7 to 11 years (MOORE, SINGH and FURBERG, 2012; LESTER et al., 2013; 
LASSER et al., 2002). This study included the most consumed drugs worldwide in the 
ambulatory care which are approved by several years and have been used to treat millions of 
people. Recent approved drugs may be more likely to be linked with unexpected serious AEs 
leading to their more rapidly regulatory actions. In this study, none of the regulatory 
decisions led to drugs withdrawal. Postmarketing drug safety requires careful evaluation of 
the existing evidence by regulatory authorities. However, timely ascertainment of drug risks 
with higher quality and better documented scientific evidence seems to deserve 
improvement (MOORE, SINGH and FURBERG, 2012). 
 Taking into account the safety issues evaluated in this study and the correspondent 
regulatory decisions, it is not possible to draw definitive recommendations about the 
Chapter VI 
 
260 
requirements of conducting meta-analyses every time safety signals are issued from data of 
longitudinal, comparative studies. Observational studies are more susceptible to bias and 
confounding and integrating data from such designs in meta-analyses may return results with 
excessive heterogeneity, as it was observed for most of the cases evaluated. In the attempt 
to reduce such uncertainty, a sensitivity analyses based on study designs was conducted but 
the results did not differ significantly. When there is little heterogeneity among studies, one 
may be willing to accept meta-analytic evidence as helping to establish a benefit/risk ratio 
(KIM and BERLIN, 2006). In the presence of substantial heterogeneity is difficult to draw 
conclusions and the acceptance of the results may be slow. This might be one of the reasons 
why regulatory authorities can take several years to conclude on an increased risk in some 
cases addressed in this study. 
 Some limitations need to be noted. The safety issues addressed in this study were 
evaluated by four major regulatory authorities. Others beyond those authorities were not 
searched for safety alerts. This could result in the exclusion of important information. This 
study intended to analyze safety alerts and communications which included early notices 
about safety issues, continuing some of them under revision at this time and without being 
known the authorities final decisions. Only the bibliographic references used as sources of 
information by the regulatory authorities to support safety alerts were considered for this 
study. Systematic reviews of bibliographic evidence for each clinical question were not 
conducted; additionally, all data sources reviewed by regulatory authorities may not have 
been completely published in their websites. Therefore, some studies may be absent from 
the cumulative meta-analyses. Despite Egger’s asymmetry test and visual inspection of funnel 
plots may not indicate publication bias for most of the cases, turning these assessments 
difficult since no specific bibliographic researches have been conducted. However, the extent 
to which regulatory authorities have taken into account all the published scientific evidence 
when a benefit/risk ratio is evaluated due to a safety issue was not subject of this study.  
 The role of meta-analysis in pharmacovigilance is a matter of ongoing debate, and 
efforts are being made to develop guidelines on the use of meta-analysis in drug safety 
assessments (COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES, 2013). 
However, there are a number of methodological considerations needed to take into account 
when designing and conducting meta-analyses, in particular when observational studies are 
included, in combination with RCTs or in exclusive (KIM and BERLIN, 2006; COUNCIL FOR 
INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES, 2013). Assessment of medicines’ 
benefit/risk ratio after a safety issue has been raised is a highly responsible scientific exercise 
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that should be supported by different sources of scientific evidence, sometimes with 
conflicting results. Nonetheless, the quality of the meta-analysis is of high importance when 
safety policy measures need to be taken (KIM and BERLIN, 2006). Although regulatory 
authorities and independent investigators may identify increased iatrogenic risks for some 
drugs previous to official risk minimization strategies be set on, uncertainties due to the 
presence of heterogeneity or even the inclusion of different study designs may delay the 
decision-making process. In conclusion, this study demonstrates that meta-analysis can be 
useful to assess drug-AE’ causal relations and, therefore, is able to predict earlier iatrogenic 
risks. Although cumulative meta-analysis has been used to evaluate how risk estimates 
perform over time with success, as in the case of rofecoxib, the results can be affected by 
considerable heterogeneity (JÜNI et al., 2004). Therefore, this technique does not replace 
further assessments during the benefit/risk ratio evaluation procedure. 
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VI.7.2. SUPPLEMENTAL DATA VI.2 – SENSITIVITY ANALYSIS - CUMULATIVE ORS AND 
95% CIS ACCORDING TO DIFFERENT STUDY DESIGNS 
 
Supplemental Table VI.1 - Cumulative ORs and 95% CIs according to different study designs. 
Safety alerts Studies Design Year Cumulative OR Heterogeneity Meta-regression PBa 
    OR (95% CI) P I2 P Estimate (SE) P P 
Fluoxetine and 
cardiovascular birth 
defects  
EMA 25-02-2010 
MALM et al. Case-control 2005 1.56 (0.64-3.78) 0.325      
KÄLLÉN et al. Case-control 2007 1.21 (0.75-1.95) 0.434      
ALWAN et al. Case-control 2007 1.21 (0.84-1.73) 0.309      
LOUIK et al. Case-control 2007 1.08 (0.81-1.43) 0.602 0% 0.702 -0.206 (0.238) 0.39 0.09 
CHAMBERS et al. Cohort 1996 4.19 (0.43-40.78) 0.217      
OBERLANDER et al. R. cohort 2008 1.28 (0.29-5.75) 0.748      
DIAV-CITRIN et al. Cohort 2008 2.08 (0.54-8.01) 0.286 67.5% 0.046 -0.07 (0.152) 0.63 0.47 
Proton pump 
inhibitors and bone 
fractures  
US FDA 25-05-2010 
EMA 22-03-2012 
VESTERGAARD et al. Case-control 2006 1.18 (1.04-1.33) 0.008      
YANG et al. Case-control 2006 1.31 (1.08-1.59) 0.007      
KAYE et al. Case-control 2008 1.18 (0.93-1.48) 0.169      
CORLEY et al. Case-control 2010 1.23 (1.07-1.40) 0.003      
POUWELS et al. Case-control 2010 1.23 (1.10-1.37) <0.001      
CHIU et al. Case-control 2010 1.27 (1.12-1.43) <0.001 79.1% < 0.001 0.018 (0.041) 0.67 0.86 
TARGOWNIK et al. Cohort 2008 1.92 (1.16-3.18) 0.011      
YU et al. Cohort 2008 1.47 (1.03-2.08) 0.034      
ROUX et al. Cohort 2008 1.66 (1.09-2.53) 0.019      
DE VRIES et al. R. cohort 2009 1.33 (1.09-1.62) 0.006      
GRAY et al. Cohort 2010 1.25 (1.13-1.39) <0.001 65.6% 0.02 -0.083 (0.089) 0.35 0.01 
Angiotensin 
receptor blockers 
and cancer 
US FDA 15-07-2010 
EMA 20-10-2011 
IRMA 2 RCT 2001 1.27 (0.26-6.13) 0.767      
RENAAL RCT 2001 1.31 (0.44-3.91) 0.627      
IDNT RCT 2001 0.86 (0.53-1.40) 0.556      
Val-HeFT RCT 2001 0.89 (0.72-1.11) 0.313      
LIFE RCT 2002 1.04 (0.92-1.18) 0.556      
ALPINE RCT 2003 1.04 (0.92-1.18) 0.557      
CHARM Alternative RCT 2003 1.04 (0.92-1.17) 0.578      
VALIANT RCT 2003 1.02 (0.91-1.14) 0.759      
CHARM RCT 2004 1.02 (0.93-1.13) 0.654      
VALUE RCT 2006 0.96 (0.88-1.03) 0.255      
TROPHY RCT 2006 0.95 (0.88-1.03) 0.221      
SCOPE RCT 2007 0.97 (0.90-1.04) 0.365      
JIKEA RCT 2008 0.97 (0.90-1.04) 0.366      
ONTARGET (vs ACEi) RCT 2008 0.99 (0.93-1.05) 0.736      
PROFESS RCT 2008 0.99 (0.93-1.04) 0.619      
TRANSCEND RCT 2008 1.00 (0.95-1.05) 0.986      
DIRECT (Overall) RCT 2008 1.01 (0.95-1.08) 0.726      
I-PRESERVE RCT 2008 1.01 (0.95-1.07) 0.828      
GISSI-AF RCT 2009 1.01 (0.95-1.07) 0,846      
HIJ-CREATE RCT 2009 1.00 (0.95-1.06) 0.900      
KYOTO RCT 2009 1.00 (0.95-1.06) 0.939      
NAVIGATOR RCT 2010 1.01 (0.96-1.06) 0.749      
ACTIVE-I RCT 2011 0.99 (0.95-1.05) 0.943 2.3% 0.43 0.0037(0.008) 0.65 0.59 
PASTERNAK et al. Cohort 2011 0.99 (0.95-1.03) 0.623 - - - - - 
Pioglitazone and 
bladder cancer 
EMA 27-05-2011 
US FDA 31-05-2011 
Health Canada 07-
06-2011 
TGA 06-07-2011 
DORMANDY et al. RCT 2005 2.84 (1.02-7.89) 0.045 - - - - - 
LEWIS et al. Cohort 2011 1.20 (0.93-1.55) 0.162      
NEUMANN et al. Cohort 2012 1.22 (1.05-1.42) 0.012 0% <0.001    
AZOULAY et al. Case-control 2012 1.83 (1.10-3.05) 0.020 - - - - - 
Combined 
hormonal 
contraceptives 
containing 
drospirenone and 
venous 
thromboembolism 
EMA 27-05-2011 
US FDA 31-05-2011 
Health Canada 07-
06-2011 
TGA 06-07-2011 
DINGER et al. Cohort 2007 0.90 (0.57-1.42) 0.652      
SEEGER et al. R. cohort 2007 0.90 (0.63-1.29) 0.566      
LIDEGAARD et al. Cohort 2009 1.15 (0.73-1.82) 0.544 72.1% 0.03 0.30 (0.112) 0.01 0.18 
VAN HYLCKAMA VIEG et al. Case-control 2009 6.30 (2.90-13.69) <0.001      
DINGER et al. Case-control 2010 2.47 (0.41-14.91) 0.977      
PARKIN et al. Case-control 2011 2.68 (0.84-8.56) 0.098      
JICK et al. Case-control 2011 2.50 (1.27-4.94) 0.008 81.1% 0.001 -0.273 (0.534) 0.61 0.66 
Statins and 
increased blood 
sugar 
EMA 10-01-2012 
PRAVASTATIN MSG RCT 1993 3.02 (0.12-75.11) 0.500      
4S RCT 1994 1.04 (0,84-1.28) 0.750      
AFCAPS/TEXCAPS RCT 1998 1.02 (0,85-1.22) 0.834      
GISSI PREVENZIONE RCT 2000 0,98 (0,84-1.14) 0.817      
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US FDA 28-02-2012* WOSCOPS RCT 2001 0.94 (0.82-1.08) 0.407      
PROSPER RCT 2002 1.01 (0.85-1.19) 0.914      
ALLHAT RCT 2002 1.04 (0.91-1.19) 0.551      
ASCOT-LLA RCT 2003 1.06 (0.95-1.19) 0.325      
HPS RCT 2003 1.08 (0.98-1.19) 0.110      
LIPID RCT 2003 1.06 (0.97-1.16) 0.216      
PROVE-IT TIMI 22 RCT 2004 1.06 (0.97-1.15) 0.183      
ATHEROMA RCT 2005 1.06 (0.98-1.15) 0.154      
MEGA RCT 2006 1.07 (0.99-1.15) 0.091      
CORONA RCT 2007 1.07 (1.00-1.15) 0.051      
GISSI HF RCT 2008 1.07 (1.01-1.15) 0.033      
JUPITER RCT 2008 1.09 (1.03-1.16) 0.006 2.8% 0.42 0.012 (0.008) 0.14 0.77 
CULVER et al. Cohort 2012 1.48 (1.38-1.59) <0.001 - - - - - 
Proton pump 
inhibitors and 
Clostridium difficile 
associated diarrhea 
US FDA 08-02-2012 
SHAH et al. Case-control 2000 0.86 (0.47-1.59) 0.625      
YIP et al. Case-control 2001 1.61 (0.37-7.06) 0.530      
CUNNINGHAM et al. Case-control 2003 1.83 (0.76-4.42) 0.179      
DIAL et al.  Case-control 2004 2.00 (1.06-3.79) 0.033      
AL-TUREIHI et al. Case-control 2005 2.13 (1.22-3.70) 0.008      
DIAL et al. Case-control 2005 2.30 (1.52-3.46) <0.001      
LOO et al. Case-control 2005 1.99 (1.24-3.22) 0.005      
MODENA et al. Case-control 2005 2.12 (1.38-3.27) 0.001      
MUTO et al. Case-control 2005 2.14 (1.46-3.15) <0.001      
GILLIS et al. Case-control 2006 2.04 (1.42-2.93) <0.001      
KAZAKOVA et al. Case-control 2006 2.11 (1.51-2.96) <0.001      
LOWE et al. Case-control 2006 1.96 (1.30-2.95) 0.001      
DIAL et al. Case-control 2006 1.89 (1.32-2.71) <0.001      
YEARSLEY et al. Case-control 2006 1.90 (1.35-2.66) <0.001      
AKHTAR et al. Case-control 2007 1.90 (1.40-2.57) <0.001      
CADLE et al. Case-control 2007 1.97 (1.46-2.65) <0.001      
JAYATILAKA et al. Case-control 2007 2.01 (1.51-2.67) <0.001      
ASEERI et al. Case-control 2008 2.07 (1.56-2.73) <0.001      
BAXTER et al. Case-control 2008 1.98 (1.54-2.55) <0.001      
DIAL et al. Case-control 2008 1.94 (1.54-2.45) <0.001      
DEBAST et al. Case-control 2009 1.92 (1.53-2.41) <0.001      
TURCO et al. Case-control 2010 1.96 (1.57-2.46) <0.001      
BAJAJ et al. Case-control 2010 2.00 (1.61-2.50) <0.001      
KIM et al. Case-control 2010 2.04 (1.65-2.53) <0.001 86.9% <0.001 0.045 (0.049) 0.37 0.10 
KYNE et al. Cohort 2002 2.19 (0.89-5.41) 0.089      
DIAL et al.  Cohort 2004 2.13 (1.34-3.66) 0.001      
PEPIN et al. R. cohort 2005 1.54 (0.85-2.81) 0.164      
BEAULIEU et al. R. cohort 2007 1.28 (0.85-1.92) 0.234      
DUBBERKE et al. R. cohort 2007 1.72 (0.85-3.47) 0.133      
DALTON et al. R. cohort 2009 1.75 (1.00-3.07) 0.050      
HOWELL et al. Cohort 2010 1.75 (1.13-2.71) 0.012      
LINSKY et al. R. cohort 2010 1.70 (1.17-2.46) 0.005 91.2% < 0.001 -0.009 (0.08) 0.91 0.98 
Statins and cognitive 
side effects 
US FDA 28-02-2012* 
JICK et al. Case-control 2000 0.29 (0.13-0.64) 0.002      
ROCKWOOD et al. Case-control 2002 0.28 (0.15-0.54) <0.001 0% <0.001 - - - 
RODRIGUEZ et al. Cohort 2002 0.58 (0.27-1.24) 0.161      
LI et al. Cohort 2004 0.90 (0.45-1.79) 0.763      
REA et al. Cohort 2005 1.06 (0.78-1.44) 0.712      
ZANDI et al. Cohort 2005 1.10 (0.88-1.38) 0.406      
BEYDOUN et al. Cohort 2011 0.91 (0.63-1.33) 0.632      
BETTERMAN et al. Cohort 2012 0.79 (0.53-1.18) 0.257 73.6%  0.002 -0.0087 (0.04) 0.03 0.53 
Proton pump 
inhibitors and 
pneumonia 
EMA 26-07-2012 
LAHEIJ et al. Case-control 2004 1.89 (1.36-2.62) <0.001      
GULMEZ et al. Case-control 2007 1.60 (1.31-1.96) <0.001      
SARKAR et al. Case-control 2008 1.80 (1.41-2.29) <0.001      
MARCINIAK et al. Case-control 2009 1.80 (1.43-2.26) <0.001      
MYLES et al. Case-control 2009 1.73 (1.42-2.10) <0.001      
RODRIGUEZ et al. Case-control 2009 1.60 (1.25-2.04) <0.001      
GAU et al. Case-control 2010 1.54 (1.22-1.94) <0.001      
EURICH et al. Case-control 2010 1.48 (1.18-1.85) 0.001      
DUBLIN et al. Case-control 2010 1.43 (1.15-1.78) 0.001      
MEIJVIS et al. Case-control 2011 1.48 (1.20-1.82) 0.003 92.4% <0.001 -0.059 (0.055) 0.29 0.11 
MALLOW et al. Cohort 2004 1.00 (0.38-2.60) 0.999      
BEAULIEU et al. R. cohort 2008 0.69 (0.45-1.06) 0.088      
ROUGHEAD et al. R. cohort 2009 0.93 (0.59-1.46) 0.742      
HERZIG et al. Cohort 2009 1.14 (0.96-1.34) 0.128      
MIANO et al. R. cohort 2009 1.10 (0.92-1.30) 0.294      
MYLES et al.(2) Cohort 2009 1.36 (1.08-1.71) 0.008      
REDELMEIER et al. R. cohort 2010 1.07 (0.92-1.23) 0.382      
KASUYA et al. R. cohort 2010 1.09 (0.94-1.26) 0.264      
LAHEIJ et al. Cohort 2011 1.32 (0.97-1.32) 0.107 79.2% < 0.001 -0.116 (0.078) 0.14 0.74 
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VII. GENERAL DISCUSSION 
 
VII.1. DISCUSSION 
 
 Despite each experimental chapter has its own discussion, this section is intended to 
discuss in a more integrated and broader manner all the research studies presented in this 
thesis. The work conducted under the presented thesis aims at answer to the general 
objectives proposed at the beginning of this dissertation. 
 
 The knowledge about the risk profile of a medical intervention is as important as its 
benefits. Both are crucial to establish the most accurate medicine’s benefit-risk profile. The 
majority of newly introduced medical interventions have small, incremental benefits when 
compared with available treatments (IOANNIDIS, 2009). Therefore, differences in safety 
profiles should have a key role in the treatments choice (IOANNIDIS, 2009). 
 Regarding a pharmacologic intervention, most of the information on its safety profile 
is produced during the pre-market clinical development. However, rare and serious AEs are 
usually identified through observational pharmacovigilance activities after a drug being 
introduced into the market (WYSOWSKI and SWARTZ, 2005; LASSER et al., 2002). Since 
observational studies are based on real world clinical data, they may better reflect the 
frequency of AEs (VANDENBROUCKE, 2004; VANDENBROUCKE, 2006). Systematically reviewing 
of both experimental and observational data on safety may provide a more balanced and 
realistic account of the likeliwood of the outcomes (HOPEWELL, WOLFENDEN, and CLARKE, 
2008). 
 Investigate uncommon or long-term AEs associated with pharmacological treatments 
is an important application of meta-analysis. However, combining data from different study 
designs through meta-analytic technique can be affected by inherent biases of the considered 
studies (KIM and BERLIN, 2006; BERLIN, CEPEDA and KIM, 2012). Taking into account these 
considerations and the objectives of this work, the first task conducted was the identification 
and the evaluation of meta-analyses from both experimental and observational studies where 
safety was found to be an outcome measure. The search was limited to meta-analyses 
published in eight medical journals from 2005 to 2010 which were selected for having the 
highest impact factor on the area of general/internal medicine.  
 According to the findings, only a limited number of meta-analyses are currently 
devoted to evaluate the safety of pharmacological interventions. The majority of the 438 
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meta-analyses identified during the 5-years studied period was designed to assess efficacy or 
non-pharmacological interventions, while only 60 (14%) assessed drug safety as a primary 
outcome. It should be noted that some meta-analyses evaluated the same clinical question 
during the studied period since some treatments were under evaluation by regulatory 
authorities (e.g., risk of cardiovascular events associated with rosiglitazone; antidepressants 
and risk of suicidal behaviors). This research identified meta-analyses devoted to evaluate the 
safety of pharmacological interventions. However, of the 60 meta-analyses evaluated, two 
included only observational studies and four included data from both observational and 
experimental studies. Moreover, of the meta-analyses which included different study designs, 
two compared to results pooled from RCTs with those pooled from observational studies, 
while in other meta-analysis observational studies were used to provide information on 
safety outcomes which was not reported in RCTs.  
 The relatively low number of meta-analyses including observational data may have 
been influenced by the choice of this set of journals. Journals covering the disciplines of 
pharmacoepidemiology and pharmacovigilance may publish relevant meta-analyses, some of 
those including different study designs as data sources (HENNESSY et al., 2001; GAGNE, 
GRIESDALE and SCHNEEWEISS, 2009; LOKE, JEEVANANTHAM and SINGH, 2009; TOH and 
HERNÁNDEZ-DÍAZ, 2007; CHEN and ASHCROFT, 2006). Nonetheless, other reasons may exist 
too for such few meta-analyses designed to evaluate drug safety have been find. Despite 
extensive study in pre-approval RCTs of safety and effectiveness, doubts can remain about 
their effects, whether unintended, harmful or beneficial (PLATT et al., 2014). Clinical trials are 
not designed to provide full assessments of drugs safety profiles. Additionally, most of the 
investigators may fear an increase in the uncertainty due to integrate data from both 
experimental and observational studies in meta-analyses. Therefore, these factors may 
contribute to the existence of a low number of meta-analyses dedicated to evaluate safety 
issues.  
 A previous study which randomly identified 60 meta-analyses published during 1995 
found that 27 of them have included observational studies. However, only 11 meta-analyses 
were conducted to evaluate therapeutic interventions and no distinction was made between 
those evaluating efficacy or safety outcomes (EGGER, SCHNEIDER and DAVEY SMITH, 1998). The 
type of studies included in systematic reviews has also been described. Hopewell and 
colleagues (2008) found that Cochrane reviews included only RCTs (95%) for both efficacy 
and adverse outcomes. In contrast, systematic reviews published in the Database of 
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Abstracts of Reviews of Effects (DARE) were more likely to include other type of studies, 
with 58% relying only on experimental designs (HOPEWELL, WOLFENDEN, and CLARKE, 2008).  
 Meta-analyses of RCTs are based on the assumption that each trial provides an 
unbiased estimate of the effect of an experimental treatment and that the variability of the 
results between the studies is attributed to random variation (EGGER, SCHNEIDER and DAVEY 
SMITH, 1998). Thus, the overall effect measure pooled from a sample of RCTs will provide an 
essentially unbiased estimate of the treatment effect (EGGER, SCHNEIDER and DAVEY SMITH, 
1998; EGGER, SMITH and PHILLIPS, 2007). This assumption is strengthened when a meta-
analysis includes RCTs having similar designs, follow-up time duration, end-points 
assessment, and patient demographics. Randomized clinical trials are designed to provide 
evidence on the efficacious treatment of disease and tend to be under-powered for 
detection of AEs. (LESKO and MITCHELL, 2012; HAUSMANN, SCHNYDER and PICHLER, 2012). 
Unexpected and rare AEs may not be identified in RCTs conducted during clinical 
development. Moreover, adverse outcomes are not always reported in a consistent way. 
Therefore, evidence on safety reported by RCTs and their associated meta-analyses is often 
insufficient. 
 Although potential biases and confounding have to be considered, observational 
studies are more likely to include a broad representation of the population at-risk and 
provide reliable estimates of the incidence of AEs in clinical practice.  Consequently, some 
AEs are only identified in observational studies, years after their introduction into the 
(STAFFA, CHANG and GREEN, 2002; LIDEGAARD et al., 2009).  
 In this work, the safety of the direct inhibitors of coagulation factor Xa, rivaroxaban 
and apixaban, and GLP-1 agonists, exenatide and liraglutide, was evaluated in two meta-
analyses. 
 Most of the thromboprophylaxis after joint surgery consists in the use of heparins or 
vitamin K antagonists, such warfarin (GEERTS et al., 2008). However, these therapies had 
specific limitations and new oral anticoagulant agents have been developed, like the direct 
inhibitors of coagulation factor Xa (WEITZ et al., 2010; BECATTINI, LIGNANI and AGNELLI, 2010; 
GROSS and WEITZ, 2008). Both rivaroxaban and apixaban have shown to be effective in 
preventing thromboprophylaxis following knee and hip arthroplasty (LASSEN et al., 2009; 
LASSEN et al., 2010; ERIKSSON et al., 2008; TURPIE et al., 2009). Yet, the safety of rivaroxaban was 
subject of discussion in scientific literature due to doubts on the risk for haemorrhages and 
wound complications (JENSEN et al., 2011; LOTKE, 2008; CAO et al., 2010; GÓMEZ-OUTES et al., 
2009). Since rivaroxaban and apixaban have been developed almost at the same time, no 
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study directly compared both oral anticoagulants. Thus, a meta-analysis of RCTs was 
conducted in order to compare the safety profile of rivaroxaban and apixaban. 
 The results of the meta-analysis suggested that thromboprophylaxis with apixaban 
after knee arthroplasty was associated with a lower risk of major, clinical relevant nonmajor, 
and total bleeding events, when indirectly compared with rivaroxaban. When hip 
arthroplasty was the case, no differences were observed. A previous meta-analysis evaluating 
the efficacy and safety of rivaroxaban confirmed its superiority to enoxaparin as a 
thromboprophylaxis agent administered after joint surgery (CAO et al., 2010). However, the 
authors did not recommended the use of rivaroxaban since a higher proportion of bleeding 
events was observed in patients receiving it as a treatment. The RCTs of both drugs used 
either the European regimen of enoxaparin, 40 mg, subcutaneously, once-daily, or the North 
American regimen, consisting in administer enoxaparin 30 mg, subcutaneously, twice-daily. 
Therefore, a sensitivity analysis was conducted in order to establish comparisons using the 
European enoxaparin regimen. As a result, statistical significance disappeared and both 
apixaban and rivaroxaban presented an identical risk for bleeding. This is suggestive of a 
higher risk of bleeding associated with twice-daily enoxaparin 30 mg. Although both 
enoxaparin regimens have never been compared, this tendency for an increased risk of 
bleeding with enoxaparin 30 mg twice-daily regime was reported in a previous meta-analysis 
(HUANG et al., 2011).  
 The bleeding endpoints evaluated in this meta-analysis were the same as those pre-
specified in the RCTs. The assessment procedure and adjudication of AEs as well as follow-
up times were the same in the phase III RCTs of rivaroxaban and apixaban. Additionally, the 
both drugs’ clinical developments programmes included patients with similar demographic 
characteristics. The comparable design of studies evaluating apixaban and rivaroxaban as well 
as the fact that only data from well-defined outcomes has been pooled may have been 
responsible for the lower levels of heterogeneity observed throughout this meta-analysis.  
 Although this meta-analysis includes results of high-quality RCTs and includes data 
from a sample of more than 28 000 patients, not all the studies assessed safety outcomes 
considered to be relevant, such as wound infection, healing or drainage rates (JENSEN et al., 
2011; LOTKE, 2008). An observational retrospective study compared the safety of 
rivaroxaban with tinzaparin in patients submitted to knee or hip arthroplasty (JENSEN et al., 
2011). The results have shown that patients who received treatment with rivaroxaban were 
more than twice as likely to return to theatre with a wound complication. The authors 
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stated that they discontinued the use of rivaroxaban based on their results, raising the need 
for further RCTs assessing the efficacy and safety of rivaroxaban in clinical practice.  
  
 Serious AEs have been linked with exenatide and liraglutide, the first two GLP-1 
agonists being marketed. Since, 2005, cases of acute pancreatitis occurring in patients treated 
with exenatide BID have been spontaneously reported to regulatory authorities, mainly to 
FDA (US FOOD AND DRUG ADMINISTRATION, 2007). Analyses of spontaneous reporting 
systems’ databases identified an increased risk for acute pancreatitis associated with 
exenatide BID (ELASHOFF et al., 2011; RASCHI et al., 2013). However, these findings were 
confirmed through observational longitudinal studies (DORE, SEEGER and CHAN, 2009; GARG, 
CHEN and PENDERGRASS, 2010; DORE et al., 2011). Nonetheless, FDA decided for the update 
of exenatide product’s labelling based on post-marketing spontaneously reported cases (US 
FOOD AND DRUG ADMINISTRATION, 2009). Acute pancreatitis was also identified in RCTs 
evaluating liraglutide (PARKS and ROSENBRAUGH, 2010). 
 Other serious adverse issue which has been linked with GLP-1 agonists is thyroid 
cancer, particularly associated with liraglutide. Benign thyroid C-cell adenomas were 
observed in rodents treated with exenatide BID but no carcinomas were reported 
(EUROPEAN MEDICINES AGENCY, 2006; DRUCKER et al., 2010). In carcinogenicity studies, thyroid 
tumours occurred in rats administered with exenatide once-weekly (EUROPEAN MEDICINES 
AGENCY, 2011). During clinical development, unspecified neoplasms have been reported in 
patients treated with exenatide BID (EUROPEAN MEDICINES AGENCY, 2006). C-cell hyperplasia 
and thyroid cancer were observed in pre-clinical toxicology studies conducted for liraglutide 
(EUROPEAN MEDICINES AGENCY, 2009; BJERRE KNUDSEN et al., 2010). Thyroid neoplasms were 
also reported during the liraglutide RCTs (EUROPEAN MEDICINES AGENCY, 2009; PARKS and 
ROSENBRAUGH, 2010). Liraglutide’s product label carries a Black Box warning noticing the risk 
for thyroid c-cell cancer (FOOD AND DRUGS ADMINISTRATION, 2010). 
 In order to evaluate the risk of acute pancreatitis, any cancer or thyroid cancer, 
associated with GLP-1 agonists, exenatide and liraglutide, a meta-analysis was carried out 
based on both experimental and observational published studies. The results suggest that 
neither exenatide nor liraglutide increase the risk for acute pancreatitis. These findings are in 
line with those reported in observational studies conducted for exenatide (DORE, SEEGER and 
CHAN, 2009; GARG, CHEN and PENDERGRASS, 2010; DORE et al., 2011). No post-marketing 
observational studies evaluating acute pancreatitis have been identified for liraglutide.  
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 Although no association between GLP-1 agonists’ exposure and acute pancreatitis has 
been established, several confounding factors should be considered. Nausea, abdominal 
discomfort and vomiting are ADRs known to be associated with GLP-1 agonists treatment 
(EUROPEAN MEDICINES AGENCY, 2006; EUROPEAN MEDICINES AGENCY, 2011; EUROPEAN 
MEDICINES AGENCY, 2009). These events are symptoms of acute pancreatitis, which may 
impair patients to recognise it and could difficult health professionals to establish a proper 
diagnosis (BALANI and GRENDELL, 2008). Only studies exclusively evaluating patients with type 
2 diabetes mellitus have been included in this meta-analysis. There is a higher risk for 
developing acute pancreatitis in patients suffering from type 2 diabetes, independently of the 
drug therapy (NOEL et al., 2009). GLP-1 agonists were initially approved as type 2 diabetes 
add-on therapy. Patients receiving GLP-1 agonists are more likely to be at more advanced 
stages of the disease and, therefore, more prone for developing acute pancreatitis. This may 
indicate that there is an increased risk for confounding by indication, particularly when 
observational studies are the case (NATHAN et al., 2009; GARG, CHEN and PENDERGRASS, 2010). 
 This meta-analysis did not identify an increased risk for any cancer associated with 
exenatide. The results remained unchanged when the analysis was stratified according to the 
therapeutic regimens or different comparators. No significant difference in the risk for 
cancer was observed regarding treatment with liraglutide, except when the analysis was 
stratified based on studies methodological quality. When only five high methodological 
quality studies where considered, it was observed an increased risk of cancer from all causes 
in patients treated with liraglutide. Nonetheless, caution should be taken when interpreting 
this result, since is the only significant association found, suggesting a possible chance of 
finding. The scale of Downs and Black (1998) was chosen since it is able to assess both 
experimental and observational studies. The number of quality assessment scales that exist 
make it unclear how to achieve the best assessment and results may vary depending on the 
scale used (JÜNI et al., 1999). 
 Although no consistent increased risk was found for both drugs, a divergence 
between the risk of cancer associated with exenatide and liraglutide was identified (-14% for 
exenatide and +35% for liraglutide, both non-significant). When only high quality studies 
were considered, this difference increases. Only RCTs were included in the meta-analysis 
evaluating the risk of cancer associated with GLP-1 agonists since observational studies were 
not identified in our search strategy. Considering that cancer is a long-latency event, the 
follow-up duration of the experimental studies may not be long enough to establish a reliable 
causality association between liraglutide exposure and cancer occurrence. Despite the few 
General Discussion 
289 
cases identified during RCTs, the proportion of patients diagnosed with thyroid carcinomas 
was higher in those receiving liraglutide when comparing with those receiving any control 
treatment; no such cases were observed in patients receiving exenatide. The small number 
of cases and the lack of biological plausibility raise some doubts between the use of GLP-1 
agonists, namely liraglutide, and thyroid cancer occurrence (DRUCKER et al., 2010). Moreover, 
the effects of this drug in humans, particularly in the human thyroid gland, are unknown and 
difficult to be extrapolated from pre-clinical studies, despite the C-cell hyperplasia in rats 
(PAROLA, 2009). The findings of this meta-analysis enhance the need for long-term well-
designed epidemiological studies devoted to assess the risk for cancer associated with GLP-1 
agonists, including thyroid cancer during liraglutide exposure. Additional studies in animals 
and the establishment of a cancer registry database to monitor the incidence of medullary 
thyroid cancer associated with liraglutide was required by the FDA (PARKS and 
ROSENBRAUGH, 2010).  
 Some limitations should be considered in this meta-analysis. Few observational 
longitudinal studies evaluated these AEs. Although three cohort studies have been identified 
in literature, none observational study evaluating the risk of cancer was found. Since the 
follow-up time to properly assess these outcomes may take some years, the results of 
additional studies are expected in the near future. Of the 22 RCTs included, only one 
considered pancreatitis as an initial outcome measure. Despite two RCTa have evaluated the 
calcitonin levels, none of them were designed to prospectively monitor for malignancies. The 
absence of malignancies and/or pancreatitis as pre-defined diagnostic criteria can lead to 
missing events. Different controls were identified in the RCTs included in this meta-analysis 
and they might be associated with different risks for acute pancreatitis or cancer, such the 
case of gliptins or pioglitazone. Because of the heterogeneity of comparators and the 
relatively small number of acute pancreatitis and cancer events reported in the studies, the 
stratification of the results at this level is difficult. According to its EPAR, several neoplasms 
occurred in patients receiving treatment with exenatide BID during the clinical development 
programme, although the type of carcinomas has not been specified (EUROPEAN MEDICINES 
AGENCY, 2006). This suggests that publication bias may be present in our meta-analysis 
despites non-significant results observed for this outcome in the Egger’s regression 
asymmetry test.  
 The significant between-studies heterogeneity observed for some comparisons 
established during the meta-analysis evaluating the risk for acute pancreatitis results from the 
inclusion of observational studies. Therefore, additional caution is needed when interpreting 
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such risk estimate results. Heterogeneity was considered low when only data from RCTs 
was included, as was the case of meta-analysis evaluating the risk of cancer or the previous 
meta-analysis evaluating the safety of coagulation factor Xa direct inhibitors. Nonetheless, 
due to the very low incidence of carcinomas, the final risk estimates confidence intervals for 
risk of cancer associated with GLP-1 agonists were found to be wider than those pooled 
when evaluating the safety of both rivaroxaban and apixaban.  
 Current available published evidence is insufficient to support an increased risk of 
acute pancreatitis or an increased risk of cancer from all causes associated with GLP-1 
agonists. Since trials’ size, duration and design may not be appropriate to accurately assess 
the risk of rare or long-term AEs, such acute pancreatitis or cancer, clinicians should rely on 
observational studies in future assessment of the risk of cancer. A rigorous monitoring of 
these outcomes should be implemented in the future studies since current evidence was not 
adequately designed to address this issue, precluding any definitive conclusion. 
  
 The contribution of meta-analysis for drug safety assessment could be measured 
through the extent in which regulatory authorities use this tool to support benefit/risk 
reevaluations. Therefore, a review was conducted in order to assess the type and publication 
status of data sources supporting benefit/risk ratio reevaluations conducted by four major 
regulatory authorities on safety issues evaluated between January 2010 and December 2012. 
The results of this study provide evidence that in the cases of the safety alerts assessed 
herein regulatory authorities reviewed, either isolated or in combination, several sources of 
information to support their decisions on safety issues. Such sources of information mainly 
comprised post-marketing spontaneous reports and experimental and observational clinical 
studies. 
 Spontaneously notified reports of cases were present in the majority of the 
benefit/risk ratio reassessments, with a considerable proportion (20%) of safety evaluations 
conducted exclusively on this source of evidence. Rare, severe and unexpected AEs, with an 
acute onset, are prone to be reported by healthcare professionals or patients when they 
occur within a relatively short period of time after the initiation of the treatment or 
following a dose increment (MADRE et al., 2006). The value of the pharmacovigilance 
spontaneous reporting systems in providing evidence on iatrogenic risk is recognized 
(WYSOWSKI and SWARTZ, 2005; MOORE, SINGH and FURBERG, 2012; LESTER et al., 2013). 
Reports of cases may be the only available evidence suggesting an association between a 
suspected drug and an AE. The warnings added to GLP-1 agonists label by FDA regarding the 
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risk of acute pancreatitis were based on spontaneously reported AEs. The results of 
experimental and observational studies did not verify such increase in the risk, as well as the 
results of the meta-analysis conducted on that subject (EUROPEAN MEDICINES AGENCY, 2006; 
DORE, SEEGER and CHAN, 2009; GARG, CHEN and PENDERGRASS, 2010; DORE et al., 2011). 
 Evidence from RCTs was found to support a significant number of regulatory 
decisions. For safety alerts where RCTs were found to be the only data sources consulted, it 
was not uncommon that the AE being evaluated was an end-point of interest of the study 
(e.g. QT interval prolongation, bleeding). In other way, several regulatory decisions on AEs 
occurring with a long-latency time from the initiation of the treatment, such as fractures, 
cardiovascular events or malignancies, were found to be based on observational designs, the 
majority being cohort and case-control studies. Although a considerable proportion of the 
safety alerts was supported by RCTs (41%), this study found that observational data also 
made a relevant contribution towards supporting safety issues, not only in post-marketing 
reports of cases (56%) but also in longitudinal studies [cohort (27 %) case-control (22 %)]. 
Since only the most consumed classes of medicines were included in this work, the 
probability of these drugs being the subject of observational research is high. 
 The results of meta-analyses have also been consulted by regulatory authorities to 
support their decisions, although not so frequently as other data sources. These were meta-
analyses conducted using data from RCTs or from observational studies; none pooled data 
from both experimental and observational studies. When meta-analyses were evaluated, 
their results were consulted along with those of longitudinal comparative studies. None 
regulatory authority took decisions based exclusively on the results of meta-analyses. Meta-
analysis is not frequently used to support regulatory decisions and, when it does, it is used 
mainly as a method to confirm the results found in longitudinal comparative studies, whether 
experimental or observational. 
 However, a number of limitations should be considered regarding these findings. 
Regulatory agencies other than FDA, Health Canada, EMA and Australian TGA were not 
searched and only websites posted in languages other than English were not considered, 
which may lead to the exclusion of relevant information. Additionally, information on data 
sources and regulatory actions may not be published in their entirety.      
 The meta-analytic technique has demonstrated its usefulness in evaluating safety 
issues. Cumulative meta-analysis has shown that appropriate and timely decisions could have 
been taken concerning cardiovascular events associated with rofecoxib (US FOOD AND DRUG 
ADMINISTRATION; 2011). In order to explore if meta-analytic technique would produce 
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reliable safety risk estimates that could lead regulatory authorities acting earlier than they 
did, we conducted an additional study. From the previous sample of safety alerts, only those 
in which regulatory authorities’ decisions were supported by longitudinal, comparative 
studies were selected. The aim of this study was evaluating how risk estimates generated 
from cumulative meta-analysis performs over time for drugs having their benefit/risk ratio 
reevaluated and, additionally, assess if the results are consistent with regulatory authorities’ 
conclusions.    
 The findings of this study show that, for the majority of the safety alerts subject of 
cumulative meta-analysis (7/9), the risk estimates were in line with the conclusions of the 
regulatory authorities. Moreover, cumulative risk estimates pointed out that warnings could 
have been added to the label of proton pump inhibitors in 2004 for Clostridium difficile 
associated diarrhea and in 2008 for bone fractures. It should be noticed that proton pump 
inhibitors’ labels were subject of first updates in 2012 and 2010 regarding those AEs, 
respectively. Increased blood sugar was associated with statins in 2008 after pooling data 
from RCTs. The inclusion of a cohort study in the estimate returned a final result which is 
statistically non-significant and associated with considerable heterogeneity. Statins’ label was 
updated to properly advise users for the risk of diabetes. 
 Nonetheless, caution is needed before taking conclusions from these results since 
they could be somehow biased due to the different study designs included (KIM and BERLIN, 
2006; BERLIN, CEPEDA and KIM, 2012). A sensitivity analysis was conducted where the results 
were pooled according to different study designs, experimental and observational. Meta-
analyses exclusively integrating data from RCTs were characterized by low between-studies 
heterogeneity. Frequent and acute AEs are regularly identified during RCTs, in particular 
when they are pre-established endpoints of interest. When regulatory authorities and 
investigators are dealing with rare AEs which may be present in experimental studies, it is 
frequent to pool data using meta-analysis. This was the case when AEs as cancer and 
increased blood sugar were evaluated (SATTAR et al., 2010; SIPAHI et al., 2010; 
VANDENBROUCKE and PSATY, 2008). 
 All the safety issues studied in this work were evaluated by at least one type of 
observational methodology when regulatory authorities reviewed their benefit/risk ratio. 
This could be due to the fact that most of these AEs being considered as rare and/or long-
latency events, such as malignancies, cardiovascular events or diabetes, which are prone to 
be better evaluated in post-authorization safety studies. These studies offer the advantage of 
a naturalistic observation, which may better represent the incidence of iatrogenic events 
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occurred in the clinical practice (PAPANIKOLAOU, CHRISTIDI and IOANNIDIS, 2006; ALVES, BATEL-
MARQUES and MACEDO, 2012). 
 Authorities’ final conclusions of benefit/risk reevaluations may, in some cases, 
contradict meta-analytic’ risk estimates. Additional data sources supporting a causal relation 
between an AE and a drug can be used to substantiate regulatory decisions. In such cases, 
meta-analyses of the existing evidence can return inconclusive results, as it was previously 
studied for GLP-1 receptor agonists which had labeling updates based on spontaneously 
reported cases of acute pancreatitis (EOM et al., 2011). In this study, an increased risk of 
pneumonia associated with proton pump inhibitors was estimated in 2009. This is in line 
with the results of previous meta-analyses which yielded increased risk estimates and were 
subsequently reviewed by EMA (GIULIANIO, WILHELM and KALE-PRADHAN, 2012; JOHNSTONE, 
NERENBERG and LOEB, 2010; EUROPEAN MEDICINES AGENCY, 2012). However, EMA 
recommended that no risk minimization activities should be taken and kept this class under 
review. The authority considered that evidence from observational studies of an association 
between proton pump inhibitors as a class and pneumonia was inconsistent and might be 
subject to residual confounding (JICK and HERNANDEZ, 2011). Methodological differences 
between recent studies and those conducted years ago is one of the reasons that may delay 
the identification of an increased risk, as it was for VTE associated with oral contraceptives 
containing drospirenone. Differences between VTE definition, risk factors associated with 
patients and the type of contraceptives previously used in control groups were pointed out 
as the reasons why the first two studies published in 2007 reported a null association (LESTER 
et al., 2013). These methodological and clinical issues were taken into consideration in later 
studies reporting increased risks (LESTER et al., 2013). This may help to explain why only in 
2011 an increased risk was pooled by cumulative meta-analysis, the same year that all 
regulatory authorities suggested labels’ updates.   
 Taking into account the safety issues evaluated in this study and the correspondent 
regulatory decisions, it is not possible to draw definitive recommendations about the 
requirements of conducting meta-analyses every time safety signals are issued from data of 
longitudinal, comparative studies. Observational studies are more susceptible to bias and 
confounding and integrating data from such designs in meta-analyses may return results with 
marked heterogeneity across studies, as it was observed for most of the cases evaluated. A 
sensitivity analysis by study design was conducted to explore its effect as potential source of 
heterogeneity, but the results did not differ significantly, particularly in those meta-analyses 
integrating data exclusively from observational studies where higher values of between-
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studies heterogeneity obtained in the primary analysis have persisted. When there is little 
heterogeneity of effects across studies, one may be willing to accept meta-analytic evidence 
as helping to establish a benefit/risk ratio (KIM and BERLIN, 2006; BERLIN, CEPEDA and KIM, 
2012). In the presence of substantial heterogeneity, however, it is difficult to draw definitive 
conclusions and the acceptance of the results may take time. This might be one of the 
reasons why regulatory authorities can take several years to conclude on an increased risk in 
some cases addressed in this study. 
 This work is subject of some limitations. No systematic bibliographic search was 
conducted and cumulative meta-analyses were based exclusively on studies used to support 
safety alerts. Additionally, some of the data sources reviewed by regulatory authorities may 
not be published on their websites. Although Egger’s asymmetry test and visual inspection of 
funnel plots may not indicate the presence of publication bias in most of the cases, such 
evaluation is difficult since no specific bibliographic searches were conducted. 
 
 The role of meta-analysis in pharmacovigilance is a matter of ongoing debate (DRUG 
INFORMATION ASSOCIATION, 2011). The Safety Planning, Evaluation and Reporting Team 
formed in 2006 recommends sponsors to develop a program safety analysis plan beginning 
with first clinical studies, as a tool to proactively plan for meta-analyses at regular intervals 
during marketed use of a product (CROWE et al., 2009). The ICH E9 guideline also states that 
meta-analyses should be prospectively planned with the RCTs program in the development 
of a new treatment (INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL 
REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE, 1998). 
  Council for International Organizations of Medical Sciences (CIOMS) Working Group 
X was established aiming at developing a consensus on scientific and methodological criteria 
that represents good practices when applied to meta-analyses of clinical data within the 
regulatory process (COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES, 
2013). These criteria are being developed to be used by both industry and regulators. The 
working group also intends to develop guidance on how to combine available information 
from both RCTs and observational studies to generate an integrated result, which is 
considered controversial. The results should be published in 2014. 
 The conclusions of the ongoing and further researches should be considered into 
guidelines where recommendations on how better to combine results from different studies 
designs in meta-analyses of AEs. Although there exist recommendations on how to conduct 
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systematic reviews and meta-analyses, none is dedicated to specifically guide researchers on 
how to integrate different data sources to better assess iatrogenics of interventions. 
 
 This work has a number of limitations. When evaluating the methodological 
differences between different study designs, it is important to consider any confounding 
factors that may account for any differences identified (GOLDER, LOKE and BLAND, 2011). The 
assessment of differences between study designs was not a primary aim of this work, but 
rather to evaluate the influence of different study designs in meta-analytic estimates.  
 Another limitation is the possibility of underrepresentation of the examples used to 
explore the initial investigational question. At the time of this researches were conducted, 
the safety of both GLP-1 receptor agonists and Xa coagulation factor direct inhibitors had 
been subject of investigation. Meta-analyses of AEs associated with drugs other than those 
evaluated in this thesis could have resulted in different conclusions. 
 All the meta-analyses conducted within this thesis have relied on data reported by 
investigators in the published studies. There was not any attempt to contact the researchers 
authoring the papers included in the meta-analyses since few hundreds of contacts would 
have to be established. This was a limitation of similar works (GOLDER, LOKE and BLAND, 
2011).    
 
 There are a number of methodological considerations that need to be taken into 
account to design and conduct a meta-analysis. The uncertainty is higher when data from 
observational studies is integrated, in particular when combined with RCTs. This may be the 
principal reason for the slowing acceptance of meta-analysis as a tool in the medicines’ 
benefit/risk ratio reevaluations following safety signals. Between-studies heterogeneity due to 
clinical and/or methodological differences may delay the conclusions of the decision-making 
process even when meta-analytic’ pooled estimates found an increase in risk. There is a need 
to explore the between-studies heterogeneity from two perspectives, clinical and 
methodological. Clinical heterogeneity refers to differences associated with the participants, 
interventions or outcomes. The participants may differ for example in age or gender, the 
interventions may differ in type, dose and duration; and the definitions of the outcomes 
measured may differ, as well as the duration of follow-up.  Methodological heterogeneity 
refers to differences in the way the studies were conducted, for example, differences in 
study design or risk of bias. Even though a review deliberately selects studies that may be 
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similar in many ways based on these factors, there can still be substantial differences that 
mean it might not make sense to pool their results. 
 The results of this work suggests that instead of restricting meta-analyses to one type 
of study design, a broad range of studies should be searched and considered for inclusion in 
the pooled estimates. Previous research recommends that systematic review of literature 
should not be restricted to specific study types and that both experimental and 
observational data should be included in meta-analyses of AEs of pharmacological 
interventions (GOLDER, LOKE and BLAND, 2011). Nonetheless, since the results of meta-
analyses including different types of studies can be associated with higher uncertainty, further 
risk assessments based on the results from other data sources should be considered in the 
decision-making process. 
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VIII. FINAL CONCLUSIONS 
 
VIII.1. CONCLUSIONS 
 
 This thesis evaluated the potential usefulness of meta-analysis for Pharmacovigilance, 
exploring if this statistical technique would produce reliable estimates when combining 
results from different data sources, namely experimental and observational studies. In order 
to answer to the initial research questions, several studies were conducted. Briefly, the most 
relevant conclusions obtained throughout the work developed under this thesis are the 
following: 
 
 The majority of meta-analyses published by the highly impact medical journals are 
designed to assess the efficacy of pharmacological interventions; only a limited 
number of meta-analyses are currently devoted to evaluate drug safety as a 
primary outcome. Randomized clinical trials are the main source of information 
from where data is pooled off; very few meta-analyses included data from both 
observational and experimental studies. Although meta-analyses including 
observational studies could be more frequently published in journals devoted to 
the pharmacoepidemiology and pharmacovigilance areas, the most read and 
quoted medical journals are those which will influence the clinical practice and 
prompt regulatory authorities to act. 
 
 The results of meta-analyses of RCTs are less affected by between-studies 
heterogeneity, in particular when such trials have similar methodological design. 
The risk estimates for bleedings associated with Xa coagulation factor direct 
inhibitors, rivaroxaban and apixaban, were characterized by lower between-
studies heterogeneity. The same was observed in the meta-analysis evaluating the 
risk of cancer associated with GLP-1 agonists, exenatide and liraglutide, although 
the rarity of this particular event have produced wider confidence intervals. In this 
particular case, the divergence between the risk of cancer associated with 
exenatide and liraglutide which was identified in the meta-analysis demonstrates 
that this technique may be useful in generating research hypothesis and, lately, 
safety signals.  
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 The inclusion of observational studies in meta-analysis, isolated or in combination 
with RCTs, leads to an increase in the between-studies heterogeneity. The risk 
estimates of such meta-analyses can produce statistical significant results, but 
should be interpret with caution due to the uncertainty produced by data pooled 
from different study designs. Pooled estimates showed no increased risk of acute 
pancreatitis associated with GLP-1 agonists. However, the inclusion of 
observational studies resulted in higher between-studies heterogeneity.      
 
 Spontaneously reported suspected adverse drug reaction support most of the 
post-marketing benefit/risk ratio reevaluations conducted by regulatory 
authorities. It was identified that post-market safety regulatory decisions could be 
supported by meta-analyses’ results, although less frequently. None regulatory 
decision used meta-analyses combining both experimental and observational 
studies as well as none authority used meta-analysis in exclusive when decided to 
act upon a safety issued. 
 
 For safety alerts based on data from longitudinal, comparative studies, namely 
RCTs and observational studies (cohort and case-control), meta-analysis was able 
to produce risk estimates in line with authorities’ conclusions in the majority of 
the situations. It was also demonstrated that cumulative meta-analysis was able to 
predict iatrogenic risks earlier than authorities’ regulatory decisions. However, 
when there is a need to integrate data from both experimental and observational 
studies, results can be affected by excessive heterogeneity. This may delay 
regulatory authorities to accept the results of meta-analyses combining data from 
different study designs. 
 
 Although reliable risk estimates have shown to be produced from meta-analyses 
conducted to evaluate drug safety issues, between-studies heterogeneity may preclude 
investigators and regulatory authorities from draw robust conclusions from those results. 
Uncertainty may increase when observational data is pooled, in exclusive or in combination 
with experimental studies. The findings of this work do not let to recommend that a meta-
analysis of the existing evidence should be conducted whenever a drug-safety alert is issued. 
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Moreover, this technique does not replace further assessments when the benefit/risk ratio 
profile of a medicine needs to be revised due to an increased risk of a suspected ADR. 
  
 
 
 
